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SOMMARIO 
La leucemia mieloide cronica (CML) è una malattia mieloproliferativa 
citogeneticamente caratterizzata da una traslocazione reciproca tra il 
braccio lungo del cromosoma 9 e del cromosoma 22 t(9;22), che porta alla 
formazione della chimera BCR-ABL1. Questo gene codifica per una tirosina 
chinasi deregolata con attività oncogenica. Attualmente i pazienti affetti da 
CML sono sottoposti a trattamento con Imatinib, un inibitore della tirosina 
chinasi. La quantificazione del trascritto BCR-ABL1 mediante qRT-PCR 
viene utilizzata di routine nel follow-up del paziente in terapia per valutare 
la risposta farmacologica individuale. Tuttavia, questa tecnica non può 
identificare cellule leucemiche trascrizionalmente silenti che possono 
essere presenti nella malattia minima residua (MRD). Per poter monitorare 
la MRD è necessario quindi sviluppare un saggio di qPCR sulle sequenze 
genomiche di BCR-ABL1, che sono paziente-specifiche. Precedenti risultati 
del gruppo del Prof. Giovanni Porta (unpublished) hanno dimostrato che nel 
30% dei tempi di follow-up valutati l’mRNA non viene rilevato mentre il test 
sul DNA risulta positivo, indicando la possibile presenza di cellule 
trascrizionalmente silenti. I punti di rottura cromosomici in questi pazienti 
sono stati caratterizzati tramite una laboriosa tecnica di long-range PCR e 
di clonaggio, non adatta per un’applicazione clinica. Al fine di superare 
questo limite tecnico, abbiamo sviluppato un saggio per isolare le regioni di 
ABL1 e BCR in cui mappano i punti di rottura canonici, che danno origine a 
differenti trascritti BCR-ABL1. Le regioni isolate sono state poi sequenziate 
con metodi di nuova generazione. Abbiamo identificato con successo i 
punti di fusione di BCR-ABL1 in 9 campioni su 10 raggiungendo una 
accuratezza al singolo nucleotide. Tutti i risultati sono stati validati con 
sequenziamento Sanger. Sui breakpoint individuati saranno sviluppati 
saggi di qPCR utili per monitorare la MRD. Questo progetto è stato 
sviluppato in collaborazione con il Prof. Porta dell’Università dell'Insubria. 
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ABSTRACT 
Chronic myeloid leukemia (CML) is a myeloproliferative disorder 
cytogenetically characterized by a reciprocal translocation between the long 
arms of chromosome 9 and 22 t(9;22) that leads to the formation of the 
BCR-ABL1 fusion gene, coding for a deregulated tyrosine kinase with 
oncogenic activity. In clinical routine, mRNA amount of the chimeric 
transcript is considered proportional to the leukemic clone and is used for 
the molecular monitoring of patients. However, qRT-PCR cannot identify 
transcriptionally silent leukemic cells that can be present in minimal residual 
disease (MRD). To monitor MRD it is necessary to develop a qPCR assay 
on DNA sequences spanning BCR-ABL1, that are patient specific. Previous 
results obtained by Prof. G. Porta’s group (unpublished) have 
demonstrated that DNA detection is positive while mRNA is not in 30% of 
time points, indicating the presence of transcriptionally silent cells. 
Breakpoints in these patients were characterized by laborious long-range 
PCR and cloning not suitable for a clinical application. To overcome this 
limiting step we set up a DNA capturing assay to target all kind of 
breakpoints that give rise to different BCR-ABL1 transcripts. Captured 
regions were then sequenced with a next generation protocol. The idea 
was to use the identified patient specific breakpoints to setup qPCR assays 
to monitor MRD. We successfully identified BCR-ABL1 fusion points in 9 
over 10 samples, with single nucleotide accuracy, by setting up a 
bioinformatics workflow specifically developed for this purpose. All findings 
were validated with Sanger sequencing. This project was performed in 
collaboration with Prof. Giovanni Porta of University of Insubria. 
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1. INTRODUCTION 
1.1 Next-Generation Sequencing (NGS) 
Next-generation sequencing (NGS), refers to sequencing technologies that 
came after the automated Sanger method. Sanger method [1] is considered 
the first-generation sequencing technology and it was used to determine 
the DNA sequence (5375bp) of the bacteriophage phi X 174 in the 1977, 
the first genome ever sequenced [2]. Improvements to the method, 
including a semi-automation, were developed in early 80’s by Smith, which 
introduced the four-color Sanger sequencing, using four fluorescently 
labeled dideoxynucleotides (ddNTP) for each base and enabling optical 
detection [3]. This method combined with capillary elettrophoresis leads to 
the development of the first fully automated DNA sequencing system, the 
ABI 370 developed by Applied Biosystem [4]. Additional improvements 
continued though the beginning of the new millennium, enabling 
parallelized sequencing of many DNA fragments up to 1 kilobases in length 
with an accuracy higher that 99,9% [5]. The development of the newer 
technologies was enhanced by the initiation of the Human Genome Project 
at the beginning of the 90’. The sequencing of the human genome was an 
exciting challenge between the public institution, the Human genome 
consortium, and the private Celera Genomics, headed by Craig Venter. 
This competition speeded up the production of the first draft of the human 
genome in 2001 [6] [7] and the final version in the 2003 [8]. The great 
investment on this project (3 billion US dollars) triggered the development 
of cheaper and higher-throughput techniques as well as bioinformatics 
algorithms and tools for the analysis of data produced by these machines. 
In 2005, 454 Life Sciences introduced the GS20, the first NGS platform on 
the market. The technique was validated by the combination of the single-
emulsion PCR with the pyrosequencing of the Mycoplasma genitalia 
(580.069 bp) with a coverage of 96% and with an accuracy of 99.96% in a 
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single run of GS20 [9]. The principle of the pyrosequencing technique is 
based on the “sequencing by synthesis”, which depends on the detection of 
pyrophosphate release on nucleotide incorporation. Differently, Sanger 
method detects the nucleotide incorporation by the chain termination with 
ddNTP. The evolution of the NGS techniques consisted in the improvement 
of the detection of the next-added fluorescently labeled base by using CCD 
camera, performing a sort of snapshot of the growing DNA chain. This 
approach was applied to a large number of samples in parallel, attached 
either to a planar support or to beads, minimizing reaction volumes so as to 
lead to miniaturized sequencing systems. In the middle of 00s, several 
platforms emerged on the market among which Roche/454, Illumina, 
Applied Biosystem. By different approaches, each technology seeks to 
amplify single strands of a fragment library and to perform sequencing 
reactions on the amplified strands. In this work the Illumina platform was 
used and the sequencer adopted was the Genome Analyzer IIx (gaIIx).  
1.2 Illumina Sequencing Technology 
Illumina sequencing technology is based on “sequencing by synthesis” 
method that utilizes reversible termination chemistry of nucleotide 
analogues [10]. As previously mentioned, there are two main core-objective 
in a typical NGS sequencing experiment: the amplification of a fragments 
library and sequencing of the amplified library. Library preparation includes 
DNA fractionation / fragmentation by nebulization or sonication, followed by 
enzymatic blunt ending and adapter ligation [11]. Adapters are key features 
for the amplification phase, which takes place on a solid support, the flow 
cell, and is performed by the Cluster Station, an automated device. The 
amplification is performed on the glass, oligonucleotide-covered surface of 
the flow cell, using solid-phase bridge PCR [12] [13]. The adaptors, which 
flank the DNA fragments, are bound to the oligonucleotide surface. A DNA 
polymerase creates copies of the template DNA fragment and the 
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immobilization ensures that all amplicons originating from the single 
molecule template are clustered together on the surface. Each cluster 
consists in hundreds of copies of the template. After cluster generation, the 
single strand amplicons are hybridized with sequencing primers at adapters 
flanking the DNA fragment [Figure 1]. At each cycle, a single base is 
incorporated with chemically modified nucleotides by using a modified DNA 
polymerase [10] [13]. After the four images have been captured at different 
channels, the sequencing cycle ends with a chemical cleavage of the 
fluorophore and the blocking group, enabling base incorporation at the next 
sequencing cycle. After n-cycles, which are setup by the user according to 
the purpose of the experiment, images of each cycles are analyzed and 
base calling is performed [10] [Figure 2]. This process allows transforming 
image-raw data to text-raw data files, which contains human readable 
reads of sequenced fragments. Hence, data are filtered in order to get rid of 
poor quality reads. The output of this data processing is a file in FASTQ 
format.  
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Figure 1. Illumina sequencing (part I) 
 After DNA is randomly fragmented (by nebulization, sonication or by the use of 
ultrasounds) it is ligated to adapters to both the ends of each fragments. DNA with 
adapters is put on the flow cell surface covered by primers that bind the adapters 
sequences. Once DNA is attached as single strand fragments, unlabeled 
nucleotides and enzymes are added and solid phase bridge amplification can 
begin. This process creates clusters. 
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Figure 2. Illumina sequencing (part II) 
All four fluorescently labeled 3’-OH blocked nucleotides are added with DNA 
polymerase to the flow cell. Here the cluster strands are primed and extended by 
one nucleotide. Once the nucleotides are incorporated, the unused nucleotides 
with DNA polymerase are washed away and in the meanwhile a scan buffer is 
added to the flow cell. After the optic system scans each lane of the flow cell by 
imaging units called tiles. The fluorescent labels and the 3’-OH block group are 
then removed. The cluster strands are now ready for another cycle of fluorescent 
nucleotide incorporation. The number of cycles determines the length of reads 
produced. 
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1.3 NGS approaches 
Originally, sequencing was a synonym for DNA sequencing. Nowadays 
NGS is routinely used to analyze DNA, RNA, proteins and to discover how 
these elements can interact each other’s. There are mainly two big fields of 
sequencing: DNA and RNA sequencing. The first aims to study the genome 
and its elements, whereas the second to quantify mature transcripts, small 
RNA and how RNA-based molecules can interact with proteins and 
genome itself. 
1.3.1 DNA Sequencing 
There are several approaches by which the genome can be studied. 
Nowadays the genome can be investigated in its whole length, or it is 
possible to analyze only coding-regions or examine specific regions of 
interest, by using whole genome, exome and target sequencing approach 
respectively. Actually, NGS platforms provide commercial solutions 
(reagents kits and software) to perform and analyze these experiments. 
They also provide custom design protocols directed to capture, enrich and 
sequence a specific regions of interest.  
1.3.1.1 Target Sequencing 
The rationale behind a target sequencing experiment is to study only the 
specific portion of the genome that is of specific interest. Targeted 
sequence enrichment refers to the set of technologies designed to isolate a 
specific genomic fraction (panels of genes or custom genomic regions) for 
subsequent NGS. It ultimately results in an enriched pool of target 
sequences such that there is an overall reduction in the genomic 
sequencing space, and hence, greater sequence coverage for each 
targeted region.  
The reduction in sequencing space confers mainly two important 
advantages over sequencing the entire genome. First reducing the 
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sequencing space required per sample, multiplexing of samples becomes 
possible the overall costs per sample decrease as well and more samples 
can be sequenced at the same cost. Then, by targeting only the fraction of 
the genome that is either necessary or informative for the biological 
question being addressed, the complexity of the analysis is significantly 
reduced.  
Several technologies exist for target enrichment, which can be classified by 
the enrichment method: hybridization based sequence capture, PCR-based 
amplification and molecular inversion probe-based amplification [14] [15]. 
Sequence capture permits the isolation of targeted loci from the 
background of the entire genome. The scale of the capture can range from 
several targeted loci to over a million target regions, making it suitable for 
both small-scale and large-scale projects. The design of a sequence 
capture experiments must be setup very carefully; indeed several key 
elements should be taken into account such as the mean depth of 
coverage for each target region, the probe specificity, the expected 
enrichment efficiency, the NGS platform in use and the genomic features of 
the target region [15] [16]. For instance, the mean coverage depth required 
for targeting a specific region relies upon the specificity of the probes used 
for that target and upon the presence of closely related sequences with 
which the target share some portions. Indeed, the genomic features of the 
target region should be analyzed very deeply in order to ensure the 
expected coverage both in terms of reads covering in depth and in 
percentage of target which can theoretically be captured. Two key features 
can negatively affect the mean coverage and the percentage of capturing. 
The first one is the GC content within the target region. It has been widely 
demonstrated that regions with a high GC content are more difficult to 
sequence [17]. The second is the presence of repeated regions. Repeated 
regions account for 56% of the genome [18], and are widely distributed 
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over the genome. Higher is the percentage of such regions in the target, 
higher will be the a-specific capturing. In order to bypass such hurdles there 
are several practice as increase the probes tailing in GC-rich regions and 
perform a cautious probe design which try to avoid the repeated sequences 
and in the meanwhile allows to maximize the theoretical percentage of 
capturing. Hence, is easy to understand how target sequencing can 
introduce a lot of bias depending on genomic region and on the 
experimental equipment (enrichment kits and NGS platform) used for the 
capture experiment. 
Target sequencing is commonly used for identifying SNPs, INDELs, copy 
number variants and structural variants. Usually, considering the lower 
amount of DNA to sequence, target sequencing data are very accurate due 
to a deeper coverage achievable, even if discrete a-specific coverage is 
present through all the genome. 
 
1.4 NGS applications on genomic data 
NGS is a high-throughput technology that produces a huge amount of data 
that must be handled, analyzed and interpreted. The progress of NGS 
technologies, has been followed by the development of computational 
methods and bioinformatics tools for analyzing data produced by NGS 
platforms. Nowadays plenty of different analyses can be performed on NGS 
data. The type of analysis depends on the approach and on the 
experimental design followed. Some analyses can be performed on 
multiple type of data, but it is recommended to perform specific-driven 
analyses suited for a specific biological issue. Data analysis is mainly 
focused on the identification of a particular feature/signature or profile of 
features, that are shared or that differ among a group of subjects/samples.  
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1.4.1 SNVs and INDELs 
The most common analysis in DNA sequencing field is the identification of 
single nucleotide variants (SNV) such as rare variants and single-
nucleotide polymorphisms (SNPs) and small insertions and deletions 
(INDELs). This kind of analysis has driven the understanding of genomic 
variability until now. SNVs and INDELs can be analyzed starting from 
whole-genome data, exome data and target sequencing data. The 
identification of these genomic features is strictly dependent on the quality 
of the data and on the coverage of the genomic region to investigate. The 
depth of coverage, or simply the reads coverage, is a value which 
describes how many times a specific point / region of the genome has been 
sequenced and read. Higher is the coverage, more accurate is the SNVs 
and INDELs call. The clinical field is particularly interested in the 
identification of genomic variants which could have great impact on protein 
functionality or transcripts expression. Indeed the most common analysis is 
the SNVs and INDELs identification on exome data in which exons and 
their flanking regions are investigated.  Several software are available to 
predict and evaluate how a specific SNVs or INDELs can impact on the 
protein functionality. Such information, along with gene and pathway 
annotation, gives the chance to rise hypothesis on disease mechanisms or 
causes. Up to now, a plethora of exome studies has been carried out, 
especially in the context of mendelian disease and family studies. 
1.4.2 Structural variants 
Besides SNV and INDELs, there are other genomic features  which are 
less studied due to the lack of bioinformatics tools and to the difficulties to 
assess and identify such variants. Among these features the are copy 
number variants (CNV) which spot duplication or loss events, inversions, 
translocations, both intra and inter chromosomal and tandem repeat 
regions. These genomic variants are called structural variants (SV) 
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because they can produce genomic rearrangements. SV are more difficult 
to detect and study than pointed-variants, like SNVs and small INDELs, due 
to the intrinsic complexity of the arrangement that they can promote. In fact, 
different classes of structural variant events can occur together in the same 
region and could be cell specific, making it difficult to study. These analysis 
can be theoretically performed both genome wide and in target regions 
(exome or custom target) even if specific requirements need to be fulfilled 
for ensure accuracy and reliability of results. For instance, CNV analysis 
should be performed at genome wide level and only with a high coverage in 
order to have a good accuracy. 
In the next chapters, the attention will be focused on a specific class of SV: 
the translocations. 
1.4.2.1 Translocations 
Translocations are abnormal chromosomes regions that contain rearranged 
genetic material. In particular, a translocation can be intra or inter 
chromosomal depending on whether the transfer of genetic material occurs 
on the same chromosome or involves different chromosomes.  
A translocation is called “Robertsonian” (ROB) when is characterized by the 
joining of long arms of two acrocentric chromosomes around a single 
centromeric region. The short arms also join to form a reciprocal product, 
which is usually lost in few cell divisions. Most of the times, ROB are non-
deleterious because the essential genes are within long arms. When the 
ROB involve chromosomes 21 and 13 or 15, the heterozygous carrier is 
phenotypically normal because there are two copies of all major 
chromosome arms and hence two copies of all essential genes. However, 
the progeny of this carrier may inherit an unbalanced trisomy 21 or 13, 
causing Down syndrome and Patau syndrome respectively [19]. 
A generic translocation, when reciprocal can be unbalanced or balanced 
depending on whether or not it affects the copy number of any portion of 
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the genome. Balanced reciprocal translocations arise from the fusion of two 
double-strand breaks [20] [21]. Depending on the type of DNA break and 
on where it occurs, different repair mechanisms are active [21]. Many 
pathological translocations fall within the category of balanced reciprocal 
translocations among non-homologous chromosome. Among them, there 
are the Philadelphia chromosome (Ph) t(9,22) that causes the 
overexpression of ABL1 kinase in CML, the translocation t(8,14), found in 
85% of Burkitt’s lymphoma cases, that leads to MYC transcription factor 
overexpression, and the translocation t(11,22) that occurs in Ewing’s 
sarcoma that brings to deregulation of the ETS transcription factor FLI1 
[22]. Translocations that generate gene fusions arise from the joining of 
double strand DNA (dsDNA) breaks that occur at different sites on non-
homologous chromosomes. In such case, dsDNA breaks are frequently 
joined by an endogenous DNA repair pathway called “non-homologous end 
joining” (NHEJ) [23]. In particular, there are two kind of NHEJ: classical and 
alternative. The classical pathway (C-NHEJ) consists in the binding of 
Ku70-80 heterodimer to broken DNA ends, then the recruitment of a 
complex of DNA protein kinase catalytic subunit and Artemis which binds to 
Ku70-Ku80-DNA complex and processes the DNA end through the 
nuclease activity of Artemis, and finally a complex with DNA ligases 
properties joins the DNA end [24]. The alternative pathway (A-EJ) also 
called microhomology-mediated end joining (MMEJ) is activate when the C-
NHEJ is deficient [25] and occurs when in the regions flanking the DNA 
breaks there are homolog sequences. Several studies  suggests that A-EJ, 
if active, produces an increased number of chromosome rearrangements 
compare to the C-NHEJ that causes a lower rate of translocation events. 
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1.4.2.2 Methods for identifying structural variants 
SV identification techniques have made a step up the ladder with the 
advent of NGS technologies, which allow reaching an accuracy level that 
before was out-of-the-way. Indeed, before the introduction of NGS 
techniques, array-CGH was the gold-standard technique for the 
identification of SVs. 
Array-CGH are cheap technologies, but are limited to the detection of “big 
size” SVs with a low accuracy in terms of genomic boundaries. Differently, 
NGS methods have been able to improve the accuracy, reaching the single 
base resolution of SV events. During the last 5 years, several 
bioinformatics tools for SV detection starting from NGS data have been 
developed [26]. Such methods belong to three different approaches [27] for 
SV identification: discordant pair approach [28], split-reads approach [29] 
and depth of coverage approach [30]. The discordant pair approach uses 
paired-end reads, which have a discordant insert size. The discordance can 
be explained as deviation from the expected insert size value, which can 
vary according to the target sequencing experimental design. BreakDancer 
[31] and SVDetect [32] are some of the software that use this approach. 
More details on the algorithm implemented in SVDetect tools will be shown 
in software section. The split-read approach is based on split-reads, which 
are reads that do not map correctly to the reference genome or that are 
unmapped. Such reads are very informative because they have a boundary 
portion that maps to the reference genome, whereas the flanking region, 
which is unmapped, spots the SV. 
There are several algorithms for SV detection starting from partially 
mapped paired-end reads, as Pindel [33], SLOPE [34] and ClipCrop [35]. 
The first and second tools use orphaned reads, unmapped reads whose 
mate maps to reference genome, as putative reads for SV identification. 
The latter, ClipCrop, takes advantage from soft-clipping information 
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included in SAM format mapping file produced by Burrows-Wheeler 
alignment tools like BWA [36] . More details on the algorithm implemented 
in ClipCrop will be shown in software section. 
The depth of coverage approach, uses the frequency of mapped reads or 
bases to each position of the reference genome (or a custom genomic 
interval) to call the SV. The rationale under this methods is pretty similar to 
the one on which array-CGH are build. Indeed, in case of duplication the 
number of mapped reads/bases to regions in the reference genome will 
increase, whereas in case of deletions it will decrease. 
Every approach has its pros and cons, and specific applications are more 
suitable for some approaches compare to others. For instance depth of 
coverage approach is suited for the identification of deletions and insertions 
but not for inversions and translocations identification. Discordant pair and 
split-reads approaches performance very well in the identification of all 
types of SV, although the latter approach is more accurate (single 
nucleotide) than the first one [27]. 
1.5 Chronic Myeloid Leukemia 
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder 
arising from an acquired alteration in hematopoietic stem cells (HSC), the 
Philadelphia chromosome (Ph) [37] [38].  
In 95% of patients, the reciprocal balanced translocation between the long 
arms of chromosomes 9 and 22, t(9;22)(q34;q11) results in a shortened 
chromosome 22, called Ph, and an elongated chromosome 9, called 
derivative chromosome (der 9) [Figure 3]. This chromosomal 
rearrangement includes the juxtaposition of the Abelson gene (ABL1), on 
chromosome 9, with the Breakpoint Cluster Region (BCR) gene located on 
chromosome 22, leading to the formation of 3’ BCR-ABL 5’ fusion gene. 
This hybrid gene encodes the Bcr-Abl oncoprotein, a constitutively 
activated tyrosine kinase that plays a crucial role in CML pathogenesis. 
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CML accounts for 15% of all leukemia forms in adults [38] and for 0.2% of 
all cancers [22].  
 
Figure 3. t(9;22)(q34;q11) reciprocal translocation 
The reciprocal translocation t(9;22)(q34;q11) occurs between the long arms of 
chromosome 9 and chromosome 22, producing a shortened (22q-) chromosome 
22 called Philadelphia chromosome(Ph) and a longer (q9+)  chromosome 9 named 
derivative 9 (der9). During this translocation, BCR and ABL1 genes are broken and 
two fusion products are formed: 5’3’ BCR-ABL1 on Ph and  
3’5’ ABL1-BCR on der9. 
 
1.5.1 Epidemiology, etiology and risk factors 
The incidence of CML is 1-2 cases per 100.000 population. The median 
age of patients is 65 years and the median age of onset is about 45-55 
years [38] according to SEER [39] . 
The cause of CML is unclear. Some associations with genetic and 
environmental factors have been reported, but in most cases no causative 
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factors can be identified. There is little evidence linking genetic factors to 
CML. Offspring of parents with CML do not have a higher incidence of CML 
than the general population [40].  
1.5.2 Course and symptoms 
CML arises in three phases: chronic, accelerated and blastic. CML in 
chronic phase (CP) is asymptomatic in 25% to 60% of cases disease is 
unmasked on routinely blood exams. 
In symptomatic patients, typical symptoms are fatigue, weight loss and 
palpable splenomegaly [41] [42] in 30% to 70% of patients [43]. If 
untreated, CML in CP is associated with a median survival of 4 to 5 years 
[37]. The accelerated phase (AP) is a brief transitional phase, usually 
symptomatic. If treated with common therapy, the estimated 4-years 
survival rate exceeds 50% and the medial survival is 1-2 years. During the 
blastic phase (BP), cells fail to mature and resemble blasts found in acute 
leukemia (AML and ALL). 
Patients in blastic phase show severe clinical conditions and have a poor 
prognosis, dying within 3 to 6 months [43]. 
1.5.3 Laboratory features 
In laboratory tests, CML exhibits an elevated white blood cells (WBC) 
count, frequently exceeding 1x1011/L [42]. The presence of leukocytosis 
(>1.2 -1.5x1010/L) in the absence of infections should prompt a workup for 
CML. In particular, the absolute lymphocyte count is elevated at the 
expense of T lymphocytes. Another common laboratory feature of CML is 
the high platelet count at chronic phase (30% to 50% of patients) that drops 
(thrombocytopenia) when the accelerated phase occurs leading to anemia. 
The bone marrow is usually hypercellular [44] [42], with a cellularity of 75% 
to 90% [43] 
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1.5.4 Diagnosis 
The diagnosis is based on the detection of some hallmarks such as 
leukocytosis with basophilia and with immature granulocytes as 
myelocytes, premyelocytes and occasional myeloblasts, thrombocytosis 
and physical findings like splenomegaly. Blood counts and differential are 
fundamental for the disease phase evaluation. The diagnosis achieved by 
blood analysis must be confirmed by cytogenetic analysis showing the 
translocation (9;22)(q34;q11) and by reverse transcriptase polymerase 
chain reaction (RT-PCR) that detects BCR-ABL1 transcripts. The 
cytogenetic diagnosis is performed by chromosome banding analysis 
(CBA) of bone marrow cells at metaphase. If bone marrow is not available, 
karyotype analysis is replaced by the fluorescent in situ hybridization of 
blood cells at interphase (I-FISH) [45]. Using this technique it is possible to 
detect BCR-ABL+ nuclei and Ph+ variants [46]. RT-PCR is performed on 
RNA from blood or bone marrow and allows to detect the transcript type 
indicating the breakpoint region in BCR (major, minor, micro) and hence the 
BCR-ABL1 protein weight (p210, p230 and p190).  
1.5.5 Staging and prognostic risk systems 
The determination of the stage of CML is the starting point to establish a 
correct therapy. A good prognosis leads to a better outcome and survival. 
Staging of CML has been changed during the last 20 years, especially as 
long as the treatment with tyrosine kinase inhibitors (Imatinib) has been 
introduced as standard therapy. The staging system is based on several 
parameters by which it is possible to classify the disease phase in patient. 
The World Health Organization (WHO) in 2001 introduced standards for the 
evaluation and classification of CML phase [47]. 95% of patients are 
diagnosed in CP. The disease can develop to an accelerated phase (AP) 
and then to a blastic phase (BP). According to WHO criteria, AP is 
characterized by blasts (10-19%), basophils (>20%), platelets (<100x109/L 
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unrelated to therapy), whereas BP by a concentration of blasts >20% and 
the presence of extramedullary blasts or large clusters of blasts in bone 
marrow. In 2006, Cortes et al. [48] demonstrated that WHO standards in 
the CML staging need to be updated and proposed, taking into 
consideration previous treatments, new criteria for defining CML stages, 
improving the survival rate and the prognosis. 
Although studies have demonstrated improvements in prognosis and 
staging, nowadays the advance in genomics analysis and treatments has 
introduced many potential parameters on which to develop new standards 
for the evaluation and staging of the disease. Nevertheless in clinics, 
persists some prognostic risk systems that were introduced in the pre-
imatinib era, as the Sokal score classification [49] (1984) and the EURO 
[50] prognostic system (1998) created for taking into account IFNα-treated 
patients. These prognostic systems take into consideration several 
characteristics including age, spleen size, WBC and platelet count, and 
percentage of blasts, eosinophils and basophils in the peripheral blood. The 
Sokal score, the first system developed, consists in the evaluation of the 
hazard ratio (HR) by using the following formula:  
HR = e
(0.0116* (age - 43.4) + 0.0345 (spleen size * 7.51) + 0.188 ((platelet / 700 x 109/l )* 2 -0.563 ) + 0.0877 (blast% - 2.1)
  
This score defines three prognostic groups: low risk (<0.8), intermediate 
risk (0.8-1.2) and high risk (>1.2) [49]. Sokal score can be used as long as 
the patient is out of treatment. More recently, EUTOS risk score [51], a new 
prognostic system that takes into consideration imatinib-treated patients, 
has been introduced. EUTOS systems is partially detached from blood 
counts and other factors like age and spleen size [51]. 
1.5.6 Treatment and therapy  
CML was discovered in 60’s and from the very beginning many efforts have 
been made to improve the clinical conditions of the patients. 
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The treatment of CML was historically based on busulfan, and on 
hydroxyurea, which is still used in for short pre-treatment phase in case of 
thrombocytosis and leukocytosis. In the 80-90’s interferon-α (IFN-α) was 
the gold standard.At the end of 90’s Imatinib, the first tyrosine-kinase 
inhibitor (TKI), was introduced [52] [53]. The advent of such drug has 
revolutionized the CML therapy. Today Imatinib is considered the gold 
standard for the first-line treatment of the disease. More recently, the 
second-generation of TKIs has been introduced in the treatment that 
include drugs like Dasatinib and Nilotinib which are currently used in 
second-line treatment in case of Imatinib failure or sub-optimal response 
[54] [55]. The choice of treatment is strictly dependent on the degree of 
cytogenetic response and on the detection of BCR-ABL mutations, which 
can negatively affect the drug action [56]. Nowadays there are three types 
of drugs that can inhibit the kinase activity with three different mechanism: 
stabilizing the inactive state (Imatinib, Nilotinib, Ponatinib), altering the 
active state (Dasatinib, Bosutinib) or by allosteric inhibition through the 
binding with regulatory domains (GNF-2, GNF-5) [57]. In particular, Imatinib 
acts by competing with ATP for the binding site on the kinase domain.  
More recently, several new TKIs like Ponatinib and Bosutinib has been 
introduced in trials [54]. These drugs are specifically designed to maintain 
efficacy in the presence of specific point mutations, which can affect the 
functionality of first and second line TKIs [58]. The last line of treatment is 
based on allogenic hematopoietic stem cells transplantation (alloHSCT) 
which is carried out if both first and second line treatment fail or prior to the 
onset of blastic phase. The patients who achieve the blastic phase have to 
this day have an unfavorable prognosis. 
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1.5.7 Disease monitoring 
1.5.7.1 Cytogenetic and RNA-based approaches 
The monitoring of CML can be cytogenetic or molecular. The cytogenetic 
monitoring is based on CBA and I-FISH. The cytogenetic response 
achieved by CBA analysis can be complete, partial, minor, minimal or none, 
depending on the percentage of Ph+ metaphases detected. In case of bone 
marrow lack, cytogenetic response is evaluated using I-FISH. In this case 
the cytogenetic response can be defined complete when the percentage of 
BCR-ABL1+ nuclei is less than 1% out of at least 200 nuclei at interphase 
[59]. The molecular monitoring is based on the quantification of BCR-ABL1 
mRNA by using qRT-PCR. This method is nowadays considered the most 
sensitive tool for disease monitoring and it is particularly useful in minimal 
residual disease (MRD) monitoring. mRNA quantification is expressed as 
the ratio of BCR-ABL1 transcripts to ABL transcripts, that is expressed as 
% of BCR-ABL1 on a log scale according to the International Scale in order 
to guarantee comparability of results among different laboratories. 
According to this scale, BCR-ABL1 % equal to 10, 1, 0.1, 0.01, 0.0032 and 
0.001 corresponds to a decrease of 2;3;4;4.5;5 logs below the standard 
baseline [59]. BCR-ABL1 expression below 3 logs corresponds to a Major 
Molecular Response (MMR). The molecular testing should be performed 
every 3 months until MMR is achieved, followed by controls every 3 - 6 
months. If transcript levels increased 5 times or more in a single follow-up 
and MMR was lost, the monitoring should be repeated in a shorter time 
interval. They are early indicators of treatment failure. Differently if a very 
deep molecular response (M4.0 – M5) is achieved during TKI treatment, 
there are the prerequisite for therapy discontinuation within controlled trials 
[59] [45]. 
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1.5.7.2 MRD DNA-based monitoring 
MRD is currently assessed by the quantification of BCR-ABL1 mRNA 
through qRT-PCR. This method is the gold standard to monitor the disease 
and make the appropriate decisions on disease treatment. However, mRNA 
quantification although very sensitive, is not a direct observation of the 
number of leukemic cells and cannot deal with potentially transcriptionally 
silent CML cells. When the qRT-PCR shows the absence of BCR-ABL1 
transcripts, two assumptions can be made: first, CML cells are not present 
in the sample or CML cells are present but are transcriptionally inactive. For 
this reason, a new sensitive method for MRD monitoring based on the 
quantification of BCR-ABL1 DNA using qPCR has been proposed [60]. This 
new method was applied by Mattarucchi and Porta [60] to 10 CML patients 
undergoing Imatinib treatment. The Authors compared BCR-ABL1 mRNA 
levels with the actual proportion of leukemic cells through quantitative 
amplification of DNA BCR-ABL1 fusion segments. They observed similar 
results with the two approaches, with most patients being positive to both 
mRNA and DNA after two years treatment. However in one of the two 
patients in which mRNA was undetectable, DNA was still present after 42 
months. In this patient Imatinib should not therefore be discontinued. On 
the contrary, in the other patient both DNA and mRNA were negative 
suggesting this patient as a possible candidate for Imatinib withdrawl. The 
idea to identify quiescent leukemic cells carrying BCR-ABL oncogene but 
transcriptionally silent was not new. Indeed Kim et al [61] as well as Zhang 
et al [62] had previously developed a protocol for the quantification of 
leukemic cells by PCR techniques. Other studies supporting the better 
performance of DNA based approach to monitor MRD have also been 
performed by Bartley et al [63]. 
More recently, Porta (unpublished data) has demonstrated that DNA-based 
monitoring can spot the presence of BCR-ABL+ cells in  30% of time 
points in which monitoring with qRT-PCR has a negative result [Figure 4]. 
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The accuracy reached with DNA-based monitoring allowed to detect MRD 
better than with RNA qRT-PCR. The same Author could demonstrate that 
in some cases, when q-PCR assay is positive to CML cells and qRT-PCR 
is not, the minimal residue is due to the presence of quiescent stems cells 
(CD34+) that can turn to be active and promote the relapse. Figure 5 shows 
how the DNA-based disease monitoring is able to spot the presence of 
CML cells when cytogenetic and RNA-based approaches fail. However, the 
limit of this method was that breakpoints were resolved with laborious long-
range PCR not suitable for a routine application.  
The data reported above have been the basis for a collaboration between 
our research group and Prof.Giovanni Porta from Insubria University, for a 
further improvement of the DNA based method, to enhance the 
management of patients affected by CML. This has been the object and the 
aim of the present PhD project. 
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Figure 4. DNA vs mRNA MRD monitoring comparison 
On the top, MRD monitoring with DNA is able to identify leukemic cells in  33 % of the total number of time points in a follow up 
study on 8 samples treated with Imatinib (IM) (Porta et al [unpublished]). In patient 6 no differences were found between DNA 
based monitoring and mRNA based monitoring due to unresponsive to IM treatment.  
On the bottom, the % of DNA and mRNA detection across samples. 
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Figure 5. MRD qPCR vs qRT-PCR 
MDR Monitoring in sample 4 and 10. In sample 4 (Pt.4) from 40
th
 month to 97
th
 
month, DNA is always detected, whereas mRNA is always undetectable except on 
69
th
 month. In patient 10 DNA analysis of MRD is always positive, whereas mRNA 
is always negative.  
 
  
24 
1.6 BCR, ABL1 and BCR-ABL1 
The hallmark of CML is a t(9;22)(q34;q11) that gives rise to the formation of 
Ph in 95% of patients [37]. At molecular level, t(9,22) is characterized by 
the fusion of the proto-oncogene ABL1, located on 9q34.1 and the 
breakpoint cluster region BCR at 22q11.2 leading to the formation of a 
fusion gene BCR-ABL1 which is translated into an oncogenic fusion protein 
[37] [64]. In the next paragraphs BCR, ABL1 and BCR-ABL1 fusion gene 
and related proteins will be described in terms of sequence, structure and 
functions. 
1.6.1 BCR 
1.6.1.1 Gene and Transcripts 
BCR is located on the long arm of chromosome 22 in the 11.23 cytogenetic 
band and is the acronym for Breakpoint Cluster Region, due to the 
presence of clusters of breakpoints in which the chromosome 22 can be 
broken during the BCR-ABL1 gene fusion. BCR is located on chromosome 
22 from coordinate 23,522,552 to 23,660,224 (137,673bp) on the reference 
genome (Hg19) [65] [66]. It is transcribed in 16 different transcripts (splice 
variants) whose only two encode for protein products [65]. The main 
transcript is 7082bp long and includes 23 exons encoding a protein of 
1271aa, whereas the alternative transcripts is 4708bp long includes 22 
exons and encodes an isoform of 1227aa according to Ensemble and 
UniProtKB [65]. The region spanned by BCR is GC rich (52.6763 ± 21.931 
%) [67] and presents a percentage of repeated sequences of 32.47% 
according to Repeat Masker [18]. The BCR gene is expressed ubiquitously 
[68] but highest mRNA levels are found in brain and hematopoietic cells 
[69]. 
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The expression of the gene occurs mainly in the early stages of myeloid 
differentiation and decrease significantly as cells mature to 
polymorphonuclear leukocytes [69].  
1.6.1.2 Protein 
Bcr protein has a very complex organization including several functional 
domains and motifs: 
 Bcr-Abl1 oligomerization domain at N-terminus essential for the 
oncogenic activity of the Bcr-Abl1 tirosine kinase; 
 Serine-threonine kinase domain located in the first exon, by which 
the protein can phosphorylate itself or several substrates like 
casein and histones. This domain includes several Src homology-2 
(SH2) binding domains, which are necessary for the binding with 
Abl1 [64]; 
 Rho-GEF domain, with Rho guanyl-nucleotide exchange factor 
activity;  
 Rho-GAP domain for  RAC1 and CDC42 GTPase activation;  
 Pleckstrin homology domain [57]  involved in the intracellular 
signaling; 
 C2 structural domain involved in targeting proteins at cell 
membrane.  
Bcr protein comes up as a homotetramer of 148 -160 KDa and resides in 
both cytoplasmic and nuclear compartments [64] [37] [64]. In normal cells, 
BCR is a GTPase-activating protein for RAC1 and CDC42, promoting the 
exchange of RAC or CDC42-bound GDP by GTP, thereby activating them 
[70]. BCR is involved in the regulation of cell cycle, in the signal 
transduction; it acts as a positive regulator of phagocytosis and negative 
regulator of inflammatory response. Moreover, it plays a role in the 
organization and biogenesis of actin cytoskeleton [68] [37] as well as brain 
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development. Indeed, sequence variants of the Bcr protein may be 
associated with bipolar disorder. However, the function of wild type Bcr in 
cells remains unclear. 
 
Figure 6. BCR annotation 
 The figure represents the BCR gene and its products (mRNA and protein) in terms 
of sequence annotation. BCR gene is characterized by 23 exons. The clusters of 
breakpoints are located mainly in three regions (µ-BCR, M-bcr and m-BCR). BCR 
is transcribed in two different isoforms differing for the presence of a 23
rd
 exon in 
the longer form. BCR protein has a complex structure including oligomerization 
domain, a kinase domain with SH binding domains, a RHO-GEF domain with 
guanyl-nucleotide exchange factor activity, the pleckstrin domain (PH) that 
mediates intracellular signaling and C2 domain for targeting proteins at cell 
membrane. 
 
1.6.2 ABL 1 
1.6.2.1 Gene and Transcripts 
The cellular ABL1 gene is the human homologue of the viral ABL (v-ABL) 
oncogene carried by the Abelson murine leukemia virus. Viral ABL1 
originates from cellular ABL1 (c-ABL), probably incorporating the 
mammalian ABL1 gene at some point during the evolution. 
ABL1 is a gene located on chromosome 9 at the following genomic 
coordinates (hg19): 133,589,333 - 133,763,062 (171,74Kb) [66]. Abl1 
contains two alternative 5' exons spliced to a common set of 3' exons to 
yield the two major ABL1 RNA transcripts. These transcripts initiate in 
 
 
27 
different promoter regions and give rise to proteins that vary in their N-
terminus. The canonical transcript according to [71] is 5766bp in length and 
it encodes an 1130aa protein, whereas the secondary transcript is 3824bp 
long and encodes for a protein of 1149 aa. The secondary transcript has a 
longer first intron compared to the canonical transcript that has a short first 
intron. The remnant sequence (from exon 2 to exon 11) is the same for 
both transcripts. The region spanned by ABL1 has a standard GC content 
(44.1186 ± 21.931 %) but presents a high average percentage of repeated 
sequences (54.29%) according to repeat masker [18] [67]. In malignant 
hemopathies, ABL1 gene is mainly fused with BCR, but further fusion 
partners (ETV6, RCSD1, SFPQ, NUP214, EML1) has been discovered 
[72]. These fusions partners have a coiled-coil or helix-loop-helix domain 
that promote the oligomerization of ABL1 and enhancement of its kinase 
activity [72]. 
1.6.2.2 Protein  
ABL1 has two isoforms (Abl1a, Abl1b) that differ only for 19 amino acids, 
due to a tiny difference between the two 1st alternative exons. 
Exon Amino acid Sequence 
1a MLEICLKLVGCKSKKGLSSSSSCYLE 
1b MGQQPGKVLGDQRRPSLPALHFIKGAGKKESSRHGGPHCNVFVEH 
 
Table 1. Alternative 1st exon in ABL1 
ABL1 has two alternative 1st exons that differ only for 19 amino acids that encodes 
for a myristoylable residue (glycine) at position 2 in the 1b exon. Such residue is 
involved in the auto-inhibition process of ABL1. 
The sequence annotation is the same for both isoforms, for less than a 
myristoylable glycine at position 2 located in the exon 1b. 
The Abl1b protein consists of a myristoylated (Myr) N-terminal region, 
followed by SH3 and SH2 domains, the SH2/kinase linker, the tyrosine 
kinase domain, and a long last exon region with a C-terminal F-acting 
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binding domain (F-ABD) [57] [73] [74]. In the carboxy-terminal region, 
besides that ABD, ABL1 contains proline-rich (PXXP) SH3 binding sites, 
three nuclear localization signals (NLS), one nuclear exporting signal (NES) 
and a DNA binding domain (DNA BD). The tyrosine kinase domain along 
with SH3 and SH2 domains are assembled in order to maintain an auto-
inhibitory structure in which SH3 and SH2 domains function as a ‘clamp’ 
that block the tyrosine kinase in the inactive state [75]. The crystal structure 
of the Abl1 core reveals that the myristic acid group binds a hydrophobic 
pocket in the C-terminal lobe of the tyrosine kinase [76]. This binding 
promotes the stability of the tyrosine kinase domain by keeping SH3-SH2 
grip in place. Indeed mutations in the myristoyl signal sequence [77] and 
mutations that affect the interaction of SH2 domains to the C-lobe of the 
protein results in the up regulation of the kinase activity. Moreover, 
deletions or mutations of the SH3 domain, as well as mutations in the SH3-
SH2 linker can promote up-regulation of the kinase activity [76] [46]. The 
regulation of tyrosine kinase activity is exerted not only by a complex 
network of intermolecular interactions but also by all the elements able to 
stabilize or destabilize the auto inhibitory conformation. For instance 
phosphatidylinositol-4,5-bisphosphate (PIP2), peroxiredoxin 1 (PRDX1), the  
tumour suppressor protein FUS1 can negatively regulate the ABL kinase 
activity [73], whereas Ras and Rab interactor 1 (RIN1), which interacts with 
both the ABL SH3 and the SH2 domains is able to up-regulate the activity 
[76].  
Moreover, the phosphorylation of specific residues (Y245, Y412) has been 
demonstrated to stabilize the active-state of the protein kinase [73]. 
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Figure 7. Protein sequence annotation 
ABL1 protein presents several domains and motifs. The Src homology domain 2,3 
(SH2, SH3), an N-CAP that in Abl1b contains the myristoyl group, the SH2-SH3 
linker, the tyrosine kinase domain (SH1) and the Y412 residue located in the 
activated loop autophosphorilation site. Proline rich elements (PXXXP) by which 
ABL1 can interact with other molecules, the NLS and NES nuclear signals for 
exerting inter and extra-cellular signaling respectively. In the C-terminal the G and 
F-actin domain necessary for cytoskeleton interactions. Figure adapted from [57].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. ABL1 tirosine kinase 
activity regulation 
The activity of ABL1 tirosine kinase 
is strictly dependent on the 
regulation of the stability of a 
complex network of interactions 
among the ABL1 functional 
domains. ABL1 is physiologically 
auto inhibited The SH3 domain 
binds to the linker sequence 
connecting the SH2 and the kinase  
domains, and the SH2 domain 
interacts with C-terminal lobe of the 
kinase (SH1) domain forming an 
SH3–SH2 clamp  structure. The 
stability of this complex is enhanced 
by the binding of myristoylated 
residue at the N-CAP (1b isoform) 
with the C-lobe kinase. When these 
molecular interactions are broken or 
simply affected, the autoinhibited 
state is loss and the tyrosine kinase 
become active. Figure adapted from 
(64). 
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ABL1 is a ubiquitously expressed and highly conserved proto-oncogenic 
tyrosine kinase. The protein is present both in the nucleus and in the 
cytoplasm of cells. It has been implicated in regulation of cell proliferation, 
differentiation, apoptosis, cell adhesion and stress response [37] [57]. The 
function of ABL1 and the pathways activated by it are different depending 
on the tissue in which is expressed. More insights on the ABL1 activated 
pathways will be described in the next chapters. 
1.6.3 BCR-ABL 1 
1.6.3.1 Mechanisms of BCR-ABL1 oncogene origin 
Chronic myeloid leukemia is characterized by the expression of the BCR-
ABL1 oncogene. In 90-95% of patients, the fusion gene arises from t(9;22) 
that leads to Ph formation. In the remnant 5%, the fusion gene can arise 
from Ph variants where the Ph is further rearranged with other 
chromosomes (Masked Ph), or from cryptic insertions of ABL1 region into 
BCR gene (or vice versa) [46]. The occurrence of these complex 
rearrangements is very difficult to explain temporary, indeed they could 
occur by serial translocations events or by a single complex simultaneous 
event. In a cytogenetic study with FISH conducted on 450 CML patients 
[46], about 9.5% of patients present chromosome rearrangements involving 
at least one (90.7%) or more (9.3%) chromosomes, in addition to the 
chromosomes 9 and 22. Among these, the 83% show classic Ph with 
masked der(9), whereas the remnant 17% a classic (der9) with a masked 
Ph. Cases with masked der(9) showed additional genetic material coming 
from different chromosomes with prevalence of 4,6 and 12. Only a small 
percentage (11%) of such cases the 5’ABL1-BCR 3’gene is retained on 
der(9). In the majority of cases the 5’ABL1/3’BCR is lost for deletions 
occurring at der(9) or is found in others chromosomes. In cases with 
“masked Ph” the 5’ BCR-ABL 3’ fusion gene has been found on der(9) or 
other chromosomes. In 42% of cases with multiple chromosomes 
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rearrangements, micro deletions events at breakpoints are detected [46]. 
This study shows how complex are the rearrangements to which the cell 
can undergo and how difficult can be the identification and understanding of 
them.  
1.6.3.2 Fusion gene and transcripts 
The fusion of BCR and ABL1 occurs in a head-to-tail way, with the 5’ end of 
ABL1 joined to the 3’ of BCR. The fusion gene can be translated in three 
types of proteins depending on the different breakpoint cluster region 
involved in the translocation. 
In BCR gene, there are three clusters regions in which the translocation 
can take place: major (M-BCR) [78], minor (m-BCR) [79] and micro (µ-
BCR) [80]. M-BCR region is an area of 5 spanning from exon 12 to exon 
16, m-BCR region range from the 1st to the 2nd exon and the µ-BCR region 
spanning from exon 19 to exon 20 [37] [64]. In ABL1 gene, the breakpoint 
can occurs over an area ranging from 3’ end of upstream gene EXOSC2 to 
the exon 2 of ABL1, but is mainly located between two alternative 1st exons 
in ABL1 [81]. Hence, BCR-ABL fusion gene can give rise to three proteins: 
p190, p210 or p230 according as the breakpoint in BCR is located in m-
BCR, M-BCR and µ-BCR respectively. Taking into account that ABL1 has 
two alternative transcripts and that the BCR breakpoint in M-BCR can occur 
over five exons (b1-b5), different fusion transcripts can be produced. In 
particular, regarding the M-BCR, breakpoints mostly take place in the 
region from exon 13 to exon 15 and the resulting fusion transcripts (b2a2 
and b3a2) give rise to two 210-kDa tyrosine kinase proteins (p210 BCR-ABL). 
ABL1 breakpoints do not affect protein weight because the impact of ABL1 
alternative transcripts (ABL1a,b) on the BCR-ABL protein length is 19 
amino acids only. The majority of patients (95%) exhibit mRNA transcripts 
with a b3a2 or a b2a2 junction and in 5-10% of cases both transcripts are 
present because of alternative splicing [82] [83] [84] [85]. 
32 
It has been widely demonstrated that the frequency of b2a2 and b3a2 
transcripts depends from the population under analysis. Generally, 
European and Eastern population have higher frequency of b3a2 transcript, 
whereas in Western countries and Africa populations, the frequency of 
b2a2 is higher [82]. 
The co-expression of both transcripts can be explained as the result of 
alternative splicing rather than by the presence of two different clones from 
which the CML can spread. Very few information are available concerning 
hybrid transcripts that arise from µ-BCR and m-BCR [82]. 
 
Figure 9. BCR-ABL1 transcripts 
On the top, ABL1 and BCR genes with exon-intron structure. Black arrows highlight 
the principal regions in which breakpoints occur in ABL1 and BCR. On the bottom 
the principal BCR-ABL1 transcripts that can arise from BCR-ABL1 fusion.  
 
1.6.3.3 Protein and function 
As said above, BCR-ABL1 oncogene can give rise to 3 distinct fusion 
proteins of molecular mass 190, 210, and 230 kD, which contain the same 
portion of the c-Abl tyrosine kinase in the COOH terminus but include 
different amounts of Bcr sequence at the NH2 terminus [86]. 
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The protein p210 is present in 95% percent of CML patients; p190 occurs 
rarely in CML and in 20-30% adults and 5% of childhood B-cell acute 
lymphocytic leukemia (B-ALL), whereas p230 is detected in neutrophilic CML 
[87]. All three forms induce a similar myeloproliferative syndrome [88]. It 
has been widely demonstrated, by using both in-vitro and in-vivo biological 
models, that BCR-ABL1 oncoprotein is a fundamental requisite for 
promoting CML pathogenesis. In vitro experiments on human CD34+ cells 
have shown that overexpression of BCR-ABL1 oncoprotein leads to 
increase of proliferation in response to growth factors, reduction of 
adhesion to fibronectin and increase of growth factor independent survival 
[57] [76]. 
The properties of BCR-ABL1 expressing cells mimics those found in CML 
progenitors cells isolated from patients [70] [57]. Studies performed by 
using a murine stem-cell retroviral vector to express the BCR-ABL 
oncogene in hematopoietic progenitor cells, have demonstrated that the 
expression of the transgene in mice BM was able to induce a 
myeloproliferative disorder (MPD) that resemble CML with 100% efficacy 
[57]. These animal models show CML specific features such as the 
increase of peripheral-blood (PB) cells (granulocytes) number, 
extramedullary hematopoiesis in liver, typical of BP, and splenomegaly 
widely present in CML patients. In vivo models, using mice expressing point 
mutation in the ATP-binding site of ABL1, do not develop CML 
demonstrating that kinase activity is essential for promoting BCR-ABL 
leukaemogenesis in vivo [88]. Hence, the deregulation of the tyrosine 
kinase activity is the key target for promoting CML and its features. By 
evidences collected from several studied performed both in vitro and in 
vivo, it has demonstrated that ABL1 kinase activity is essential but not 
sufficient for leading to CML-like MPD [88]. Several motifs and domain such 
as SH3, SH2 and the N-terminal coiled coil oligomerization domain of BCR 
are necessary to promote MPD [88] [57]. Mutations and deletions in these 
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domains negatively affect the kinase activity [57]. The oncogenic activity of 
BCR-ABL1 is exerted by the phosphorylation of several substrates that 
activate multiple signaling pathways. In particular, BCR-ABL1 promotes the 
development of a malignant phenotype by altering cells adhesion 
properties, activating the mitogenic signaling and in the meanwhile 
inhibiting the apoptosis [75] [69] [37]. The cellular adhesion is impaired by 
the regulation of integrins expression along with the phosphorylation of Crkl 
that regulates the cellular motility and the integrin-mediated cell adhesion 
[70]. The activation of mitogenic signaling along with the inhibition of 
apoptosis is hold by the phosphorylation of several molecules in RAS, 
STAT3 and 5, PI3K-AKT, NF-B and JUN pathways [57] [70] [37] [89]. 
Uncontrolled signaling through these pathways induces abnormal 
proliferation and neoplastic expansion in addition to ability to escape from 
the negative regulation of cell proliferation by stromal cells. 
Others researches have demonstrated that BCR-ABL1 is able to decrease 
the apoptotic response to mutagenic stimuli, providing an additional survival 
advantage to the leukemic clone [90]. 
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2. AIM OF THE WORK 
The fusion gene BCR-ABL1, that arises from the t(9:22) translocation, is 
the hallmark of Chronic Myeloid Leukemia (CML) and the specific target of 
pharmacological treatment. The detection of BCR-ABL1 transcript is used 
to follow up patients under treatment and to monitor treatment efficacy. 
However, this RNA based technique can lead to errors in quantifying tumor 
cells  under expressing the fusion gene [60]. Thus, a DNA based marker of 
the translocation could overcome this limit and will facilitate patient 
management by confirming the absence of leukemic cells.  
The primary aim of this project was to apply Next Generation Sequencing 
technology to identify BCR-ABL1 breakpoints in CML.  
The patient specific breakpoints will be used to setup qPCR assays to 
monitor Minimal Residual Disease (MRD). 
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3. METHODS AND SOFTWARE 
The project as a whole included both an experimental and a bioinformatics 
part. From now onwards the discussion will focus primarily on the 
bioinformatics analysis carried on by myself. Considering that the work of 
this thesis was pivoted around bioinformatics analysis, we decided to split 
the “materials and methods” section in “methods and software” section to 
emphasize the bioinformatics tools used in the data analysis. 
3.1 Samples 
The samples analyzed included K562 cells (CCL-243) and 9 samples 
belonging to CML patients. K562 cells (CCL-243) were purchased from 
ATCC (http://www.lgcstandards-atcc.org) and cultured according to ATCC 
instruction. The nine human samples came from peripheral blood or blood 
marrow specimen. Samples were from patients with CML diagnosed at 
chronic phase. Patient’s clinical conditions and relative laboratory data are 
shown in the table below Table 2. Informed consent for the use of cells for 
research was obtained in accordance with the Declaration of Helsinki and 
with approval of the Ethics Committee of the Insubria University and 
Hospital of Bergamo, Italy.  
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Sample Age 
Molecular 
transcript 
Anamnesis 
Cytogenetic 
CBA nuc ish ish 
CL.1 --- p210 -    
PT.2 N.A p210 N.A N.A N.A N.A 
PT.3 N.A p210 N.A 
46,XY,t(9;22) 
(q34;q11)[19] 
N.A N.A 
PT.4 55 p190 
Asthenic. Pain in the hands and 
feet. Pallor. 
46,XY [23] N.A N.A 
PT.5 85 p230 N.A N.A N.A N.A 
PT.6 69 p210 (b3a2) 
Asthenia, and splenomegaly. 
Previous ischemic heart disease 
N.A N.A N.A 
PT.7 13 p210 (b3a2) N.A 
46,XX,t(9;22) 
(q34;q11)[18] 
(ABL,BCR)x2[400] N.A 
PT.8 42 p210 (b3a2) 
Neutrophilic leukocytosis, 
heterozygous beta-thalassemia, 
insulin-dipendent by the age of 15, 
diabetic retinopathy 
46,XX,t(9;22) 
(q34;q11)[23] 
N.A N.A 
PT.9 41 p210 (b2a2) Leukocytosis 46,XY[17] 
(ABLx3,BCRx2) 
(ABL con BCRx1)[300] 
t(X;9;22)(p11;q34;q11) 
(ABL+,BCR+;ABL+; 
BCR-)[10] 
PT.10 60 p210 (b3a2) 
Hypertensive 
Hypercholesterolemia 
46,XX,t(9;22) 
(q34;q11)[20] 
N.A N.A 
 
Table 2. Sample features 
Several features including the molecular transcript, the clinical condition and the cytogenetic of patients at diagnosis are 
described. Cytogenetic formula are formatted according to the International System for Human Cytogenetic Nomenclature 
(ISCN). In squared brackets, the number of metaphases (for CBA) and nuclei (FISH) at interphase [nuc-ish] or metaphase [ish] 
analyzed. 
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3.2 Methods 
The methods section will focus on the chronological description of the 
procedures implemented in the different phases of the project. 
3.2.1 Cytogenetic analysis 
Conventional cytogenetic analyses, carried out routinely, were subjected to 
quality control according to ISO 9001:2000 accreditation of the laboratory, 
and samples that did not conform to standards were rejected. Cytogenetic 
analysis was performed in laboratories of analysis at Bergamo Hospital 
(Italy) and Varese Hospital (Italy) by using three methods: CBA, FISH at 
metaphase (ish) and FISH at interphase (nuc-ish). All the findings are listed 
in Table 2. 
3.2.2 Probes design for target enrichment of BCR-ABL1 region 
In order to analyze only the regions of interest where the t(9,22) occurs, we 
developed a customized sequencing target enrichment protocol. The 
rationale was to select the best and most selective subset of probes to both 
maximize the capturing of the area of interest and minimize the “non-
specific” capturing. During the probe design, as mentioned in the 
introduction, it is important to take into consideration the genomic context in 
which the target region is located. Starting from BCR-ABL1 breakpoints 
regions reviewed in literature [81] [64] [60] [91] four target regions were 
chosen, in particular three regions for BCR (major, minor and micro 
breakpoints regions) and one region for ABL1 Table 3. 
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Region Chr Interval Length (kb) %GC %RR 
M-BCR 22 23,629,346 - 23,638,343 8.897 55.25 ± 20.82 18 
m-BCR 22 23,523,148 - 23,596,167 73.020 50.44 ± 22.37 40.12 
µ-BCR 22 23,652,511 - 23,660,223 7.713 56.64 ± 20 3.8 
ABL1 9 133,577,268 - 133,730,483 153.215 43.51 ± 23.36 58 
  
Table 3. Targeted regions 
The table shows in each column: the type of targeted region, chromosome, 
genomic interval, region length, %of GC and % of repeated regions according to 
repeat masker [18]. 
Probes design was carried out using eArray software provided by Agilent 
(https://earray.chem.agilent.com/earray/). 
The experimental design of the probes was performed considering the two 
main factors that can affect capturing, which are the GC percentage and 
the presence of repeated sequences. Hence, different sets of probes were 
tested to determine those that could capture the higher percentage of the 
regions of interest (ROI). 
The probes design was based on tuning of two parameters: the tiling of the 
probes, which represent the number of times that the probes cover the 
target region, and the number of bases that overlap the repeated 
sequences (RS). In theory, in order to avoid unspecific capturing, repeated 
regions should be totally masked. However, in order to have the right 
balance between specificity and capturing rate of ROI, we also designed 
probes that span 20-40 bp of RS. Repeated sequences were masked with 
two programs: repeat-masker (RM) [18] and window-masker (WM) [92]. 
Tests were then performed by using genomic coordinates of repeated 
sequences detected by RM and those detected by both RM and WM.  
For BCR target regions, it was established that the best sets of probes 
were those with a 5x tiling and with the overlapping on the repeated 
sequences detected by both RM and WM sets to 20 bp for the M-BCR 
[Table 5] and to 40 bp for m-BCR [Table 6] and the µ-BCR region [Table 7].  
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Concerning to the ABL1 region, the best set of probes was found to be the 
one with tiling at 4x and with 40bp overlapping with the coordinates of 
repeated sequences common to RM and WM [Table 8].  
Using the top probe-set designed for M-BCR, we performed a test to 
assess its ability to capture 27 breakpoints in M-BCR previously identified 
by the Porta group. As can be seen from the table [Table 26], only two 
breakpoints could not be captured because they fell in a repeat sequences 
299 bp long (AluSx1 [chr9: 23633112-23633411]). 
This probe-set was also used for capturing. No further tests were 
performed on other three target regions. The tests performed to validarte 
the probe sets showed that the design of the probes is particularly affected 
by repeated sequences [Table 4]. Indeed ABL1 and m-BCR, that are 
characterized by the highest amount of repeated sequences, 58% and 40% 
respectively, could theoretically be captured for 63.5% and 74.8% of their 
length respectively [Table 8, Table 6]. Conversely, M-BCR and µ-BCR have 
a lower amount of repeats regions (18% and 3.8% respectively) and could 
be theoretically completely captured [Table 5, Table 7]. Using as masking 
set the coordinates of repeated sequences common to both methods (RM 
and WM) the capturing efficiency was higher than that obtained by using as 
masking set the coordinates of repeated sequences detected by RM only. 
This phenomenon is related to number and extension of the repeated 
elements. Higher is the extension of the genomic portion to mask lesser will 
be the percentage of capturing. The difference between the percentage of 
capturing using the coordinates of repeated sequences detected by RM 
and that obtained with coordinates detected by both software (RM+WM) 
resulted similar in all regions ranging from 11 to 16 and correlated with the 
size of the region itself [Table 4]. Longer is the region to target higher will 
be the chance to have different sets of repeated regions detected by the 
two different software (RM and WM). The only exception is the µ-BCR that 
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is both short in length and poor of repeated sequences, which are equally 
detected by both software [Table 4]. 
The main three-breakpoint cluster regions within BCR gene (M-bcr, m-bcr 
and µ-bcr) on chromosome 22 and the region from the exon 8 of EXOSC2 
gene to exon 3 of ABL1 gene on chromosome 9 were captured. The total 
size of captured region was ~250 kb. Agilent RNA probes, of 120-bp, were 
with 4x tile across ABL1 and 5x across BCR. 
 
 
Region Masking Overlap Tiling % capture  capture (Both –RM) 
M-BCR both 20 5x 93.0 11.1 
M-BCR RM 20 5x 81.9  
m-BCR both 20 5x 71.361 12.26 
m-BCR RM 20 5x 59.102  
µ-BCR both 20 5x 96.331 0 
µ-BCR RM 20 5x 96.331  
ABL1 both 20 5x 55.975 16.46 
ABL1 RM 20 5x 39.515  
Table 4. Theoretical capturing with RM and RM  WM masking 
The table summarizes the theoretical percentage of capturing achievable by using 
probe sets with tiling 5X and overlap with repeated sequences of 20bp. The % of 
capture is collected both using probe set masked with RM and masked with 
coordinates common to WM and RM. In the last column the difference of % 
capturing between WM  RM and RM. 
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M-BCR region  (chr22:23629346 - 23638343) 
 
Test name 
Tiling 
Frequency 
Avoid 
Overlap 
Total Number 
of Baits Info 
Total Bases 
Covered by Baits 
Target 
Length 
% Target Base 
Pairs Covered 
BCR_2x_RM_over20 2x 20 111 7073 8998 78.6 
BCR_5x_RM_over40 5x 40 283 7367 8998 81.9 
BCR_5x_RM_over20 5x 20 279 7367 8998 81.9 
BCR_4x_RM_over20 4x 20 225 7373 8998 81.9 
BCR_3x_RM_over20 3x 20 172 7423 8998 82.5 
BCR_3x_RM_over40 3x 40 175 7463 8998 82.9 
BCR_3x_both_over20 3x 20 197 8333 8998 92.6 
BCR_4x_both_over20 4x 20 260 8333 8998 92.6 
BCR_3x_both_over40 3x 40 201 8343 8998 92.7 
BCR_5x_both_over20 5x 20 325 8364 8998 93.0 
BCR_5x_noRep 5x 1 371 8998 8998 100.0 
BCR_3x_noRep 3x 1 223 8998 8998 100.0 
 
Table 5. M-BCR probe sets evaluation 
The table shows in each column: probe set name, tiling frequency (number of baits covering each base), base pairs overlapping 
repeated sequences, number of baits included in the probe set, base pairs covered by baits, length of the targeted sequence., 
% of target covered by the baits. On the top the region name with genomic coordinates. The best probe set is highlighted with 
bold character. 
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m-BCR region (chr22: 23,523,148 - 23,596,167) 
 
Test name 
Tiling 
Frequency 
Avoid 
Overlap 
Total Number 
of Baits Info 
Total Bases 
Covered by 
Baits 
Target 
Length 
% Target Base 
Pairs Covered 
BCR_minor_3x_RM_over20 3x 20 966 42940 73020 58.806 
BCR_minor_5x_RM_over20 5x 20 1575 43156 73020 59.102 
BCR_minor_4x_RM_over20 4x 20 1273 43300 73020 59.299 
BCR_minor_5x_RM_over40 5x 40 1594 43804 73020 59.989 
BCR_minor_4x_RM_over40 4x 40 1289 43870 73020 60.079 
BCR_minor_3x_RM_over40 3x 40 989 44180 73020 60.504 
BCR_minor_3x_both_over20 3x 20 1148 51380 73020 70.364 
BCR_minor_4x_both_over20 4x 20 1516 52026 73020 71.249 
BCR_minor_5x_both_over20 5x 20 1880 52108 73020 71.361 
BCR_minor_3x_both_over40 3x 40 1234 54585 73020 74.753 
BCR_minor_5x_both_over40 5x 40 2007 54632 73020 74.818 
BCR_minor_4x_both_over40 4x 40 1620 54742 73020 74.968 
 
Table 6. m-BCR probes set evaluation 
The table shows in each column: probe set name, tiling frequency (number of baits covering each base), base pairs overlapping 
repeated sequences, number of baits included in the probe set, base pairs covered by baits, length of the targeted sequence., 
% of target covered by the baits. On the top the region name with genomic coordinates. The best probe set is highlighted with 
bold character. 
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µ-BCR region  (chr22: 23,652511-23,660,223) 
 
Test name 
Tiling 
Frequency 
Avoid 
Overlap 
Total Number 
of Baits Info 
Total Bases 
Covered by 
Baits 
Target 
Length 
% Target Base 
Pairs Covered 
BCR_micro_3x_RM_over20 3x 20 182 7430 7713 96.331 
BCR_micro_3x_both_over20 3x 20 182 7430 7713 96.331 
BCR_micro_3x_RM_over40 3x 40 182 7430 7713 96.331 
BCR_micro_3x_both_over40 3x 40 182 7430 7713 96.331 
BCR_micro_5x_RM_over20 5x 20 302 7430 7713 96.331 
BCR_micro_5x_both_over20 5x 20 302 7430 7713 96.331 
BCR_micro_5x_RM_over40 5x 40 302 7430 7713 96.331 
BCR_micro_5x_both_over40 5x 40 302 7430 7713 96.331 
BCR_micro_4x_RM_over20 4x 20 243 7445 7713 96.525 
BCR_micro_4x_RM_over40 4x 40 243 7445 7713 96.525 
BCR_micro_4x_both_over40 4x 40 243 7445 7713 96.525 
BCR_micro_4x_both_over20 4x 20 243 7445 7713 96.525 
 
Table 7. µ-BCR probes sets evaluation 
The table shows in each column: probe set name, tiling frequency (number of baits covering each base), base pairs overlapping 
repeated sequences, number of baits included in the probe set, base pairs covered by baits, length of the targeted sequence., 
% of target covered by the baits. On the top the region name with genomic coordinates. The best probe set is highlighted with 
bold character. 
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ABL1 region (chr9:133577268-133730483) 
 
Test name 
Tiling 
Frequency 
Avoid 
Overlap 
Total 
Number of 
Baits Info 
Baits 
Removed Due 
to Avoid 
Overlap 
Total Bases 
Covered by 
Baits 
Target 
Length 
% Target 
Base Pairs 
Covered 
ABL1_3x_RM_over20 3x 20 1266 553 59328 153216 38.722 
ABL1_5x_RM_over20 5x 20 2051 818 60543 153216 39.515 
ABL1_4x_RM_over20 4x 20 1662 690 60645 153216 39.581 
ABL1_5x_RM_over40 5x 40 2146 712 63687 153216 41.567 
ABL1_4x_RM_over40 4x 40 1749 591 63795 153216 41.637 
ABL1_3x_RM_over40 3x 40 1355 452 64335 153216 41.99 
ABL1_3x_both_over20 3x 20 1748 1173 83582 153216 54.552 
ABL1_5x_both_over20 5x 20 2834 1702 85763 153216 55.975 
ABL1_4x_both_over20 4x 20 2302 1426 85955 153216 56.101 
ABL1_5x_both_over40 5x 40 3239 946 96899 153216 63.243 
ABL1_3x_both_over40 3x 40 2032 635 96980 153216 63.3 
ABL1_4x_both_over40 4x 40 2650 766 97332 153216 63.526 
Table 8. ABL1 probes sets evaluation 
The table shows in each column: probe set name, tiling frequency (number of baits covering each base), base pairs overlapping 
repeated sequences, number of baits included in the probe set, base pairs covered by baits, length of the targeted sequence., 
% of target covered by the baits. On the top the region name with genomic coordinates. The best probe set is highlighted with 
bold character. 
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3.2.3 Sequencing Library preparation 
Genomic DNA (gDNA) of each patient was extracted from peripheral blood 
(PB) or bone marrow specimen (BM) by using standard methods and from 
K562 as well. SureSelect XT Target Enrichment kit (Agilent Technologies, 
Santa Clara, CA, USA) was used for DNA library preparation and capturing 
of the target regions. 
In brief, 4 µg of each gDNA were sheared on Covaris Instrument (Covaris, 
Woburn, MA, USA) and a fragment size distribution ranging from 100 to 
1000 bp was verified on Bioanalyzer 2100 (Agilent Technologies). The DNA 
fragments were end-repaired, ligated to Illumina adapters (Illumina, San 
Diego, CA, USA) and the fragments ranging from 400 bp to 700 bp in 
length were selected on 2% agarose gel. After 10 cycles of PCR, each 
amplified adapter-ligated library was run on Bioanalyzer 2100 for 
quantification. 500 ng of each library was treated with the capture 
biotinylated RNA probes for 24 h at 65°C. The RNA/DNA hybrid target 
regions were then selected onto the streptavidin-coated magnetic beads 
DynabeadsMyOne Streptavidin T1 (Invitrogen Life Technologies, Carlsbad, 
CA, USA). Finally, each targeted DNA library was PCR enriched and during 
this step index tags were also added to each construct. 
Two pools of libraries with different index tags, one with 5 and the other 
with 4 libraries, were setup and each pool was then sequenced in four 
lanes of a flow cell on GAIIx, an illumina platform. Sequencing was 
performed with a paired-end protocol to produce sequences of 114 bp in 
length. 
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3.2.4 Data analysis Pipeline 
BCR-ABL1 breakpoints identification was achieved by setting up an 
automatic bioinformatics pipeline. The rationale was to look for reads pairs 
that did not map with an expected insert size, in particular pairs in which 
one read maps in chromosome 22 (in one of the BCR breakpoint regions), 
and its mate maps in chromosome 9 in ABL1. The bioinformatics pipeline 
includes five core modules [Figure 10]: 
1) Quality control checks on raw reads 
2) Pre-alignment data processing 
3) Reads alignment to the human reference genome (Hg19) 
4) Post-alignment data processing  
5) BCR-ABL1 breakpoints identification 
 
Figure 10. Data Analysis Workflow 
The chart briefly depicts the data analysis workflow adopted in this study. Raw data 
were checked for quality and appropriate procedures were carried out to ensure 
the best quality data to align to human reference genome (hg19). Aligned data 
were than processed to increase the data quality. Finally we performed BCR-ABL1 
fusion point identification using a two-steps procedure: identification of the 
breakpoints regions with discordant pair approach (SVDetect) and refinement to 
single nucleotides breakpoint using split-read approach (ClipCrop + BLAT).   
QC- Raw data 
Pre-alignment 
data 
processing 
Reads 
alignment to 
Hg19 
Post-
alignment 
data 
processing 
BCR-ABL1 
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3.2.4.1 Quality control checks on raw reads 
The quality control was performed with FastQC (v.0.10.0) [93] evaluating 
several metrics such as “per sequence quality score” and “per base 
sequence quality”. The first metric allows detecting subsets of sequences 
that have a low score and the second allows spotting base quality drops 
during sequencing run. More details about these metrics and statistics will 
be discussed in the software section. 
3.2.4.2 Pre-alignment data processing 
Raw data were trimmed using Prinseq [94]. Trimming is a read-cutting 
operation for increasing the quality of the reads that have to be aligned to a 
reference genome. In general, trimming is a data pre-processing practice 
that allows to work on very high quality reads only. In the current project, 
most of the targeted area is characterized by a large amount of repeated 
sequences. In this case, it has been proved that with a high quality set of 
reads the percentage of reads mapped to the reference is increased [95] 
[96]. In our pipeline, a dynamic trimming was setup to ensure both high 
quality and low loss of nucleotides. In particular, the trimming was setup for 
cutting low quality bases from 3’ end using the following parameters: -m 30 
-l 90 –t 20. The t value defines the maximum base quality score for 
trimming nucleotides; the l value is the minimum read length allowed and 
the m value defines the minimum mean base quality over the whole read. 
Filters were applied in this order: t, l and m. The trimming proceeded from 
3’ to 5’ until the next-cutting nucleotide had a quality score greater than 20. 
At this point if the read length was greater than 90, the m value was then 
checked. If both m and l parameters were not satisfied the read was 
discarded. After the pre-processing step a subset of raw reads was 
produced, in which the minimum reads length was 90bp and the minimum 
average base quality was 30. Scores are expressed in Phred format [97], 
which will be discussed later in the software section.  
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3.2.4.3 Reads Alignment and data processing 
The alignment to the reference genome (Hg19) was carried on by using the 
Burrows-Wheeler Aligner (BWA v.0.6.2) [98] with default parameters. The 
choice to use default parameters arise from several tests tuning mainly two 
parameters such as the n, l and k that account for maximum mismatch 
bases allowed, seed length and maximum differences occurring in the seed 
respectively. These tests did not show any improvement in mapping. 
Several tries to align reads using multi-hits aligner like mrFAST [99] to 
Hg19 were also carried on. Results obtained by this latter approach were 
not satisfactory and are not presented here. 
We used as reference sequence the human reference genome (Hg19) 
retrieved by UCSC repository [100].  
Aligned reads were then processed by Genome Analysis Toolkit (GATK) 
[101] in order to ensure high quality mapped reads for breakpoint 
identification. The most used and recommended procedures were applied: 
reads duplicates marking (DM), local realignment around INDELs (LRAI) 
and base quality score recalibration (BQSR) [102]. 
3.2.4.4 Breakpoints identification 
The identification of breakpoints coordinates on Hg19 was carried out in 
two phases. In the first phase we identified the region in which the 
breakpoints occur by using the discordant pair approach, whereas in the 
second phase we refined the breakpoints coordinates through a split-read 
approach. 
3.2.4.4.1 Breakpoints detection 
We used SVDetect [32] for detection and ClipCrop [35] and BLAT [103] for 
refinement. Among the methods developed to identify SV from NGS, 
SVdetect use the discordant pair approach, whereas ClipCrop use the split 
read approach. SVdetect, as described in detail in the software section, is 
able to find structural variations such as translocations, inversions, 
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deletions and small duplications, by using paired-end reads that do dot map 
with concordant/normal insert size. The insert size is the distance between 
the paired-end adapters (forward and reverse). This distance should be 
theoretically equal to the length of the DNA fragments captured by the 
probes. The insert size is the difference between the start coordinates of 
reverse and forward reads. Hence, considering that the library size without 
adapters was ~ 500bp in length [Figure 11] and both adapters used were 
60bp in length, the expected insert size was ~380bp.  
 
 
 
Figure 11. Library size - Bioanalyzer 
The figure shows the distribution of the sequenced fragments’ lengths.  On the X-
axis the length of the fragments (bp) whereas on Y-axis the frequency of fragments 
expressed as fluorescent signal (FU). The peak is at 500 bp. 
 
 
 
The “normal” insert size was calculated as the mean insert size (µ) of 
normally mapped paired-end reads [32]. In order to select a subset of 
paired-end reads, which do not map with a typical range of insert size, a 
sigma threshold (t) parameter is setup. This parameter defines how many 
standard deviations from (µ) can be accepted to consider the insert size as 
normal.  
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Hence, reads which had an insert size outside the interval ( µ - t * < I < µ 
+ t *), were used for SV identification. 
In particular, two different t (it , dt) were set for INDELs and duplication 
detection respectively. More details regarding the computational 
mechanisms, which underlie the SVs identification, will be described in the 
software section.  
 
Sample µ  
K562 348 91 
02 372 82 
03 364 79 
04 340 81 
05 340 85 
06 352 103 
07 349 77 
08 346 84 
09 342 81 
10 330 79 
 
Table 9. Insert size and sigma value 
The table shows the average insert size (µ) and the value  corresponding to a 
single s.d from the normal distribution of the insert size length. 
 
The SVdetect output was primary inspected for inter-chromosomal 
translocations that occur between chromosome 22 and 9. A secondary 
analysis was performed for identifying intra-chromosomal structural variants 
such as deletions, insertions and inversions, but results will not covered in 
this work. Both inter and intra SV detected were filtered by tuning the 
nb_pairs_threshold to a value of 20. The best breakpoints, in terms of 
reads pairs and final score, spotting both BCR-ABL1 and ABL1-BCR fusion 
products were selected for coordinate’s refinement. The parameters set in 
the configuration file are listed in (Table 10). 
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Parameter Value 
Split link file 1 
Strand filtering 1 
Order filtering 1 
Insert size filtering 1 
Nb pairs threshold 20 
Indel sigma threshold 2 
Dup sigma threshold 3 
Final score threshold 0.85 (INTER) / 0.95 (INTRA) 
Mu length (µ) Sample dependent [table CC] 
Sigma length() Is calculated as 1 st.dev from µ 
Window size Suggest value for detecting translocation is 
equal to:     √    
Step length ½ to ¼ of windows size value is the value 
suggested.  
Table 10. SvDetect Parameters. Put description 
The table summarizes the parameters used in SVDetect analysis. From top 
to bottom: first 4
th
 rows set output characteristics and filtering, Nb pairs threshold 
describe the number of discordant pair reads supporting the SV, Indel and Sup 
sigma threshold establish how many s.d consider to use read in indel or dup 
calling. The final score threshold set a score to filter output results,  and  
described in Table 9, window size is the size of the sliding window to cluster PEM 
reads and create links. In the last row the step length that define how to slide 
across windows. 
 
3.2.4.4.2 Breakpoints coordinates refinement  
The breakpoints coordinates refinement was carried out using ClipCrop, a 
tool for detecting structural variations with soft-clipping information. Soft-
clipped sequences are partially unmatched fragments in a mapped read.  
BWA aligner is able to re-map part of a read whose alignment failed in its 
whole length. If the read is mapped partially, the information of the partial 
mapping is stored into SAM format as clipping information [104].  
ClipCrop can calculate the putative breakpoints using the boundary position 
between mapped sequence and the soft-clipped sequence in the clipped 
read. Then it remaps soft-clipped sequences around the detected putative 
breakpoints and infers which type of SV is really occurring in that region. 
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This procedure is natively implemented in ClipCrop by using BWA or 
Shrimp [105] as aligner for the re-mapping phase of clipped portions of 
split-reads.  
In our pipeline instead of using BWA or Shrimp, we used BLAT for the 
remapping of the clipped reads. Details concerning the algorithm 
implemented in ClipCrop will be described in the relative software section.  
BCR-ABL1 breakpoints identified by ClipCrop were filtered out for records 
that did not fall near (± 400bp) the boundaries coordinates of the breakpoint 
region identified by SVDetect. Therefore, the best-refined coordinates for 
each patient breakpoint were selected considering the direction of soft-
clipped sequence in clipped reads. In particular, the coordinates of the 
breakpoints spotted by right-clipped reads in BCR and the coordinates of 
the breakpoints identified by left-clipped reads in ABL1 determined the 
BCR-ABL1 breakpoints, whereas the contrary for ABL1-BCR. More details 
can be found in the related software section. The setup parameters are 
listed in table [Table 11]. 
 
PARAMETER VALUE 
BAM FILE Sample_02.bam 
FASTA FILE Hg19.fasta 
BP FILTER PROCESSES 12 
MAX BREAKPOINT DIFF 2 
MIN BP CLUSTER SIZE 8 
MIN MEAN BASE QUAL 10 
MIN SEQ LENGTH 10 
BASES AROUND BREAK 1000 
MAX SV DIFF 10 
MIN SV CLUSTER SIZE 8 
MAPPER bwa 
MAPPER THREADS 12 
 
Table 11. ClipCrop parameters 
The table shows parameters setup in ClipCrop analysis.  
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3.2.5 Sanger sequencing validation 
Sanger sequencing validation was carried out in outsourcing. 
Chromatograms, received as .abl1 files, were visualized by CromasLite 
[http://technelysium.com.au/] and extracted in FASTA format. FASTA files 
from each patient were then aligned with BLAST [106] and BLAT [103] to 
the reference genome in order to validate the breakpoints coordinates 
identified during the analysis.  
3.2.6 BCR-ABL1 and ABL1-BCR breakpoint analysis 
The description was carried out highlighting: 
 The distance between the breakpoints and the repeated sequences 
in surrounding regions. 
 The localization at gene level (distance to nearest exon) 
 The type of DNA break (inferring) 
 
Moreover, a specific and deeper analysis was performed for sample 7 and 
in order to shed light on the complex rearrangement found in it.  
3.3 Bioinformatics Tools 
3.3.1 Data processing Tools 
The following section will include the description of the software used in 
data processing from raw reads to breakpoints identification.  
3.3.1.1 QC on raw data – FastQC and PrinseQ 
The quality control on raw data produced by GAIIx was performed by 
FastQC. This program outputs a series of metrics and statistics starting 
from sequences files in FASTA (Sanger) or FASTQ (Illumina) format. The 
output can be exported both in text and charts-like format. The metrics and 
statistics produced are: 
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1. Basic Statistics 
2. Per base sequence quality 
3. Per sequence quality scores 
4. Per base sequence content 
5. Per base GC content 
6. Per sequence GC content 
7. Per base N content 
8. Sequence length distribution 
9. Sequence level duplication 
10. Overrepresented sequences 
11. Kmer content 
The most important metrics that describe the quality of the data are the “per 
base sequence quality” and “per sequence quality scores” metrics. The 
former describes how the quality of the base changes during sequencing 
cycles, whereas the latter expresses the distribution of the average base 
quality score along the reads. Base quality score usually decreases while 
proceeding in the sequencing cycles. This is due to the drop of efficiency 
that affect the DNA polymerase during sequencing. The Illumina base 
quality score ranges from 2 to 40 according to Phred score [97]. Phred 
quality scores Q are defined as a property which is logarithmically related to 
the base-calling error probabilities P. Q is equal to: 
 
Q = -10*Log10P , so P = 10 
(-Q/10) 
 
Hence, a quality score of 40 means an error every 10000 base call, so a 
percentage of error of 0.01% or base call accuracy of 99,99%. Following 
this formula, a Phred score of 20 is linked to a base call accuracy of 99%. A 
Phred score of 20 is considered an appropriate cut off value for considering 
a base reliable or not.  
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The “per sequence quality scores” metric allows to view how the “basecall 
goodness” is distributed in the pool of reads produced. A good run shows a 
single peak of frequency around a mean Phred quality score of 36-40. 
Per base sequence content, kmer content and overrepresented sequences 
are good metrics for identifying possible contaminations or the presence of 
sequencing adapters and indexes.  
Other metrics such as the duplication levels and the sequence length 
distribution are strictly associated to the nature of the region sequenced 
and to the experimental (PCR-amplification cycles) and data processing 
procedures, such as the trimming, adopted.  
Trimming was performed by PrinseQ (v0.20.1), a tools for NGS data quality 
control. The program has many features for processing raw data (trimming, 
filtering and reformatting) and generates many statistics. The only 
additional features implemented in PrinseQ compared to fastQC are the 
reads’ complexity analysis and metrics that concern the composition of tag 
sequences and poly-A/T tails. The trimming procedure can be carried on in 
several ways as removing the 3’ or 5’ ends by a fixed number of bases or 
remove entirely a reads that has an average base quality below a fixed 
threshold or remove a percentage of the reads, and so on. The trimming 
procedure implemented in this work has been described in chapter 3.2.4.2. 
3.3.1.2 GATK, Samtools and PicardTools 
The Genome Analysis Toolkit (GATK) is a suite of bioinformatics tools for 
handling and analyzing NGS data. GATK is structured in walkers, single 
computational modules, which can analyze NGS data in several ways., 
Differently by other competitor software, GATK includes different modules 
for the fine processing of mapping data. In particular there are two modules 
exclusively implemented in this suite: the local realignment around indels 
(LRAI) and the base quality score recalibration (BQSR). LRAI is a module 
that realign mapped reads in complex regions in which the mapping could 
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be more difficult for the presence of gaps like small insertion and deletions. 
The BSQR is a procedure that reassign the basecall score taking into 
consideration the genomic context in which the reads map [102]. GATK 
include also two different modules for SNPs and INDELs call: 
GenotypeCaller and HaplotypeCaller. The first one is more driven to 
SNPcall, whereas the second perform better in INDELs call. Details on the 
algorithms beyond such modules are described in [102]. GATK comprises 
also a modules for coverage statistics (DepthOfCoverage) that was used 
for the production of the coverage statistics [101]. 
Samtools [104] has been mainly used for handling mapping files (sorting, 
indexing and file format conversion).  
PicardTools [116] was used for marking of duplicates. This procedure 
consists in the removing of duplicate reads that usually comes when the 
number of PCR cycles is too high. The percentage of duplicates can vary 
depending on the target size and on the library preparation. Theoretically 
smaller is the target region, greater will be the probability to have 
duplicates, because the chance to produce the same fragments during the 
library preparation is higher. 
3.3.2 Ph Breakpoints identification Tools 
The identification of the breakpoints was made using two software: 
SVDetect and ClipCrop. It was decided to use these software for several 
reasons: SVDetect is able to identify a number of events greater than 
GASV [107] and BreakDancer [108] and has the peculiarity to generate 
input files to be used with Circos [109]. ClipCrop compared to competing 
software in the category of split-read methods (Pindel and BreakDancer) 
has proven to be more accurate [35]. Moreover, intermediates files 
produces by ClipCrop were used as input files for custom scripts, for 
instance to align split-reads with BLAT. 
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3.3.2.1 SVDetect 
SVDetect is a bioinformatics tools developed by Zeitouni et al. [32], to 
identify genomic structural variations from paired-ends reads and mate-pair 
from NGS data produced by ILLUMINA and SOLID platforms. SVDetect 
falls into the category of software that rely on discordant-pair based 
methods.  
Compared to similar software like BreakDancer and GASV it can detect 
duplications, discriminate balanced and unbalanced events, support 
multisample SV analysis and last but not least, provide a graphical output 
for SV viewing by using Circos.  
The workflow analysis implemented in SVDetect can be summarize in four 
steps:  
1. anomalous reads selection 
2. creation of links through window-sliding approach 
3. filtering and clustering of putative links 
4. detection of SV type based on links features 
 
The first steps select all paired-end reads that can be potentially support a 
SV event. In particular, paired-end reads, which map with incorrect 
orientation and with a non-typical insert size, are selected.  
At this step the mean insert size of normally mapped paired-end reads (µ) 
and the calculated standard deviation (s.d) value from the distribution of 
normally mapped paired-end reads () are collected.  
The second step is to split the reference genome into overlapping windows 
of fixed size and using a windows-slide approach to identify groups of pairs, 
which shared the same genomic region. If a read, by its ends, can anchor 
two windows, a link between the pair of windows can be formed. Every link 
that connect two genomic fragments (windows size length) is then 
annotated with several features like chromosomal location, number of 
reads pairs that cover these fragment, orientation and order of paired-end 
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reads. Starting from these features, the SVDetect algorithm performs two 
operations: links filtering and clusters call. The links filtering is based on a 
collection of parameters, which can be set by the user. There are both 
boolean and floating parameters. Strand, order and insert size filtering 
parameters are boolean, and can be set 1 or 0 depending on the choice to 
filter or not on strand, order and insert size features. These parameters are 
strictly dependent on µ and  parameters. Among the floating parameters, 
there are the nb_pairs_threshold (npt), the indel_sigma_threshold (ist) and 
the nb_pairs_order_threshold (npot). The first parameter determines the 
minimum number of pairs within the cluster in order to call the cluster itself. 
The second one establishes the number of s.d from sigma for insert size 
filtering and for the INDELs calling (if the mean insert size of the cluster is 
greater than µ + ist *  a deletion is called; whereas if it is lower than µ + ist 
*  an insertion is called). The last parameter sets the minimum number of 
pairs in a subgroup of paired-end reads for balanced events.  
The last step consists in the detection of SV type starting from features of 
paired-ends reads within the clusters. In particular, nine structural variants 
can be detected: deletions [Figure 12], insertions [Figure 13], duplications, 
inversions, duplicated inversions, balanced [Figure 14] and unbalanced 
[Figure 15] translocations and balanced/unbalanced inverted 
translocations. The description of each event by visualization of discordant-
pair mapping is provided inside the figures captions. The sets of features, 
which allow discriminating these events, are summarized in Table 12. 
Translocation events can be intra-chromosomal or inter-chromosomal, if 
the pairs of the paired-end reads maps on the same or on different 
chromosomes respectively. 
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SV type 
Mapping 
chromosome 
Strand 
sense of 
cluster 
Mean insert 
size of 
cluster 
Balancing 
Deletion Same Normal >  (µ + ist* ) - 
Insertion Same Normal <  (µ + ist* ) - 
Inversion Same Reverse - Balanced 
Duplication Same Reverse >  (µ + dst* ) - 
Duplicated 
inversions 
Same Reverse <  (µ + dst* ) - 
Unbalanced 
translocations 
Different Normal  Unbalanced 
Balanced 
translocations 
Different Normal  Balanced 
Unbalanced 
inverted 
translocations 
Different Reverse  Unbalanced 
Balanced inverted 
translocations 
Different Reverse  Balanced 
Table 12. Structural events detectable by SVDetect 
The table shows the structural events detectable by SVDetect including different 
features. The 2
nd
 column describe if the SV is intra or inter chromosomal, the 3
rd
 
one the strand sense of the cluster that identify the event, the 4
th
 one describes the 
mean insert size and the last column shows the balancing of the event. 
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Figure 12. SVDetect deletion event 
The figure shows how paired-end mapping reads (PEMs) are used by SVDetect to 
detect a deletion event. In particular a deletion event is called when the insert size 
distance is greater than (µ +2) and pairs are on normal strand sense. 
 
 
 
 
Figure 13. SVDetect insertion event 
The figure shows how paired-end mapping reads (PEMs) are used by SVDetect to 
detect a deletion event. In particular a deletion event is called when the insert size 
distance is lower than (µ - 2) and pairs are on normal strand sense. 
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Figure 14. SVDetect – Balanced translocation event 
The figure shows how discordant pairs reads map to the genome when SVDetect 
calls a balanced translocation event. In the sample (on the top) the mates of a pairs 
map to different chromosomes, whereas in reference they map with the expected 
(normal) insert size. The translocation is balanced because in sample the genomic 
portions coming from different chromosomes is preserved.  
 
 
Figure 15. SVDetect – Unbalanced translocation event 
The figure shows how discordant pairs reads map to the genome when SVDetect 
calls a balanced translocation event. In the sample (on the top) the mates of a pair 
map to different chromosomes, whereas in reference they map with the expected 
(normal) insert size. The translocation is unbalanced because in sample the 
genomic portions coming from different chromosomes are not preserved. 
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3.3.2.2  ClipCrop 
ClipCrop is a bioinformatics tool that aim to identify SV by using split-read 
approach. ClipCrop uses clipping information to infer the breakpoints 
boundaries that lead to different types of SV. In particular, ClipCrop 
analysis consists in the following steps: 
  
 selection of soft-clipped reads;  
 discard of soft-clipped reads with both ends clipped;  
 listing of breakpoints from clipping information;  
 remapping of soft-clipped fragments with length greater than a 
specific threshold set by user around the breakpoint position 
 SV type inference.  
The selection of clipped reads is based on the analysis of the CIGAR field 
in the SAM mapping format [104]. The CIGAR string describe how the read 
maps to the genome. It contains both numerical and character elements, 
the numbers describe how many times the associated feature (expressed 
by the character) is contiguously detected within the read. The CIGAR 
string contains several character values as shown in Table 13. For instance 
a read with CIGAR 22S50M2I30M is a read that is clipped at the left-side 
for 22 nucleotides, it then match the reference sequence for 50 nucleotides, 
then it has an insertion of 2 bases and ends with a perfect match of 30 bp. 
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Symbol Description 
M alignment match (can be a sequence match or mismatch) 
I insertion to the reference 
D deletion from the reference 
N skipped region from the reference 
S soft clipping (clipped sequences present in SEQ) 
H hard clipping (clipped sequences NOT present in SEQ) 
Table 13. Cigar field 
The table describes values included and described in CIGAR field. On the left 
column the tag included in the CIGAR field in SAM files whereas on the right the 
description of each tag. 
 
ClipCrop selects all reads that contains the soft-clipped information (S) and 
discards the ones that contain soft-clipped portions at both sides (ends). 
These reads are not informative because is not possible to infer the 
directionality of the event they can lead to. Hence, starting from these reads 
as input, a list of breakpoints is created. The breakpoint is denoted as the 
marginal point between the clipped portion and the matched portion of the 
soft-clipped read. When the left-side of the read is clipped the breakpoint is 
designated as L-breakpoint, instead R-breakpoint when the clipped portion 
is on the right side. Once breakpoints are identified, they are sorted and 
clustered within 5-base differences. Hence, soft-clipped fragments with a 
length greater than 10bp are remapped by using BWA aligner (default) or 
Shrimp to a portion of genome flanking 1000bp (default) at both sides of 
each breakpoint in order to reduce the probability of wrong mapping and so 
minimize the a-specific mapping to other regions. This step is particularly 
important when the breakpoint falls near repeated sequences. Once 
remapped, ClipCrop infers the type of SV taking into consideration the re-
mapping pattern of clipped portion of split-reads. When the clipped portion 
of an L-breakpoint maps to the left side of an R-breakpoint and vice versa, 
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it denotes a deletion event  [Figure 16]. When the clipped portion of an L-
breakpoint maps reversely to the left side of an R-breakpoint and vice 
versa, it denotes an inversion event [Figure 17]. In insertions and 
translocations, an L-breakpoint and an R-breakpoint are in the same 
position. If the clipped portion of the reads remaps to the reference 
genome, it denotes translocation [Figure 18], otherwise it indicates an 
insertion event.  
 
 
Figure 16. ClipCrop: Deletion event 
The figure depicts how split-reads will map when a deletion event occur in a 
sample. On the left, light-blue reads mapping to the reference genome. Clipped 
portions (L and R) are then remapped (pink remapped reads). On the right the 
same concept using donor and reference regions. 
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Figure 17. ClipCrop: Inversion event 
The figure depicts how split-reads will map when an inversion event occur. On the 
left, light-blue split reads mapping to the reference genome. Clipped portions (L 
and R) are then reversely remapped (pink remapped reads). On the right the same 
concept using donor and reference regions. 
 
 
 
 
Figure 18. ClipCrop: Insertion – Translocation event 
The figure depicts how split-reads can spot insertion and translocation events. On 
the left, light-blue split reads mapping to the reference genome. Clipped portions (L 
and R) can unmap (insertion) or map to another chromosome (translocation). On 
the right the same concept using donor and reference regions. 
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4. RESULTS 
The results section will be divided in three parts: the first will be focused on 
the description of the target sequencing experiment; the second will deal 
with BCR-ABL1 breakpoints identification along with the analysis of regions 
surrounding the breakpoints and the final part will be dedicated to the 
sample-specific examination of BCR-ABL1 and ABL1-BCR breakpoints. 
The analyses, from raw data to breakpoints identification, has been 
performed for each sample in two different ways. Firstly, we identify the 
breakpoints by using four independent set of reads belonging to each lane, 
and secondly we performed the analysis merging the reads of different 
lanes (belonging to the same sample) and removing duplicate reads.  
4.1 BCR-ABL1 target sequencing 
The BCR-ABL1 oncogene target sequencing was performed in two stages. 
First, we assessed its feasibility with the inclusion in the experiment of 
known BCR-ABL1 breakpoints in 2 patients and 1 cell line; the second 
effort was made to reproduce the experiment in patients with unknown 
breakpoints. The following paragraphs will deal with the results obtained by 
quality control procedures and with all metrics and statistics concerning the 
capturing performance of the targeted regions.  
4.1.1 Raw data and QC 
Total raw reads yield per lane ranged from 11.182.874 (sample 03a) to 
15.043.842 (sample 09b). Raw reads were subjected to quality control 
using fastQC. Reports showed a base quality drop in the 3’-tail of both 
forward and reverse pair sequences [Figure 19]. In order to achieve reads 
of better quality, dynamic trimming with Prinseq was performed on both 
forward and reverse fastq files for each sample. Trimming parameters were 
setup in order to filter out reads with a mean quality score below 30 and 
length below 90 by trimming bases with quality lower than 15 at 3’ tail. As 
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shown in Figure 19 the trimming allows reaching a very good quality over 
all cycles. About 15% of raw reads were filtered by trimming [Table 14]. The 
procedure discarded more reverse reads than forward ones. This due to 
the worst quality of reverse run compared to the forward one. This behavior 
is common and it is mainly related to loss of enzymatic efficiency with the 
proceeding of the sequencing run. Until the 40th cycle, boxplots build on raw 
and trimmed data look very similar; the difference become impressive from 
80th nucleotide. This operation was applied at lane level for all samples. The 
assessment of data quality was also focused on the evaluation of additional 
metrics such as % of duplicates reads, overrepresented sequences, 
nucleotides distribution across reads and, finally, on the GC content across 
the whole length of each sequence. These metrics resulted appropriate for 
all samples [data not shown]. 
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Figure 19. Quality scores across cycles 
The boxplot shows the base quality distribution across the read length or 
sequencing cycles. On the x-axis the position in the read corresponding to the n
th
 
cycle. The y-axis on the graph shows the quality scores in phred scale. The higher 
the score the better the base call. The background of the graph divides the y axis 
into very good quality calls (green), calls of reasonable quality (orange), and calls 
of poor quality (red). The top of the yellow bar identify the 75
th
 quartile, whereas the 
bottom the 25
th
. In red the median, in blue the average. A) Raw reads. B) Trimmed 
reads.  
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ID Forward Reverse Raw Sum 
Forward 
trimmed 
Reverse 
trimmed 
Sum trimmed 
% post 
QC 
01a 6298984 6298984 12597968 5582294 5405213 10987507 87.22 
01b 6245678 6245678 12491356 5424569 5131898 10556467 84.51 
01c 6272058 6272058 12544116 5445172 5141276 10586448 84.39 
01d 6215971 6215971 12431942 5406444 5100260 10506704 84.51 
02a 6873272 6873272 13746544 6090082 5880683 11970765 87.08 
02b 6813484 6813484 13626968 5928364 5589577 11517941 84.52 
02c 6845934 6845934 13691868 5956084 5602601 11558685 84.42 
02d 6787296 6787296 13574592 5913891 5552674 11466565 84.47 
03a 5591437 5591437 11182874 4846211 4616106 9462317 84.61 
03b 5915061 5915061 11830122 5097600 4906853 10004453 84.57 
03c 5746450 5746450 11492900 5022928 4786576 9809504 85.35 
03d 5682093 5682093 11364186 4918338 4715153 9633491 84.77 
04a 6510983 6510983 13021966 5676865 5460383 11137248 85.53 
04b 6893835 6893835 13787670 5982786 5809473 11792259 85.53 
04c 6690856 6690856 13381712 5878924 5657736 11536660 86.21 
04d 6605158 6605158 13210316 5750975 5567247 11318222 85.68 
05a 6714394 6714394 13428788 5815957 5628058 11444015 85.22 
05b 7125113 7125113 14250226 6139873 5999514 12139387 85.19 
05c 6914936 6914936 13829872 6038700 5842232 11880932 85.91 
05d 6827293 6827293 13654586 5906003 5752984 11658987 85.39 
06a 6451019 6451019 12902038 5604187 5494971 11099158 86.03 
06b 6403522 6403522 12807044 5451617 5247123 10698740 83.54 
06c 6431008 6431008 12862016 5480468 5258877 10739345 83.50 
06d 6375667 6375667 12751334 5434635 5223633 10658268 83.59 
07a 6680855 6680855 13361710 5971620 5821508 11793128 88.26 
07b 6639650 6639650 13279300 5835840 5565893 11401733 85.86 
07c 6665204 6665204 13330408 5856595 5574653 11431248 85.75 
07d 6625632 6625632 13251264 5829918 5540070 11369988 85.80 
08a 6457976 6457976 12915952 5704888 5563177 11268065 87.24 
08b 6418113 6418113 12836226 5554926 5294073 10848999 84.52 
08c 6441913 6441913 12883826 5577178 5299877 10877055 84.42 
08d 6388912 6388912 12777824 5538572 5257775 10796347 84.49 
09a 7091128 7091128 14182256 6160652 5948520 12109172 85.38 
09b 7521921 7521921 15043842 6506909 6344707 12851616 85.43 
09c 7288332 7288332 14576664 6383166 6166581 12549747 86.09 
09d 7194879 7194879 14389758 6241464 6071898 12313362 85.57 
10a 6817322 6817322 13634644 5896515 5698274 11594789 85.04 
10b 7222619 7222619 14445238 6222264 6072113 12294377 85.11 
10c 7005020 7005020 14010040 6112097 5909014 12021111 85.80 
10d 6925311 6925311 13850622 5987301 5825735 11813036 85.29 
Table 14. Reads coverage 
In the table, the number of raw and trimmed reads for all samples in single lanes, 
including forward, reverse and their sum. In last column the % of reads that are 
available for mapping after trimming operation.  
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4.1.2 Reads alignment 
The alignment has been performed on all samples in each lane separately. 
Mapped data were than submitted to data processing in GATK for ensure 
the best quality possible. All lanes that belonged to the same sample were 
merged together in a single file. The percentage of mapped reads ranged 
from 93.93% to 97.95%. The mapping percentage is very similar among 
samples, and no marked differences arise comparing the performance of 
cell line and patients samples. The percentage of reads duplicates is 
comprised from 10.32 to 17.66 with a mean of 14.74 [Table 15]. Taking into 
consideration the size of targeted sequence (< 500Kb), the observed value 
is coherent with the expected value.  
 
Sample Total Mapped Duplicates % mapping % duplicates 
1 – K562 42637126 41763473 5961218 97.95 14.27 
2 46513956 45401025 6444009 97.61 14.19 
3 38909765 37660181 6235252 96.79 16.56 
4 45784389 44297334 6386250 96.75 14.42 
5 47123321 45904750 6275431 97.41 13.67 
6 43195511 40575236 7164256 93.93 17.66 
7 45996097 44857207 7125263 97.52 15.88 
8 43790466 42565090 6534884 97.2 15.35 
9 49823897 47932582 4947932 96.2 10.32 
10 47723313 46007733 6956108 96.41 15.12 
 
Table 15. Mapping Statistics 
Starting from left to right column: samples, total and mapped reads, number of 
duplicate reads, percentage of mapped and duplicated reads. 
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4.1.3 Capturing performance and target enrichment 
The performance of the target enrichment experiment and the coverage 
distribution have been assessed both at lane and sample level, for each 
region separately. The target regions boundaries and features are 
summarized in Table 16.  
Samples were multiplexed, pooled into two pools and loaded in 4 lanes. By 
using DepthOfCoverage module in GATK we assessed the mean coverage 
and the percentage of target capturing at a specific coverage depth. Mean 
coverage indicate the average number of reads covering each single base 
within the target. Higher is the coverage, higher will be the chance to detect 
SV, INDELs and SNV, along with a higher reliability of the detection itself. 
The average mean coverage reached at lane level across patient samples 
(from 2 to 10) was higher in BCR-major region (152.24 ± 21.92), similar for 
micro and minor region (130.94 ± 14.54; 133.96 ± 13.65) and lower in ABL1 
(101.59 ± 12.50). The same trend was observed at sample level Table 16. 
The mean coverage at sample level does not correspond to the value at 
lane level multiplied for a factor of four because, once lanes are merged, 
the duplicates were removed. 
Region 
Average Mean Coverage 
(Lane level) 
Std.dev 
Average Mean Coverage 
(Sample Level) 
Std.dev 
Abl1 101.59 12.50 319.61 58.32 
M-BCR 152.24 21.92 486.16 79.99 
m-BCR 130.94 14.54 435.47 56.00 
-BCR 133.96 13.65 415.62 64.14 
Table 16. Mean coverage in target regions 
In rows the four targeted regions, in columns the average of mean coverage across 
patients samples, both at lane level (2
nd
 column) and at sample level with merged 
lanes (4
th
 column). In 3
rd
 and 5
th
 column the corresponding standard deviation for 
2
nd
 and 4
th
 column respectively. 
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Differently by patient samples, K562 cell line are covered by 2474.28 reads 
in ABL1, 3081.03, 1191.95 and 373.68 reads in m-BCR, M-BCR and µ-
BCR region respectively [Data not shown]. The K562 cell line has been 
covered  7.75, 7, 2.45 and 0.9 times more than the sample average in 
ABL1, m-BCR, M-BCR and µ-BCR region respectively. The percentage of 
capturing, at X coverage, is expressed as the percentage of the targeted 
region that is covered by at least X reads. Higher is the percentage, greater 
will be the uniformity of coverage at a given threshold of read depth. 
The percentage has been calculated at four different thresholds, 1, 20, 50 
and 100X, for each target region. In Table 17 and Table 27, Table 28, 
Table 29 and Table 30, the percentages of enrichment both at sample and 
lane level for each target region are shown. At sample level, data capturing 
at 1X show that ABL1 and m-BCR are not completely captured by the 
probes, whereas major and micro BCR target regions do not have 
uncovered portions Table 17. Contrariwise, the data related to the capturing 
at 100X reveal that BCR major and micro regions are almost completely 
covered (except for patient 10 with a 92% of capturing). These results are 
modeled both on the regions’ length and on the percentage of repeated 
sequences included in the region. Indeed BCR-minor and ABL1 show a 
higher percentage compare to µ-BCR and M-BCR as well as a bigger size. 
The presence of many repeated regions affects the accuracy of mapping 
increasing the unspecific mapping through all the genome. Taking into 
consideration that ABL1 and m-BCR region account for 93% of the whole 
target size, the unspecific mapping is an issue that concern the whole 
experiment.  
The mean on-target mapping percentage at lane level is around 2.5%. This 
means that 97.5% of reads map over the entire genome. This phenomenon 
is attributable to the small size of the target region along with the extreme 
high percentage of repeated sequences. In K562 cell line, this value is 
around 18.5 % (data not shown). 
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Table 17. Sample-level % of capturing at X coverage 
In the sub-tables, the percentage of capturing of the different regions at 1X, 50X 
and 100X coverage. 
 
The analysis at lane level shows an overall decrease of the percentage of 
capturing at 50 and 100X for all patients and regions, except for M-BCR 
where the capturing at 50X is near 100% in all samples [Figure 21]. The 
lane level capturing at 100X is much lower compared the one obtained at 
sample level, especially in ABL1 region and in the lanes belonging to 
sample 5 and 6 [Figure 20]. This data demonstrated that is not possible 
reaching a good percentage of capturing at high coverage in all regions 
using a single lane. However, considering the theoretical percentage of 
capturing calculated during probe design, the targeting efficiency is very 
77 
good. Indeed, taking as reference the percentage of capturing at 50X, the 
experimental capturing is more than the theoretical one, passing from 63% 
to 91% for ABL1, from 93% to 100% for M-BCR, from 74% to 92% and 
from 96% to 100% for µ-BCR. This phenomenon can be explained by the 
fact that probes designed in portions of repeated regions (20-40 
nucleotides overlapping) can capture nonspecific regions and this can lead 
to decrease of capturing percentage. 
 
 
Figure 20. ABL1 region capturing 
On the x-axis, the samples divided in lanes. On y-axis the percentage of capturing 
of the ABL1 region at different depth of coverage: blue=1x, orange=20x, grey=50x 
and yellow=100x.This chart has been produce from data in Table 27.  
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Figure 21. M-BCR region capturing 
On the x-axis, the samples divided in lanes. On y-axis the percentage of capturing 
of the M-BCR region at different depth of coverage: blue=1x, orange=20x, grey = 
50x and yellow=100x.This chart has been produce from data in Table 28. 
 
 
Figure 22. Micro-BCR region capturing 
On the x-axis, the samples divided in lanes. On y-axis the percentage of capturing 
of the ABL1 region at different depth of coverage: blue = 1x, orange = 20x, grey = 
50x and yellow = 100x.This chart has been produce from data in Table 30. 
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Figure 23. m-BCR region capturing 
On the x-axis, the samples divided in lanes. On y-axis the percentage of capturing 
of the ABL1 region at different depth of coverage: blue = 1x, orange = 20x, grey = 
50x and yellow = 100x.This chart has been produce from data in Table 29. 
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4.2 BCR-ABL1 breakpoints identification  
In this chapter will be discussed the results of the identification of 
breakpoints that lead to the formation of BCR-ABL1 fusion oncogene. 
Results obtained by discordant pair approach and split-reads approach will 
be discussed separately. Afterwards results obtained by Sanger validation 
will be presented. Moreover, a comparison of breakpoint identification 
performance among the different methods will be discussed. Finally, a 
patient-specific analysis will be conducted in order to highlight genomic 
features and complexity of the breakpoint regions. The description will 
include all samples analyzed. 
4.2.1 Breakpoints detection with SVDetect 
The detection of breakpoints was performed with SVDetect by using a 
discordant-pair approach. In Table 19 are described all breakpoints that 
identify the BCR-ABL1 oncogene and the ABL1-BCR reciprocal fusion 
product, if present.  
In all samples two breakpoint coordinates, both in BCR and ABL1 regions, 
were detected, except for the K562 cell line and samples 2,7,8,9 Table 19. 
We have tagged the breakpoint that support the BCR-ABL1 fusion as BP1 
(mapped to BCR) and BP4 (mapped to ABL1) whereas BP2 (located at 
BCR) and BP3 (mapped to ABL1) support the ABL1-BCR fusion. 
Coordinates that define the fusion of BCR with ABL1 to form the BCR-ABL1 
oncogene were identified by discordant pairs in which the forward read 
mapped in BCR identifying BP1 whereas its reverse mate mapped in ABL1 
identifying the BP4. On the contrary, discordant pairs in which the forward 
read mapped to ABL1, defining the BP3, and its reverse mate mapped in 
BCR, spotting the BP2, detected the ABL1-BCR fusion segment. BP1 and 
BP4 were identified in all patients except for patient 8, whereas BP2 and 
BP3 were detected in six patient samples (3, 4, 5, 6, 8 and 10). By the 
analysis of SVDetect top results, BCR-ABL1 fusion gene seems to be 
81 
formed by the t(9;22) translocation in all samples, except for samples 4 and 
5 whose BP1 breakpoints fall in m-BCR and µ-BCR region respectively. In 
these two samples seemed that BCR-ABL1 fusion arise from the insertion 
of a fragment of BCR into gene ABL1 without Ph formation. However, the 
refinement analysis with ClipCrop have shown that in both samples the 
break of chromosome 9 and 22 was blunt-like with a partial insertion of few 
bases at the junction point both in Ph and der (9). A deeper analysis of 
such breakpoints will be performed in the next sample specific analysis.  
In patient 7 and 9 inverted translocations concerning ABL1-BCR fusion 
were detected. In particular, in patient 7 the region downstream to the ABL1 
breakpoint of the BCR-ABL1 fusion segment was found to be involved in an 
inverted translocation with a sequence located at the following genomic 
interval chr9: 36900847-36901054 mapping to the FOXRED2 gene. Patient 
9 showed an inverted translocation detected by discordant pair reads 
mapping in a region near telomere (chr9:136985521-136985696) and 
upstream (14 bp) to BP1. These findings will be described in detail in the 
sample specific analysis.  
The number of pair-end reads that support the BCR-ABL1 breakpoints was 
variable, ranging from 38 to 348 with a mean of 174.25 ± 95.83. At first 
glance, the distribution of supporting reads across samples seems to 
correlate with the overall number of mapped reads, but this phenomenon 
could be associated to the concentration of Ph+ cells and hence by the 
clinical phase of CML. Although all specimen analyzed were taken at the 
disease onset, no info were available to determine the disease progression 
of each sample. Otherwise, this phenomenon could be explained simply by 
the chance to capture a less number of Ph+ cells from the DNA aliquot used 
in analyses. 
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4.2.2 IGV analysis 
In order to confirm the breakpoints coordinates identified in SVDetect, a 
simple quality control was performed using the Integrative Genome 
Browser (IGV). The confirmation of BCR-ABL1 breakpoints was carried on 
looking for paired-end reads in which the forward read map in 5’ to 3’ 
direction BCR and the reverse read mapped in the opposite direction in the 
ABL1 gene. On the contrary, ABL1-BCR fusion points were visually 
inspected by looking for paired-end reads in which the forward read 
mapped in ABL1 with 5’ to 3’ direction and its reverse pair mapped in the 
opposite direction to the BCR region. In IGV, reads whose mate pair maps 
to another chromosome are painted with different colors according to the 
specific chromosome. In particular, reads whose mate maps to the 
chromosome 9 are “fluorescent green”, whereas reads whose mate pair 
maps to the chromosome 22 are “dark grey” [Figure 24]. The visual check 
for the breakpoints coordinates that lead to the formation of BCR-ABL1 are 
summarized in Table 18. 
 
Sample chr9 (ABL) chr22 (BCR) 
K562 133607140 23632762 
2 133648882 23631930 
3 133593828 23632124 
4 133590571 23575268 
5 133708492 23654742 
6 133658098 23634051 
7 133684300 23634602 
8 ----------- ------------ 
9 133663988 23631897 
10 133696999 23634590 
Table 18. IGV visual check 
BP1 and BP4 coordinates identified by visual checking in IGV.   
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Figure 24. BCR-ABL1 breakpoints identified by paired-end reads 
Reads pointed with green arrow represent reads (light green) in forward orientation (5’ to 3’), located in BCR gene, which have a 
mate pair (dark grey) in reverse orientation (3’ to 5’) in ABL1 gene. Light grey reads identify reads, which do not have a mate 
pair that map in other chromosome or to a distance that is different from the expected insert size. Reads of other colors identify 
the ones which have a mate pair that map in other chromosome different from 22 and 9 (each different chromosome has its own 
color). 
BCR 
ABL1 
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Sample Chr 
type 
SV type BAL type N pairs Breakpoint chr9 start-end Breakpoint chr22 start-end 
K562 INTER Transloc UNBAL 1059 133606963-133607140 23632762-23632844 
2 INTER Transloc UNBAL 146 133648580-133648884 23631930-23632065 
3 INTER Transloc UNBAL 38 133593517-133593826 23632124-23632341 
 INTER Transloc UNBAL 32 133593826-133594081 23633315-23633550 
4 INTER Ins_fragmt BAL 348 133590346-133590561 
133590582-133590771 
23575268-23575206 
 INTER Ins_fragmt BAL 338 133590346-133590561 
133590576-133590771 
23575268-23575206 
5 INTER Ins_fragmt BAL 91 133708269-133708492 
133708509-133708819 
23654742-23654774 
 INTER Ins_fragmt BAL 86 133708269-133708492 
133708502-133708819 
23654742-23654774 
6 INTER Transloc UNBAL 227 133657760-133658098 23634051-23634167 
 INTER Transloc UNBAL 42 133658314-133658578 23634263-23634637 
7 INTER Transloc UNBAL 213 133684073-133684300 23634602-23634800 
 INTER Inv_transloc UNBAL 185 133684252-133684469 36900847-36901054 
8 INTER Transloc UNBAL 41 133694955-133695297 23632677-23632905 
9 INTER Transloc UNBAL 132 133663848-133663988 23631897-23631966 
 INTER Inv_transloc UNBAL 114 136985521-136985696 23631690-23631884 
10 INTER Transloc BAL 204 133696783-133696999 23634590-23634635 
 INTER Transloc BAL 98 133696783-133696999 23634590-23634658 
Table 19. SVDetect breakpoints detection 
The table shows the top SV supported by PE reads in which one read maps to BCR and its mate maps to ABL1. The column 
describe if the SV is Inter / Intra chromosomal,  the type of SV (translocation, inverted translocation, insertion fragment), the 
balancing, the number of pairs supporting the SV call, and the breakpoints coordinates at chr9 and chr22. The start coordinates 
and the end coordinates describe the most 5’ and 3’ coordinates of the reads included in the group of reads that support the 
breakpoint. In red BP1 and BP4 whereas in green BP2 and BP3. 
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4.2.3 Breakpoints refinement with ClipCrop 
As previously explained in section 3.2.4.4.2, ClipCrop was used to refine 
the breakpoints coordinates identified by SVDetect. From now to onwards 
we will refer to ClipCrop refinement including the re-mapping procedure 
using the aligner BLAT. The results are listed in [Table 20] and [Table 21]. 
All breakpoints identified by SVDetect were refined by ClipCrop according 
to the clipping orientation of splitted reads. The refinement was achieved by 
setting the parameter “min sv cluster size” equal to 8, that allowed to spot 
all breakpoints identified by SVDetect. By setting the “min sv cluster size” to 
20 it lead to a failure in the detection of BP4 in samples 3, BP3 in sample 5 
and 8 and BP2 in sample 10. The consistency of cut-orientation with 
breakpoints coordinates discovered by SVDetect was perfect. As expected, 
the breakpoints that lead to the formation of BCR-ABL1 fusion gene are 
identified by R-breakpoints in BCR and L-breakpoints in ABL1 Table 20, 
whereas the breakpoints that give rise to ABL1-BCR counterpart are 
spotted by R-breakpoints in ABL1 and L-breakpoints in BCR Table 21. 
According to SVDetect, BP1 and BP4  were found in all patients except for 
patient 8.  
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Patient Chromosome Start End Cut-orientation Reads 
2 22 23631911 23631912 R 91 
2 9 133648890 133648891 L 41 
3 22 23632128 23632129 R 51 
3 9 133593827 133593828 L 13 
4 22 23575251 23575252 R 168 
4 9 133590570 133590571 L 155 
5 22 23654765 23654766 R 202 
5 9 133708495 133708496 L 150 
6 22 23634033 23634034 R 180 
6 9 133658107 133658108 L 23 
7 22 23634578 23634579 R 177 
7 9 133684306 133684307 L 166 
9 22 23631875 23631876 R 143 
9 9 133663994 133663995 L 195 
10 22 23634573 23634574 R 111 
10 9 133697000 133697001 L 8 
 
Table 20. ClipCrop: BCR-ABL1 fusion points 
The table lists BP1 and BP4 identified by ClipCrop according to clipped direction in 
the 400bp surrounding the BPs coordinates identified by SVDetect. The last 
column shows the number of splitted reads supporting the breakpoint. 
 
Patient Chromosome Start End Cut-orientation Reads 
3 22 23633556 23633557 L 163 
3 9 133593804 133593805 R 35 
4 22 23575206 23575207 L 82 
4 9 133590569 133590570 R 76 
5 22 23654766 23654767 L 58 
5 9 133708499 133708500 R 10 
6 22 23634639 23634640 L 53 
6 9 133658310 133658311 R 53 
8 22 23632908 23632909 L 37 
8 9 133694989 133694990 R 13 
10 22 23634640 23634641 L 100 
10 9 133696780 133696781 R 32 
Table 21. ClipCrop: ABL1-BCR fusion points 
The table lists BP2 and BP3 identified by ClipCrop according to clipped direction in 
the 400bp surrounding the BPs coordinates identified by SVDetect. The last 
column shows the number of splitted reads supporting the breakpoint. 
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4.2.4 Breakpoints validation with Sanger Sequencing 
This chapter will deal with the results obtained from the analysis of 
chromatograms obtained by the validation of the breakpoints using Sanger 
method. In particular, an illustrative analysis of chromatograms and their 
relative nucleotide sequence will be conducted on sample 6.  
4.2.4.1 Chromatogram Analysis 
The validation of BCR-ABL1 breakpoints coordinates was performed using 
Sanger sequencing as alternative sequencing method. All the 
chromatograms were visually inspected with Chromas [Figure 25] and 
associated FASTA sequences were extracted. For each sample two 
chromatograms were provided, one for the forward primer (FW) and one for 
the reverse primer (RV). The visual inspection was performed manually in 
order to ensure the reliability of the findings. Once FASTA sequences were 
obtained, Blat and Blast alignment were performed for all files. FASTA 
sequences obtained with FW and RV [Figure 26] were aligned to human 
genome with BLAT and BLAST using as reference the GRCh37p13 
Primary Assembly. The sequenced fragments obtained by Sanger method 
had different length depending on the primers position. For instance, in 
sample 6, the sequence obtained by FW was 795bp long whereas the 
fragment got by RV was 802bp in length.  
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Figure 25. Illustrative chromatogram from Sanger sequencing 
Below, peaks color represent different nucleotides: C(Blue), G(Black), A(Green), 
T(Red). On the top, the position along the sequenced fragment and the signal 
intensity related to each base position. Higher are the peaks, higher is the signal 
intensity and higher the reliability of the basecall at that position. 
 
 
Figure 26. Sanger FASTA sequence (Patient 6) 
FASTA sequences obtained from chromatograms of fusion fragments obtained 
using forward (top) and reverse (bottom) primers.  
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4.2.4.2  BLAT and BLAST alignments 
The BLAT alignment showed that both segments (obtained by FW and RV) 
spanned the BCR-ABL1 breakpoint. Indeed, by using the FW primer 
designed at the 5’ of the BCR breakpoint, the fragment aligned to BCR from 
the 27th nucleotides to the 133th nucleotides (23633922-23634033) with a 
100% of identity whereas it aligned to ABL1 from the 124th nucleotides to 
the 895th (133658102-133658868) with an identity of 98.1%. By using the 
RV primer designed at the 3’ of the ABL1 breakpoint, the fragment aligned 
from the 24th nucleotides to the 750th nucleotides to ABL1 (133658102-
133658827) with a 99.1% of identity whereas it aligned to BCR from the 
741th nucleotides to the 890th with an identity of 98.7% [Figure 27]. The 
mapping coordinates are consistent among each other’s, indeed, the 
breakpoint coordinate of BCR-ABL1 fusion gene are the same using both 
FW and RV primers to BCR-ABL1 amplicon. Hence, the breakpoint 
coordinates for BCR-ABL1 are 23634033 on chromosome 22 and 
133658102 on chromosome 9. Moreover, it emerged that at the junction 
point BCR and ABL1 share 9 nucleotides (CTGCCTGGC). The same 
findings, including breakpoints coordinates and shared nucleotides were 
verified by using BLAST alignment [Figure 28]. In Figure 29 and Figure 30 
the BLAST alignments of BCR and ABL1 portions of the fusion segment 
obtained by FW are showed. The matching is not perfect, due to the 
presence of insertions/deletions as well as SNVs. For instance, the BCR 
portion has a 100% of matching in BLAT and 95% in BLAST report. This 
behavior is due to the presence of 5 gaps that are deal by two aligners in 
different way. Regarding the ABL1 portion the identity in BLAST report is 
98% due to the presence of 9 gaps including 7 deletions and 2 insertions 
both of 1bp and 5 SNVs.  
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Figure 27. BLAT on fusion segment obtained by FW and RV primers 
The figure shows the BLAT alignment report. In the 4
th
 and 5
th
 column the start and 
end positions of segments that maps at start (10
th
column) and end (11
th
 column) 
coordinates on Hg19. In the 6
th
 column the query size that is the length of the 
Sanger sequenced segment. The 7
th
 column describe the percentage of identity 
without considering gaps. In the 8
th
 and 9
th
 column the chromosome and the strand 
(+/-). The last column describe how many bases of the query sequence span and 
match the Hg19 reference genome. 
 
 
Figure 28. Blast overview: BCR-ABL1 fusion 
In red the ABL1 portion, whereas in violet the BCR portion. Note the overlapping 
near the junction point. 
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Figure 29. BLAST alignment: BCR portion 
The figure shows the alignment report regarding the BCR portion of the BCR-ABL1 
fusion segment. The range of the alignment on the NCBI reference genome 
(GRCh37.p13) is 23633918-23634033 (chr22). The identity is 110 out of 116 bp 
(95%), all unmatched bases are due to deletions in the query sequence. 
 
Figure 30. BLAST alignment: ABL1 portion 
The figure depicts the alignment report regarding the ABL1 portion of the BCR-
ABL1 fusion segment. The range of the alignment on the NCBI reference genome 
(GRCh37.p13) is 133658102-133658868 (chr9). The identity is 761 out of 774 bp 
(98%). The thirteen unmatched bases include 7 deletions, 2 insertions and 5 SNVs 
in the query sequence. 
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This illustrative procedure was performed for all samples. After the 
chromatograms checking and the alignment of the BCR-ABL1 fusion 
segments the following breakpoints coordinates were defined [Table 22]. 
The Sanger validation was not performed for ABL1-BCR breakpoints.  
Sample Breakpoint (Chr22) Breakpoint (Chr9) 
2 23631911 133648891 
3 23632128 133593828 
4 23575248 133590571 
5 23654765 133708496 
6 23634033 133658102 
7 23634578 133684310 
8* 23633411 133694917 
9 23631875 133663995 
10 23634573 133697001 
Table 22. Sanger BCR-ABL1 breakpoints 
In this table the breakpoints coordinates (BP1 and BP4) identified by the analysis 
of BCR-ABL1 fusion segments obtained by Sanger sequencing.* Sample 8 
coordinates were not detected starting from NGS data results, but from PCR based 
techniques. 
 
4.2.4.3  BCR-ABL1 fusion point analysis 
The analysis of BCR-ABL1 fusion segments obtained by Sanger 
sequencing have shown that at the junction point the BCR and ABL1 
segments share several nucleotides (micro homologies), as recently 
demonstrated in [110], [81] and [21].The length of the homology ranged 
from 1bp to 9bp. Moreover, insertion events were detected in 2 samples (3 
and 7). In particular, in sample 7 we validated the insertion of 33bp 
detected in the NGS data analysis. More details regarding this insertion will 
be covered in the chapter dedicated to the 7th sample. In patient 5 and 10 
neither overlapping events nor insertions were detected as expected by the 
results obtained in the NGS data analysis.  
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Sample Event Size 
2 Micro-homology 1bp (G) 
3 Insertion 2bp (CC) 
4 Micro-homology 3bp (TGC) 
5 None none 
6 Micro-homology 9bp (CTGCCTGGC) 
7 Insertion 34bp 
9 Micro-homology 1bp (A) 
10 None none 
Table 23. Arrangements at BCR-ABL1 fusion point 
The table shows the rearrangements that occur at BCR-ABL1 junction. The 
analysis has been performed starting from fusion sequences obtained by Sanger 
sequencing. 
 
 
4.2.5 Breakpoints coordinates comparison 
The breakpoints coordinates were then compared to those discovered with 
SVdetect and ClipCrop software. No comparison was made for breakpoints 
in ABL1-BCR fusion segment because Sanger validation was driven to spot 
BCR-ABL1 breakpoints only. The difference between coordinates predicted 
by software and those validated with Sanger sequencing resulted in few 
bases [Table 24] and [Table 25].  
Discordant-pair approach using SVDetect permitted to spot BCR-ABL1 
breakpoints with an accuracy of 15.89 ± 7.50 bp for BCR breakpoint and 
6.37 ± 2.77 bp for ABL1. Refinement with soft-clipped reads using ClipCrop 
allowed increasing the detection performance with an accuracy of 0.44 ± 
1.01 bp for BCR breakpoints and 1.22 ± 2.22 bp for ABL1 breakpoints. The 
gain in accuracy achieved by ClipCrop refinement is greater in the BCR 
region compare to the ABL1 region, indeed the discordant-pair approach 
resulted to performed better in ABL1 compare to BCR, whereas ClipCrop 
refined the breakpoints coordinates better in BCR compared to ABL1. This 
behavior can be explained by the percentage of repeated regions that is 
much higher in ABL1. Repeated regions can be handled in an easier way 
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by using the discordant-pairs approach than using the split-read approach. 
The difference between validated breakpoints coordinates and breakpoints 
coordinates detected by SVDetect is strictly dependent on the coverage 
achieved in the targeting experiment. Higher is the coverage, higher will be 
the chance to have a paired-end in which the pairs map with the 3’ or 5’ 
end to the breakpoints in BCR or ABL1 respectively. In patient 8 the 
breakpoints coordinates for BCR-ABL1 fusion gene were not detected.  
 
Sample BCR Breakpoint 
(SVDetect) 
BCR Breakpoint 
(SVDetect + 
ClipCrop) 
BCR Breakpoint 
(Sanger) 
K562 23632762 20 23632742 0 23632742 
2 23631930 20 23631911 1 23631910 
3 23632124 4 23632128 0 23632128 
4 23575267 19 23575251 3 23575248 
5 23654742 23 23654765 0 23654765 
6 23634051 18 23634033 0 23634033 
7 23634602 24 23634578 0 23634578 
8 N.D - N.D - 23633411 
9 23631897 22 23631875 0 23631875 
10 23634577 4 23634573 0 23634573 
 
Table 24. BP1 coordinates comparison in different detection methods 
 The table shows the BP1 coordinates identified by discordant pair approach 
(SVDetect), refined by split-read approach (ClipCrop with BLAT) and validated by 
sanger sequencing. Sub-columns describe the difference in bp from the detected 
and the validated coordinates. 
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Sample ABL1 Breakpoint 
(SVDetect) 
ABL1 Breakpoint 
(SVDetect + 
ClipCrop) 
ABL1 Breakpoint 
(Sanger) 
K562 133607140 5 133607145 0 133607145 
2 133648884 8 133648891 1 133648892 
3 133593826 3 133593828 1 133593829 
4 133590561 10 133590571 0 133590571 
5 133708492 4 133708496 0 133708496 
6 133658098 4 133658108 6 133658102 
7 133684300 10 133684307 3 133684310 
8 N.D - N.D - 133694917 
9 133663988 7 133663995 0 133663995 
10 133696999 2 133697001 0 133697001 
Table 25. BP4 coordinates comparison in different detection methods 
The table shows the BP1 coordinates identified by discordant pair approach 
(SVDetect), refined by split-read approach (ClipCrop with BLAT) and validated by 
sanger sequencing. Sub-columns describe the difference in bp from the detected 
and the validated coordinates. 
 
 
4.2.6 Scaling the breakpoints identification 
In order to establish the minimum number of reads that were needed for 
detecting the BCR-ABL1 breakpoints, we performed the breakpoints 
identification at lane level using the same procedure adopted at sample 
level. With the analysis at lane level, as shown in Table 31 and Table 32, 
the breakpoints that give rise to the formation of the BCR-ABL1 oncogene 
were detected only in some samples. Moreover, considering the results on 
the different lanes in which each sample has been loaded, we observed 
heterogeneity across lanes for the same sample. This is primarily due to 
the low number of reads that can spot the breakpoint in a single lane. In 
samples 1,2,4,6,7,9 and 10 the BCR-ABL1 fusion was identified in each 
individual lane, whereas in samples 3 and 8 breakpoint identification 
completely failed, while in sample 5 only some lanes gave a useful reads 
yield. Is it worth highlighting that in samples 4 and 5 in some lanes the best 
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hits are tagged as translocation events and not as insertion fragment 
events. This finding shows how the SV call can be highly influenced by the 
set of mapping reads, in this case the discordant pairs, that span the fusion 
points. Looking at the number of paired-end reads supporting the 
breakpoints, is evident how breakpoints in K562 cell-line are easily 
detectable (267 ± 9.8 pairs) compared to those in patients (62.2 ± 20 pairs) 
with a fold-value of ~4x of reads supporting the translocation event. The 
failure of the detection in sample 3 could be related to the lower number of 
reads in this sample (3.76 M reads) compared to the others samples (4.46 
M ± 2.26 M reads). This hypothesis could be valid if we suppose that in all 
patient specimens analyzed a similar number of Ph+ cells was present. If 
not, the failure of the detection could be explained by a different amount of 
Ph+ cells or by chance. In sample 5, in which only some lanes are able to 
spot the breakpoints, the number of pairs supporting the breakpoints is very 
close to the cut-off threshold used in SVDetect (20 pairs). This interesting 
finding allow us to define 4M as the lowest number of reads necessary to 
spot the BCR-ABL1 junction. 
4.3 Sample Specific Breakpoints analysis 
In order to facilitate the reading of the next chapters we will used the 
following shortcuts: 
 BP1: Breakpoint in BCR that spot the BCR-ABL1 fusion 
 BP2: Breakpoint in BCR that spot the ABL1-BCR fusion 
 BP3: Breakpoint in ABL1 that spot the ABL1-BCR fusion 
 BP4: Breakpoint in ABL1 that spot the BCR-ABL1 fusion 
 DPA: Discordant pairs approach 
 SRA: Split-Reads approach 
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4.3.1 K562 cell line 
K562 cell line sample, along with samples 2 and 3, was analyzed in the 
pilot phase of the project with a prior knowledge of the breakpoints 
coordinates that give rise to Ph and hence to BCR-ABL1 oncogene. The 
known breakpoints coordinates of K562 cell line were chr22:23632742 and 
chr9:133607147. By using SVDetect we detected two breakpoints 
coordinates in each chromosome. In particular BP1 mapped at chr9: 
133607140, whereas BP4 mapped at chr22:23632762 [Table 19]. We then 
refined these coordinates to chr9:133607145 and chr22:23632742 
respectively [Table 20]. There was no difference in bp with known 
coordinates both for BP4 [Table 25] and BP1 [Table 24]. The fact that we 
identified only two breakpoint is probably due to the fact that ABL1-BCR 
could be loss, as already reported in literature [46], [111], [112].  
By enabling the visualization of the soft-clipped reads we can see also how 
single reads are splitted at the breakpoint. In particular, in BCR region, the 
breakpoint (BP2) is identified by reverse R-clipped split reads, whereas in 
ABL1 region the breakpoint (BP4) is identified by forward L-clipped split 
reads. This pattern allows to spot BCR-ABL1 breakpoints in all samples, as 
previously described in methods. Reads spanning the BCR-ABL1 junction 
can map in two ways. The first way is when one mate maps in BCR and the 
other maps into ABL1 regions (discordant pairs approach). The second way 
(split-reads approach) occurs when only one of the two mates span the 
junction point with a portion of its sequence mapping to BCR and the other 
portion mapping to ABL1. For this reason, in BCR the split reads are in 
reverse orientation and R-clipped. If the right clipped read were the forward 
oriented and not the reverse oriented, it would mean that an inversion occur 
at that point. This procedure of analysis will be carry out for all samples. A 
deeper analysis of the Figure 31 shows that both at the BCR and ABL1 
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breakpoint a dramatically coverage drop (from ~2500X to ~200X) occurs 
[Figure 32] and Figure 31. 
 
 
Figure 31. K562 cell line: BCR-ABL1 fusion point at BCR gene 
 This picture shows how BP1 is spotted by discordant pairs (green forward reads) 
and right-clipped split reads (grey reads with a coloured unmapped portion). On the 
top the chromosomal localization and the genomic coordinates on the reference 
human genome (Hg19). Light-grey reads are normally mapped reads. 
 
This occurrence is a tangle demonstration of the der(9) loss. In Figure 32 
reads were sorted to highlight the paired-end reads whose mate maps to 
different chromosomes. In Figure 32 is clear how the junction point on 
ABL1 could be detected by using discordant pair approach only.   
BP4 is localized within a L1ME3A [Table 33], a member of the L1 repeat 
family, which belongs to the Long Interspersed Elements (LINEs) class. 
This repeat sequence maps to the Hg19 with the following coordinates: 
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chr9:133606693-133607233. Near BP4 there are also other repeated 
elements such as AluSx1 and L1MD [Table 33].  
BP1 is far from repeated sequences but is proximal (142bp) to the end of 
the 14th exon (22:23632526-23632600) [Table 38]. 
 
 
Figure 32. K562 cell line: BCR-ABL1 fusion point at ABL1 gene 
This picture shows how discordant pairs (dark grey reverse reads) spot the BP4 at 
ABL1. On the top, the chromosomal localization and the genomic coordinates on 
the reference human genome (Hg19) and the annotation of repeated regions 
located at these coordinates [blue lines]. 
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4.3.2 Patient 2 
Patient 2 was analyzed during the pilot phase together with the cell line and 
patient 3. For patient 2 BP1 and BP4 were already known (chr22:23631910 
and chr9:133648892). By using SVDetect we identified BP1 and BP4 only. 
In particular, BP1 was localized at chr22:23631930, whereas BP4 at 
chr9:133648884. The difference in nucleotides between the SVdetect 
findings and the known coordinates was 20bp and 8bp for BP1 and BP4 
respectively [Table 24] and [Table 25]. The refinement using ClipCrop 
allowed reaching an accuracy of 1bp for both BP1 and BP4 
(chr22:23631911 and chr9:133648891) [Table 24], [Table 25]. BP1 is 
located 102 nucleotides from the 3’ end of the 13th exon (23631704-
23631808) [Table 38] in a region devoid of repeated sequences [Figure 33]. 
On the contrary BP4 is located within the AluJb (chr9:133648840-
133649166) a repeat element belonging to the Short Interspersed Elements 
(SINEs) and near (64bp) to the 3’ end of L1MEd, a LINE located at 
chr9:133648742-133648826 [Table 33]. BP2 and BP3 were not found and 
this is likely due to the low number of discordant pairs and split reads 
supporting them. Indeed there are only 9 paired-end reads that span the 
ABL1-BCR fusion point that are not enough to call the translocation event. 
Split reads analysis with ClipCrop was also unable to detect the BP3 due to 
the extremely low number of split reads (only 4) supporting it [Figure 35], 
even if in the BCR region the number of split reads that support BP2 is 
much higher [Figure 33]. This phenomenon could arise from the high 
density of repeated elements in the ABL1 region that make the mapping 
difficult. As depicted in Figure 35, both BP3 and BP4 are located within a 
region dense of repeated elements (AluJb, L1MEd, AluSp). The visual 
inspection enabling split reads view allows localizing the ABL1-BCR 
junction point at the following coordinates (chr9:133648781 - 
chr22:23632974). BP2 and BP3 were then confirmed manually by aligning 
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clipped reads using BLAT. Both BP2 and BP3 fall within a repeated 
element: L1ME1 [Table 36] and L1MEd [Table 37].   
 
Figure 33. Sample 2: BP1 at BCR gene 
Discordant pair reads (DPR) whose mate maps to chromosome 9 are colored in 
light green. DPR with 5’  3’ direction along with R-clipped reads spot BP1. On the 
bottom (blue box) the exon 13 in BCR.  Clipped portion is characterized by colored 
nucleotides. 
This manual and deeper analysis had pinpoint complications that can arise 
when the breakpoint region falls into a repeat-rich region. The low coverage 
of the ABL1-BCR junction could also be explained biologically by 
hypothesizing an unbalanced keeping of the der(9) in the cells analyzed. 
Moreover, considering the coordinates of the fusion points of both BCR-
ABL1 and ABL1-BCR we could infer the following chromosomal break 
[Figure 34]. 
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Figure 34. Sample 2: DNA break 
On the top to the left the BCR gene (green) with BP1 and BP2, on the top to the 
right the ABL1 with BP3 and BP4. On the bottom to the left the BCR-ABL1 fusion, 
whereas on the bottom to the right the ABL1-BCR fusion product. All the four 
images depict genomic sequences with 5’ to 3’ direction. In both BCR and ABL1 
genes a deletion occurs after the break. 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Sample 2: ABL1 breakpoints 
The figure depicts the region in which BP3 and BP4 occur. Dark grey reads  
(5’  3’) and R-clipped reads spot BP3 whereas BP4 is detected by dark grey 
reads (3’  5’) and L-clipped reads. L and R-clipped reads denote left and right 
clipping direction.  
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4.3.3 Patient 3 
In patient 3, BP1 and BP4 were already known (chr22:23632128 and 
chr9:133593829). The analysis with SVDetect returned four breakpoints. 
BP1 and BP4 were located to chr22:23632124 and chr9:133593826, 
whereas the coordinates for BP2 and BP3 were chr22:23633550 and 
chr9:133593826 respectively [Table 19]. The number of discordant pairs 
supporting the junction points for BCR-ABL1 oncogene and ABL1-BCR 
fusion segment were 32 and 36 respectively. Taking into account the 
coordinates identified by SVDetect, BP1 and BP2 are 1426 bp distant, 
whereas BP3 and BP4 share the same coordinates supposing that in ABL1 
there is neither loss nor gain of genomic material on Ph or der(9). The 
refinement with ClipCrop along set BP1 at chr22:23632128 and BP4 at 
chr9:133593828 [Table 20], whereas BP2 at chr22:23633556 and BP3 at 
chr9:133593805 [Table 21]. Hence the distance between BP1 and BP2 is 
1428bp whereas between BP3 and BP4 only 23 bp [Figure 36]. The BP1 
coordinate confirm that the breakpoint in BCR is located between exon 13 
and 14 leading to BCR-ABL1 b2a2 transcript. The translocation is 
molecularly unbalanced and we can suppose that lead to the formation of 
both Ph and der(9), losing 1428bp in chromosome 22 and 23 bp in 
chromosome 9 . Regarding the proximity to repeated sequences, both BP3 
and BP4 do not map within repeat elements but are flanked by two 
Charlie1a (DNA repeat AT-rich elements) which map to the following 
intervals: chr9:133593729-133593794 and chr9:133593835-133593985 
[Figure 37] [Table 33]. These two repeated DNA elements are 9bp and 7bp 
far from BP3 and BP4 respectively [Table 37],[Table 33].  
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Figure 36. Sample 3: DNA break 
BCR (green) and ABL1(grey) genes both have two breakpoints. A+D segment 
depicts the BCR-ABL1 fusion whereas C+B segment depicts the ABL1-BCR 
reciprocal fusion product. Both at BCR and ABL1 genes a deletion after the 
translocation event occur (striped rectangles).  
 
Figure 37. Sample 3: ABL1 breakpoints 
On the top the genomic coordinates at ABL1 gene. Blue lines depict repeated 
elements such as SINE (1
st
 row) and low-complexity DNA elements (4
th
 row). DPR 
with 5’ to 3’ direction and R-clipped reads spot BP3 whereas DPR with 3’ to 5’ 
direction and L-clipped reads identify BP4.  
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In the BCR region, the breakpoint BP1 that spot the BCR-ABL1 junction 
maps in a genomic region free from repeated sequences, whereas BP2 
maps within a L1ME1 (chr22:23633414-23633642) [Table 36] a L1 repeat 
that belongs to the LINEs [Figure 38].  
 
Figure 38. Sample 3: BP2 spotted by L-clipped split reads 
Left-clipped (colored nucleotides) split reads spotting BP2. The blue box near the 
top is the L1ME1 repeated reads located at the BP2 coordinates. On the extreme 
top the cytogenetic band. 
Hence, in sample 3 both fusion products (BCR-ABL1 and ABL1-BCR) were 
detected. Clipped reads orientation was as expected by theory and no 
strange phenomena were detected except for the loss of 1426 bp in 
chromosome 22 and a dramatic decrease in coverage in the region 
upstream (100-200bp) to BP3 [Figure 37]. This latter event can be linked to 
the extremely high density of repeated sequences such as Alu elements 
and DNA AT-rich repeat elements.  
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4.3.4 Patient 4 
In this sample and in the following as well, BCR-ABL1 breakpoints were 
unknown. In these patient only the detection of mRNA had been performed 
by RT-PCR [Table 2]. In sample 4, by using SVDetect, four possible likely 
breakpoints were identified. However, the best results identified by 
SVDetect are tagged as an “Insertion fragment” event and not as a 
translocation event. This phenomena, has been observed in patients 4 and 
5 whose breakpoints map in m-BCR and µ-BCR [Table 38]. In Figure 39 
discordant pairs that map at the breakpoints in BCR and ABL1 are shown 
respectively. As we can see, both in BCR and ABL1 the paired-end reads 
that span the junction point of the BCR-ABL1 oncogene and ABL1-BCR 
fusion segment map very close (sometimes overlapping as in BCR) to the 
breakpoint with opposite direction [Figure 39].  
 
Figure 39. Sample 4: Overlapping discordant pairs 
On the left discordant pair reads (mapped at BCR), whose mate maps into 
chromosome 9 (ABL1), overlap with each other’s’ (5’ 3’ direction with 3’  5’ 
direction . The same event occurs at ABL1 gene. 
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This phenomenon could occur when the break is “blunt-like” and does not 
bring to loss of genetic material. In this case, the overlapping of forward 
with reverse paired-end reads that span the breakpoint in BCR [Figure 39] 
indicates that BP2 is upstream to BP1. This could be explained by a dsDNA 
blunt break in ABL1 and by a dsDNA protruding break (or ssDNA in two 
different point) in BCR gene [Figure 40].  
  
Figure 40. Sample 4: DNA break 
BCR (green) and ABL1(grey) genes both have two breakpoints. A+D segment 
depicts the BCR-ABL1 fusion whereas C+B segment depicts the ABL1-BCR 
reciprocal fusion product. In ABL1 a deletion after the translocation event occur 
(striped rectangles). In BCR, a strand specific protruding dsDNA break occurs.  
 
The BP1 and BP4 coordinates identified by SVDetect were  
chr22:23575267 and chr9:133590561 whereas those that identify the 
ABL1-BCR fusion (BP2 and BP3) were chr22:23575206 and 
chr9:133590576 [Table 19]. The refinement with ClipCrop along with the 
visual check using IGV have spot the following breakpoints coordinates: 
chr22:23575252 - chr9:133590570 [Table 20] and chr22:23575206 – 
chr9:133590570 [Table 21] for BCR-ABL1 and ABL1-BCR fusion 
respectively. Split-read approach had highlight very clearly how BCR and 
ABL1 fragments were joined. In Figure 41 we can see that in ABL1 at the 
coordinate chr9:133590570 there are two types of clipped reads, L-clipped 
that spot the BCR-ABL1 junction and R-clipped that identify the ABL1-BCR 
fusion. In patient 4 the break of chromosome 9 occurs in a single point, or 
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better, is not followed by a gain or a loss of genetic material that would 
have spaced BP3 and BP4.  
 
Figure 41. Sample 4: Split reads spot BP3 and BP4 
L and R clipped split reads at ABL1 detect the same breakpoint. This result lead to 
consider the DNA break in this patient “blunt like” on the ABL1 gene. On the top 
the genomic coordinates on the Hg19 reference genome. 
 
Regions sorrounding both breakpoint in BCR and ABL1 lack of repeated 
elements. The only repeated sequence in proximity of the breakpoints is 
the AT-rich repeat DNA element named Charlie4z (chr9:133590242-
133590294) [Table 33], [Table 37].  
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Figure 42. Sample 4: Split-Read identify breakpoints in BCR 
Split-Reads (L-clipped and R-clipped) identify BP2 and BP1 respectively. BP2 is 
upstream to BP1. 
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4.3.5 Patient 5 
Sample 5 was from a CML patient hat express the p230 transcript and 
related oncoprotein. This fusion transcript is formed when BP1 is located in 
µ-BCR between exon 19 and 20 [Table 2]. The analysis with SVDetect had 
define the rearrangement as an insertion fragment, similarly to that 
identified in patient 4. The breakpoints coordinates identified with SVDetect 
were four: chr22:23654742 (BP1), chr9:133708492 (BP4) and 
chr22:23654774 (BP2), chr9:133708509 (BP3) that identify the BCR-ABL1 
and ABL1-BCR junction points respectively [Table 19]. ClipCrop analysis 
had refined BP1 to chr22:23654766 and BP4 to chr9:133708495 [Table 
20], whereas BP3 chr9:133708500 and BP2 to chr22:23654766 [Table 21]. 
This breakpoint distribution is opposite to that occurs in patient 4. In sample 
5 there is a unique breakpoint (BP1 equal to BP2) in BCR [Figure 44], 
whereas in ABL1 two breakpoints occurs [Figure 45]. In this case BP4 
(133708495) is upstream to BP3 (133708500) of only 5 bp. This event is a 
balanced translocation with neither gain nor loss of material [Figure 43].  
 
Figure 43. Sample 5: DNA break 
In BCR two breakpoints occur in a blunt-like way and are followed by nucleotide 
loss. In ABL1 the DNA break is protruding with BP3 downstream to BP4.On the 
bottom the two fusion products: BCR-ABL1 and ABL1-BCR. 
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The explanation of this rearrangement is similar to the one hypothesized 
before but in this case the protruding break occurs at chromosome 9 
instead of chromosome 22. The tag “insertion fragment” provided by 
SVDetect is probably a mistake that arise from the overlap of discordant 
pairs that support BCR-ABL1 and ABL1-BCR fusion points. Among the 
non-best results at sample level, there are several records tagged as 
translocation events with the same coordinates assigned to the “insertion 
fragment” findings [data not shown]. Moreover, at lane-level analysis the 
presence of the translocation event has been found as best hits [Table 31] 
and [Table 32]. The coordinates that give rise to BCR-ABL1 oncogene were 
validated with Sanger sequencing [Table 22]. As in patient 4, breakpoints in 
patients 5 are far from repeated sequences. Breakpoints that occur at BCR 
are locate between exon 19 and exon 20, confirming the previous info 
collected for patient [Table 38]. 
 
Figure 44. Sample 5: split-reads identify BP1 and BP2 
Split-Reads (L-clipped and R-clipped) identify BP2 and BP1 respectively. In this 
case BP1 and BP2 are coincident, denoting a blunt chromosomal break. 
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Figure 45. Sample 5: Split reads spot breakpoints in ABL1 
Split-Reads (L-clipped and R-clipped) identify BP2 and BP1 respectively. In this 
case BP1 and BP2 are coincident, denoting a blunt chromosomal break. 
 
 
 
 
 
 
4.3.6 Patient 6 
The only prior knowledge concerning this patient was that it expressed the 
p210 (b3a2) isoform of BCR-ABL1 transcript [Table 2]. This means that the 
breakpoints in BCR should map between exons 14 and 15. The analysis 
with SVDetect has indicated four breakpoints. BP1 at chr22:23634051, BP4 
at chr9:133658098, BP2 at chr22:23634637 and BP3 at chr9:133658314 
[Table 19]. Breakpoints that occur at BCR are located between exon 14 and 
exon 15, confirming the previous info collected for patient [Table 38]. 
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Figure 46. Sample 6: Spotting BP3 and BP4 in ABL1 gene 
Discordant pair reads (forward and reverse oriented) and split-reads (right and left 
clipped) identify BP3 and BP4 respectively. On the top, flanking repeated elements 
as blue lines (SINE miRb on the left and LINE L2b on the right). 
 
In ABL1 the discordant-pair reads that spot BP3 and BP4 overlap with each 
other’s. This means that BP4 is upstream to BP3. Instead BP2 is 
downstream to BP1, supposing the loss of genetic material ranging 
between these coordinates [Figure 48]. The number of reads pairs 
supporting the translocations identified in SVDetect results unbalanced 
towards the BCR-ABL1 fusion (227 reads) compared to the ABL1-BCR 
fusion (42 reads) [Table 19]. The refined analysis by using ClipCrop and 
the visual check with IGV have spotted the following coordinates: 
chr22:23634034 – chr9:133658107 [Table 20] and chr22:23634639 – 
chr9:133658311 [Table 21] for BCR-ABL1 and ABL1-BCR fusions 
respectively.  
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Figure 47. Sample 6: DPRs and split-reads identify BP1 and BP2. 
Discordant pair reads (forward and reverse oriented) and split-reads (right and left 
clipped) identify BP1 and BP2 respectively. On the top, flanking repeated elements 
as blue lines (SINE on the left and AT-RICH on the right). 
 
The number of clipped reads that support the BCR-ABL1 fusion (180 R-
clipped and 23 L-clipped) [Table 20] is higher than that spotting the ABL1-
BCR (53 right-clipped and 53 left-clipped) [Table 21] . The low number of 
left-clipped reads in ABL1 is probably due to their proximity (37bp) to the 
SINE MIRb (chr9:133657864 - 133658070) [Table 37]. The low number of 
supporting clipped reads for ABL1-BCR could be ascribed to deletion of 
der(9) genomic regions [46]. This trend is common to all samples having 
both BCR-ABL1 and ABL1-BCR junction except for patient 3 in which the 
number of clipped reads that support BCR-ABL1 fusion is lesser than the 
one that support the ABL1-BCR fusion [Table 20], [Table 21]. Hence, BCR 
region probably underwent to dsDNA break with a loss of genomic material 
(605bp), whereas in ABL1, an unbalanced protruding dsDNA break 
occurred differently in chromosome 9 strands [Figure 48]. BP1 and BP4 
that support the BCR-ABL1 fusion were found near (20bp) to the LINE L2b 
(chr22:23633847-23634014) [Table 35] and proximal (37bp) to the SINE 
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MIRb (chr9:133657864-133658070), [Table 34]. BP2 and BP3 that support 
the ABL1-BCR fusion were proximal (83bp) to the LINE L1MC4 
(chr9:133658394 - 133658520) [Table 37] and very close (2bp) to the AT-
rich DNA element (chr22:23634615-23634637) [Table 36]. Validation with 
Sanger sequencing provided the following breakpoints coordinates: 
chr22:23634033 (BP1) and chr9:133658102 (BP4) [Table 22]. The 
difference between such coordinates with the ones identified by the 
software analysis is 1bp and 5bp for BP1 and BP4 respectively.  
 
Figure 48. Sample 6: DNA break 
In BCR two breakpoints occur in a blunt-like way and are followed by nucleotide 
loss. In ABL1 the DNA break is protruding with BP3 downstream to BP4.On the 
bottom the two fusion products: BCR-ABL1 and ABL1-BCR. 
 
4.3.7 Patient 7 
SVDetect results revealed that patient 7 presents a translocation event 
spotting BCR-ABL1 fusion gene and an inverted translocation event that 
involves the ABL1 and FOXRED2 genes Table 19]. More details about this 
latter rearrangement will be discussed further in the chapter after the 
description of the BCR-ABL1 fusion. About patient 7, it was only known that 
the p210 (b3a2) transcript form was expressed [Table 2]. Breakpoints 
coordinates (chr22:23634602 and chr9:133684300) that identify the BCR-
ABL1 fusion gene confirmed that the junction is located in BCR between 
the 14th and 15th exon [Table 38]. Refinement with ClipCrop and visual 
check using IGV have rounded the coordinates to the following boundaries: 
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chr22:23634578 and chr9:133684307 [Table 20]. The number of paired-
end reads supporting the junction as well as the number of right-clipped 
(BCR) and left-clipped (ABL1) reads was very high: 227, 177 and 166 
reads respectively [Table 19, Table 20]. BP1 is located 37bp upstream to 
the AT-rich DNA element (chr22:23634615-23634637) [Table 35],  
[Figure 49].  
 
Figure 49. Sample 7: BCR-ABL1 fusion point at BCR 
This figure shows how DPR whose mate map to chromosome 9 (light green 
forward reads) as well as R-clipped reverse reads can spot BP1. AT-Rich low 
complex element (small blue line at right-top) is located 37 bp downstream BP1. 
 
This DNA element is the same found very close to the BP2 in sample 6 
[Figure 47]. This finding could support the hypothesis that this low-
complexity genomic region can actively promote the DNA break.  
Regarding the ABL1 region, BP4 mapped within the L1MEc 
(chr9:133684219-133684749) LINE [Figure 52], [Table 34]. By performing 
the re-alignment of the longest clipped portion of the L-split reads around 
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BP4 by using BLAT, it was noticed that it did not map completely into BCR 
but also in a region upstream to the breakpoint itself in ABL1 at 
chr9:133684210-133684242 with an inverted orientation [Figure 50]. This is 
a clear evidence that these clipped reads are able to span both the 
junctions between BCR (5’ to 3’) with an inverted fragment of 33bp 
(chr9:133684210-133684242) and the fusion of the latter with the remnant 
ABL1 portion (5’ to 3’). This phenomenon lead to suppose that at the BCR-
ABL1 junction point an insertion of the fragment chr9:133684210-
133684242 is present. 
 
 
Figure 50. BLAT alignment: L-clipped split reads at ABL1  
The figure shows the BLAT alignment of the L-clipped read at ABL1 spotting BP4. 
The first 40
th
 nucleotides map to BCR, whereas from 38
th
 to 70
th
 nucleotide the 
fragment map to ABL1 reversely.   
 
Sanger sequencing validated the breakpoints coordinates (chr22:23634578 
and chr9:133684310) [Table 22]. The difference among the calculated and 
the validated coordinates was 0 and 3bp for breakpoints coordinates in 
BCR and ABL1 respectively. The hypothesis of the inserted fragment was 
validated. In fact, the alignment of the FASTA sequence obtained by 
Sanger sequencing with BLAT and BLAST demonstrated that the fusion 
segment contains the insertion of a small fragment (37bp), which maps 
from chr9:133684206 to chr9:133684242 [Figure 51]. 
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Figure 51. BCR-ABL1 fusion: Sanger Sequencing Validation 
The figure shows the BLAT alignment of the fusion fragment sequenced by sanger 
method.  
The alignment with BLAT shows also a micro homology (3bp) between the 
BCR segment and the 37bp-inserted fragment, verifying the length (33bp) 
observed in reads analysis. SVDetect found an inverted translocation with 
the following coordinates: chr9:133684252 and chr22:36901054 [Table 19] 
that were refined to chr9:133684236 and chr22:36900838 [Table 21]. The 
analysis of this inverted translocation has pinpointed a very complex 
rearrangement that occur during the DNA break in the BCR region. 
Considering the breakpoints coordinates obtained by SVDetect analysis, it 
seems that instead of ABL1-BCR fusion segment, an ABL1-FOXRED2 
fusion segment is formed without BCR implication [Figure 54]. The manual 
and curated analysis of the breakpoints regions allowed to speculate that 
during the formation of der(9), a fragment of FOXRED2 has been inserted 
at the fusion point between ABL1 and BCR.    
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Figure 52. Sample 7: DPRs and split-reads spot BP3 and BP4 
The figure shows BP3 and BP4 detected by R-clipped and L-clipped split-reads 
respectively as well as forward and reverse discordant pair reads whose mate 
maps to chromosome 22 (dark grey). On the top blue lines describe repeated 
elements (LINEs). 
 
Figure 53. Sample 7: FOXRED2 gene region (zoom in) 
The figure depicts the FOXRED2 gene region involved in the formation of the 
ABL1-BCR fusion segment. Blue reads describe an insertion event, whereas green 
forward reads, which spot BP2, are the mate pair of discordant pair reads spotting 
BP3 at ABL1 gene. The inverted orientation of green reads as well as that of split 
reads is due to the inversion event occurring at BCR in the region upstream to BP1 
[Figure 55]. 
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To demonstrate this hypothesis, all the information available from the reads 
(split-reads, discordant pair, strand orientation, insert size and so on) were 
used. We noticed that mate pairs of the forward-oriented discordant reads, 
mapping in ABL1, instead of mapping in BCR with reverse direction as 
expected, they mapped to the FOXRED2 gene with forward direction 
[Figure 53]. This means that ABL1 is fused with FOXRED2 gene that 
appear inverted. This is also demonstrated by: 1) the clipped portion of L-
split reads in ABL1 that map inverted to FOXRED2 and 2) by the clipped 
portion of R-split reads in FOXRED2 that map to ABL1 inversely and 
contiguously to that at point 1) [Figure 52] and [Figure 53].   
 
Figure 54. ABL1-FOXRED2 fusion detected by SVDetect 
The figure shows the fusion ABL1-FOXRED2 detected by both discordant pairs 
and split reads (half orange and blue). The fragment is positioned with a 5’ to 3’ 
direction. The inverted FOXRED2 gene fragment is fused with ABL1.  
 
Once established that ABL1 was fused with FOXRED2, in the way depicted 
in Figure 54, we analyzed the clipped portion of L-split reads mapping to 
FOXRED2 [Figure 53]. What came out was that this clipped portion map to 
BCR inversely and contiguously to the clipped portion of R-split reads that 
instead map to FOXRED2 inversely and contiguously to the former clipped 
portion. This means that FOXRED2 (inverted) is fused with BCR [Figure 
56]. This arrangement is also confirmed by blue colored paired-end reads 
that spot insertion events. In this case, the insertion size computed over 
blue-reads in reverse direction mapping into BCR is positive meaning that 
the pairs of such reads map downstream to them [Figure 55].  
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Figure 55. FOXRED2 insertion at BCR 
The figure shows the insertion (FOXRED2 fragment) identified by reverse blue 
reads upstream to BP1. 
 
 
Indeed FOXRED2 is downstream to BCR. The fact that these pairs mapped 
not only downstream but also inverted, in reverse direction as their mate in 
BCR gene, demonstrated that FOXRED2 is inversely fused with BCR 
[Figure 53]. These findings lead to define the following chromosomal 
rearrangement [Figure 56]. 
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Figure 56. Sample 7: ABL1/FOXRED2/BCR fusion segment 
The figure shows the ABL1/FOXRED2/BCR fusion taking as reference the forward 
direction 5’  3’. The fragment of the FOXRED2 gene is inserted inversely at the 
ABL1 and BCR junction. +/- described the strand. 
 
 
The analysis of this patient had pinpointed how complex could be the 
rearrangements at the breakpoint. Both BCR-ABL1 oncogene and ABL1-
BCR fusion segment underwent to the insertion of an inverted fragment of 
DNA. In the case of BCR-ABL1 oncogene, the insertion of an inverted 
ABL1 sequence upstream to the BCR-ABL1 breakpoint at ABL1 occurred, 
whereas regarding the ABL1-BCR fusion segment, the insertion of an 
inverted fragment of the FOXRED2 gene occurred. Sanger sequencing 
validated the breakpoints coordinates that give rise to the BCR-ABL1 
oncogene and the ABL1 inserted fragment [Table 22]. No validation were 
carried out for the ABL1-BCR fusion segment.  
 
  
inv 
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4.3.8 Patient 8 
Patient 8 was the only one in which the identification of BP1 and BP4 
breakpoints failed. The only coordinates identified with SVDetect were 
those related to BP2 and BP3 with the following coordinates 
(chr22:23632905 and chr9:133694955) [Table 19]. Such coordinates were 
then refined with ClipCrop to chr22:23632908 and chr9:133694990 [Table 
21]. These coordinates were used to set up PCR for amplifying the BCR-
ABL1 fusion segment. After several try, we succeeded to amplify the BCR-
ABL1 fusion segment. Sanger sequencing of this amplicon provided the 
following coordinates: chr22:23633411 (BP1s) and chr9:133694917 
(BP4s). The first coordinate map to the 3’ end of the SINE, AluSx1 
(chr22:23633113-23633411) and 3bp upstream to the 5’ end of L1ME1 
(chr22:23633414-23633642), member of LINEs [Table 35]. The breakpoint 
in the ABL1 region is located 3bp upstream to the 5’ end of the AluSx3 
(chr9:133694920-133695226) [Table 34].  
 
Figure 57. Sample 8: BP1 at BCR 
The figure shows the genomic region in which the breakpoint BP1 is identified by 
PCR map. In particular the two dashed vertical lines sport the nucleotide at which 
the break occurs. BP1 is flanked by two repeated elements such as AluSx1 (left 
blue line) and L1ME1 (right blue line). At the bottom the nucleotide sequence with 
a long stretch of A (green). 
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The proximity to repeated sequences (2 SINEs and 1 LINE) along with the 
low-complexity of both regions has made it impossible to detect BP1 and 
BP4 both with discordant pair approach and split read approach. The 
region upstream to the BP1s is featured by a long stretch of nucleotide A 
[Figure 57], whereas sequence downstream to BP4s is characterized by a 
long stretch of Thymine (23) [Figure 58]. Achieve a reasonable coverage of 
this genomic region is very difficult both for the low-complexity of the 
genomic sequence and for the high density of SINEs and LINEs that 
exacerbate this issue. BP1 coordinate confirm the b2a3 transcript isoform 
previously detected in RT-PCR [Table 2], indeed it maps between exon 14 
and 15 [Table 38]. 
 
Figure 58. Sample 8: BCR-ABL1 breakpoint at ABL1. 
The figure shows the genomic region in which the breakpoint BP4 is identified by 
PCR map. In particular the two dashed vertical lines sport the nucleotide at which 
the break occurs. BP4 is very close at 3’ to the AluSx3 (blue box). At the bottom 
the nucleotide sequence with a long stretch of T (red). 
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Moreover, considering the coordinates of the fusion points of both BCR-
ABL1 and ABL1-BCR we could infer the following chromosomal break 
[Figure 59]. 
 
 
Figure 59. Sample 8: DNA break 
In BCR (green rectangle) the break occur in a protruding way producing two 
breakpoints in which BP2 is upstream to BP1. Also in ABL1 the DNA break is 
protruding with BP4 upstream to BP3.On the bottom the two fusion products: BCR-
ABL1 and ABL1-BCR. 
 
4.3.9 Patient 9 
Sample 9 belongs to a patient in which has been monitored the levels of 
the p210 b3a2 transcript. BP1 and BP4 have the following refined 
coordinates: chr22:23631876 and chr9:133663994 [Table 20]. No 
breakpoints leading to ABL1-BCR fusion product were identified. BP1 is 
located in a region free from repeated sequences, whereas BP4 maps 
within the LINE, L1M4c (chr9:133663585-133664351) [Table 34]. In 
addition to the BCR-ABL1 fusion points, SVDetect has identified a reverse 
translocation with the following coordinates: chr9:136985521 and 
chr22:23631884 [Table 19]. Mapping with BLAT the clipped portion of the 
L-splitted reads at chr9: 136985521 to the reference genome it resulted that 
it mapped partially to very small fragments that belong to chromosome 2 
and chromosome 3. This findings could be explained by the presence of 
the AluSz (chr9:136985256-136985553). Probably a piece of chromosome 
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9 near to the telomere rearranged with BCR. The same finding has been 
reported previously in [91]. Considering the breakpoints coordinates 
identified we could infer the DNA break depicted in [Figure 62]. 
 
 
Figure 60. Sample 9: BP4 at ABL1 region 
The figure shows how split-reads (half light grey and half mixed colored) and 
reverse discordant pair reads (dark grey) spot BP4 at ABL1 gene. On the top the 
blue line that describe the LINE L1M4c. 
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Figure 61. Sample 9: BP1 and BP2 at BCR region 
The figure shows BP1 and BP2 spotted by R-clipped and L-clipped split reads 
respectively. These breakpoints are also identified by forward and reverse 
discordant pair reads (light green colored). At the bottom the blue line that 
describes the exon 13. At the top the genomic coordinates according to Hg19. 
 
 
 
Figure 62. Sample 9: DNA break 
The figure shows how DNA could be broken in this sample. BP1 is upstream to 
BP2 as well as BP3 is upstream to BP4. Such feature lead to hypothesize that 
DNA break is blunt like and is followed by loss of nucleotides. Only the fusion 
product BCR-ABL1 is formed. 
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4.3.10  Patient 10 
Sample 10 belongs to a patient in which has been found a translocation 
t(9;22) by using CBA technique. Moreover, the p210 (b3a2) transcript has 
been identified by RT-PCR. This prior knowledge was verified by the 
analysis. SVDetect reported the following breakpoints that give rise to the 
BCR-ABL1 oncogene: chr22:23634590 (BP1) and chr9:133696999 (BP4) 
[Table 19]. These coordinates were then refined by ClipCrop and visually 
checked in IGV. The results are the following: chr22:23634574 (BP1) and 
chr9:133697000 (BP4) [Table 20]. Sanger sequencing validated these 
breakpoints coordinates [Table 22].  
 
Figure 63. Sample 10: BP1 and BP2 at BCR 
The figure shows BP1 and BP2 spotted by R-clipped and L-clipped split reads 
respectively. These breakpoints are also identified by forward and reverse 
discordant pair reads (light green colored). At the top the blue box that describe a 
DNA element of low complexity very close to BP2. At the top the genomic 
coordinates according to Hg19. 
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In addition others two breakpoints spotting the ABL1-BCR fusion segment 
were found by SVDetect and refined with ClipCrop [Table 21]. BP2 and 
BP3 identified by ClipCrop were chr22:23634640 and chr9:133696781 
respectively [Table 21]. The coordinates of BP2 and BP3 are easily 
viewable in Figure 63 and Figure 64 respectively. The number of discordant 
pairs that span both fusions segments was very high, 204 reads supporting 
the BCR-ABL1 fusion and 98 spotting the ABL1-BCR fusion [Table 19]. 
Differently the number of split-read, which support both fusions in ABL1, 
was very low (8 and 32 reads for BCR-ABL1 and ABL1-BCR fusion 
segment) [Table 20] and [Table 21]. This phenomenon arises from the high 
density of repeated elements that surround the breakpoints. In particular, 
both breakpoints that occur in ABL1 region mapped within a L1ME1 
(chr9:133696617-133697051) LINE and near to several SINE such as 
AluSx (chr9:133697052-133697227), AluY(chr9:133697228-133697523) 
and the AluSx8 (chr9:133696313-133696616) [Table 34][Table 37]. The 
Figure 64 shows very well how these repeated elements are thickened and 
how their tightly consecution can lead to a very low capturing. The high 
number of discordant pair reads that spot the BCR-ABL1 fusion in ABL1 
gene can be explained with the efficient capturing of their mates that map in 
BCR. Indeed, very few clipped-reads (only 8) were able to identify the BCR-
ABL1 breakpoint [Table 20]. Regarding the breakpoints found at BCR, BP1 
is located in a region free from repeated elements, whereas BP2 falls very 
near to a DNA region with low complexity [Figure 63]. Sanger sequencing 
validated the breakpoints coordinates that spot the junction BCR-ABL1 
[Table 22]. Concerning the mechanism of DNA break that occurred in this 
sample we can infer that both chromosomes (22 and 9) underwent to 
dsDNA break with a partial loss of genetic material: 219 bp at chromosome 
9 and 66bp at chromosome 22 [Figure 65]. BP1 coordinate confirm the 
b2a3 transcript isoform previously detected in RT-PCR [Table 2], indeed it 
maps between exon 14 and 15 [Table 38]. 
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Figure 64. Sample 10: Breakpoints in ABL1 region 
The figure describes the genomic region at which BP3 and BP4 are located. R-
clipped and L-clipped split reads spot BP3 and BP4 respectively. These 
breakpoints are also spotted by reverse and forward discordant pair reads (dark 
grey). Both BP3 and BP4 reside within a L1ME1 repeated element. This genomic 
region is highly dense of repeated sequences (AluSx, AluY, AluSc8). 
 
Figure 65. Sample 10: DNA break 
The figure shows how BCR and ABL1 are broken and fused in two hybrid products: 
BCR-ABL1 and ABL1-BCR. In this samples the breaks at chromosome 9 and 22 
are blunt-like with loss of nucleotides. Indeed BP1 is upstream BP2 as well as BP3 
is upstream BP4. 
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4.4 Discussion 
We have described: 1) the specific capture and enrichment of the genomic 
region spanning the breakpoints in ABL1 and BCR that produce the 
chimeric gene BCR-ABL1, 2) the NGS protocol, 3) the bioinformatics 
analysis used to identify the BCR-ABL1 fusion points. This approach has 
been applied to a cell line (K562) and to 9 DNAs from CML patients.  
Breakpoint identification was successful for K562 cell line and for 8 over 9 
CML patients analyzed.  
As a general comment, we observed that the identification of BCR-ABL1 
fusion points in K562 cell lines is much easier than in CML patients. The 
average reads coverage, as well as the capturing efficiency is in fact much 
higher in the cell line compared to that observed in patients. This is 
primarily due to the fact that in cell lines all cells carry the BCR-ABL1 fusion 
gene. On the contrary, patient DNAs were obtained from peripheral blood 
(PB) at disease onset. At this stage the % of cells carrying the translocation 
is variable and normal cells are also present. The lower is the % of BCR-
ABL1+ cells, the higher is the difficulty to identify the translocation event.  
In one patient (Patient 8), the precise identification of BCR-ABL1 fusion 
points failed and we could only detect the coordinates of the reciprocal 
ABL1-BCR fusion. Based on these coordinates, we could restrict the 
genomic region to set up a PCR assay to amplify BCR-ABL1 and sequence 
this amplicon in Sanger. After having resolved the breakpoints in Sanger 
sequencing, we could establish that the initial failure in breakpoints 
detection was mainly attributable to the very low number of reads covering 
these region, due to their low complexity (long stretches of A and T at both 
portions of the fusion) that can affect sequencing performance.  
Sanger sequencing validated the identified BCR-ABL1 fusion coordinates in 
all samples. The bioinformatics pipeline implemented in this PhD project 
allowed us to identify the BCR-ABL1 fusion points with an accuracy of 1.01 
± 0.44 bp in BCR and 1.22 ± 2.22 bp in ABL1. In fact, in most samples the 
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breakpoints coordinates identified by NGS were identical to those obtained 
using Sanger method.  
As supplementary analysis besides the identification of BCR-ABL1 
breakpoints in each sample, we used NGS data to infer additional 
information on DNA breaks and rearrangement events that are described 
below. 
Using the pipeline, the reciprocal ABL1-BCR fusion was found in 6 out of 9 
samples (excluding the cell line) and was detected by curated manual 
analysis in patients 2 and 7 in which the number of supporting reads did not 
pass the software thresholds (sample 2) and a DNA insertion occurred 
between the ABL1 and BCR segments (sample 7).  
The analysis of sequencing data in each patient suggests possible 
explanation on how the breaks occur at chromosomes level and why a 
variable number of breakpoints are detected on chromosome 9 and 22. In 
fact, the analysis has shown that most patients present four breakpoints, 2 
on chromosome 22 and 2 on chromosome 9. What we expected was to find 
a single breakpoint in each chromosome. The presence of two breakpoints 
in both chromosomes could be explained either by the loss of genomic 
material or by a protruding break in which the two strands are differently 
broken. Taking into account this concept we could infer that in patients 2, 3 
and 10 the dsDNA break was blunt and followed by a DNA loss. The loss of 
genomic DNA was observed thanks to the coordinates of both the fusion 
products (BCR-ABL1 and ABL1-BCR) that are produced by the reciprocal 
translocation t(9;22). The difference in coordinates between the breakpoints 
that spot the two fusion products in each chromosome has shown that the 
loss of DNA is variable ranging from few bases to thousands. The analysis 
of these breakpoints suggests that initially a single dsDNA break occurred 
both in chromosome 9 and chromosome 22 and this was followed by a 
DNA loss at the ends of the broken chromosomes.  
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The analysis of patients 4 and 5 has shown that the DNA break can be 
blunt without loss of DNA at one chromosome end and protruding in the 
other chromosome. In particular, in patient 4 the DNA break on 
chromosome 22 (BCR) is protruding producing two breakpoints coordinates 
in which the BP2 (which spots the ABL1-BCR fusion) is upstream BP1 
(which spots the BCR-ABL1 fusion). On chromosome 9 the break is blunt 
without loss of genomic DNA.  On the contrary, patient 5 has a protruding 
DNA break on chromosome 9 (ABL1) producing two breakpoints 
coordinates in which BP3 (which spot the ABL1-BCR fusion) is downstream 
BP4.  
Patient 6 is characterized by protruding break at ABL1 and blunt break at 
BCR with loss of DNA at the ends. 
The analysis of patient 7 was peculiar and has demonstrated the 
complexity of DNA rearrangement that follows chromosome break. We 
established that a protruding DNA break occurred at BCR, whereas a DNA 
break with loss of DNA occurred at ABL1. In particular, in this patient both 
BCR-ABL1 and ABL1-BCR fusion products have a DNA insertion at the 
juntion. BCR-ABL1 fusion segment includes a reverse inverted fragment 
which is located upstream BP3, whereas the ABL1-BCR fusion segment 
includes a reverse inverted portion of the FOXRED2 gene located 
downstream BP1 and BP2 on chromosome 22. Finally the analysis of 
patient 9 identified the BCR-ABL1 fusion product but could not identify the 
reciprocal ABL1-BCR. The results of the global analysis have shown that 
many breakpoints occur within or very close to repeated elements such as 
SINEs (Alu family) or LINEs (L1 family). In particular, in samples 4 and 5, 
the breakpoints in BCR occur in m-BCR and µ-BCR respectively and are 
located in regions that lack of repeated elements. These breakpoints derive 
from blunt DNA break without loss of nucleotides. On the contrary, 
breakpoints in samples 6 e 7 that could derive from protruding DNA breaks 
are located close to repeat elements. A similar feature was detected in 
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samples 2,3 and 10 in which blunt DNA breaks were followed by 
nucleotides loss. However it has to be noted that the sample size of the 
present study does not allow to establish if sequence itself can really affect 
the type of break (blunt or protruding) and nucleotide loss.  
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5.  CONCLUSIONS 
Next-generation sequencing (NGS) is gradually making its way into clinical 
laboratories due to the decreasing of costs. 
NGS can be used  to identify both sequence and structural variants. 
The work described in this thesis has demonstrated that NGS technology 
can be applied to monitor minimal residual disease (MRD) in CML. The 
workflow implemented to analyze NGS data allowed us to identify 
breakpoints that give rise to BCR-ABL1 oncogene, with single nucleotide 
accuracy and in a genomic landscape featured by a high density of 
repeated sequences.  
This is important because the initial idea was to use breakpoints 
identification with NGS as the starting point for the design of a patient 
specific qPCR assay to be used in patient follow up during IM treatment.  
Targeted next generation sequencing has been previously used to describe 
translocations in leukemia.  In particular, Duncavage et al [113], focused on 
the identification of gene mutations such as translocations, SNVs and 
INDELs in five leukemia cell lines including K562,NB4,OCI-AML3, kasumi-1 
and MV4-11. The authors also applied this method to identify the t(9;11) in 
a bone marrow sample from a patient affected by AML. Shibata et al, [114] 
developed Anchor chrom-PET technique to capture the BCR-ABL1 
translocation in K562 cell line and in Ph+ and Ph- patients. In this study 
they targeted only M-BCR region by using a custom capture and 
enrichment protocol not applicable for clinical purpose. Finally Chen et al. 
[115], performed shotgun sequencing on flow sorted derivative 
chromosomes using NGS in lymphoblastoid cell lines. 
The present PhD work has innovative character because is the first NGS 
approach specifically designed to target all the potential breakpoints that 
give rise to the BCR-ABL1 fusion gene.   
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The method developed in our lab can detect patient-specific breakpoints 
simultaneously in multiple samples.   
Moreover, we demonstrated that we could spot small insertions / deletions 
that can occur during the translocation event. These secondary 
rearrangements are undetectable by cytogenetic techniques such as CBA 
or FISH. The additional original character of this work is the fine analysis of 
the BCR-ABL1 fusion points along with their reciprocal (ABL1-BCR), to 
infer DNA break mechanism in CML using NGS data. Different features of 
DNA break in CML have been observed in this analysis. This could offer 
new clues to understand the mechanism of the translocation. A possible 
future analysis could focus on the regions surrounding the breakpoints in 
order to spot the presence of recurrent DNA patterns that can promote 
DNA break or the translocation event.  
In order to increase the statistical power of the study we are collecting 
DNAs of further 40 CML samples in major molecular response (no BCR-
ABL1 transcript detected for two years). We plan to apply our capturing 
protocol in these patients, identify breakpoints, and design the patient 
specific assay for DNA quantification in real time during the follow-up. 
DNA quantification in these samples will help to take clinical decisions on 
disease treatment.  
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APPENDIX 
 
Breakpoint Chromosome Coordinate Annotation N° of probes 
BP1 22 23632041 intron 13-14 5 
BP2 22 23631917 intron 13-14 5 
BP3 22 23632170 intron 13-14 5 
BP4 22 23631956 intron 13-14 5 
BP5 22 23632256 intron 13-14 5 
BP6 22 23632142 intron 13-14 5 
BP7 22 23632501 intron 13-14 5 
BP8 22 23632360 intron 13-14 5 
BP9 22 23632133 intron 13-14 5 
BP10 22 23631981 intron 13-14 5 
BP11 22 23632365 intron 13-14 5 
BP12 22 23633068 intron 14-15 2 
BP13 22 23633696 intron 14-15 5 
BP14 22 23632845 intron 14-15 5 
BP15 22 23632443 intron 13-14 5 
BP16 22 23633595 intron 14-15 5 
BP17 22 23633803 intron 14-15 5 
BP18 22 23632580 exon 14 5 
BP19 22 23633263 intron 14-15 not covered 
BP20 22 23632883 intron 14-15 5 
BP21 22 23632682 intron 14-15 5 
BP22 22 23634158 intron 14-15 5 
BP23 22 23632742 intron 14-15 5 
BP24 22 23631916 intron 13-14 5 
BP25 22 23633377 intron 14-15 not covered 
BP26 22 23631838 intron 13-14 5 
BP27 22 23632196 intron 13-14 5 
Table 26. Theoretical capturing evaluation of known breakpoints 
The table shows the testing of the best probe set for M-BCR region in order to 
evaluate if this probe set can theoretically cover 27 breakpoints already detected 
by Prof. G. Porta. Only two breakpoints were not covered because they fall within 
an AluSx1 element.  
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Sample Target 
Total 
cov 
Average 
cov 
Q1 median Q3 1X 20X 50X 100X 
02a ABL1 19021875 124.15 63 119 180 98.7 91 80 58 
02b ABL1 18362295 119.85 60 113 172 98.5 90.7 78.9 55.7 
02c ABL1 18281256 119.32 60 114 171 98.6 90.6 79 56.6 
02d ABL1 18195013 118.75 59 114 172 98.5 90.4 78.9 55.7 
03a ABL1 15268209 99.65 44 87 144 98.5 88.2 70.9 43.1 
03b ABL1 16024382 104.59 47 92 151 98.6 88.8 72.9 45.5 
03c ABL1 15823051 103.27 46 89 148 98.4 88.4 71.9 44.9 
03d ABL1 15462313 100.92 45 89 145 98.4 88.6 71.6 43.4 
04a ABL1 16996561 110.93 57 103 155 98.6 90.9 78.3 51.5 
04b ABL1 17956429 117.2 62 109 166 98.5 91.5 80.1 54.4 
04c ABL1 17566485 114.65 61 106 162 98.3 91.2 79.8 53 
04d ABL1 17221366 112.4 59 105 159 98.5 91 78.9 52.1 
05a ABL1 12363399 80.69 40 71 111 98.5 87.5 66.7 29.8 
05b ABL1 12994710 84.81 42 74 117 98.4 88.2 68.5 33.1 
05c ABL1 12843026 83.82 42 73 116 98.3 88.1 68.3 32.9 
05d ABL1 12645128 82.53 41 72 113 98.2 87.9 67.8 31.5 
06a ABL1 12817986 83.66 41 71 112 99 89.6 67.5 30.8 
06b ABL1 12473458 81.41 41 70 108 98.4 89.1 66.3 28.8 
06c ABL1 12499065 81.58 40 70 109 99 88.9 66.1 29.4 
06d ABL1 12472852 81.41 41 69 110 98.7 89.1 66.3 29.7 
07a ABL1 17342929 113.19 56 108 164 98.5 90.2 77.4 53.7 
07b ABL1 16638946 108.6 52 105 158 98 89.7 75.6 52 
07c ABL1 16738957 109.25 52 106 159 98.1 89.6 75.7 52.3 
07d ABL1 16739703 109.26 52 106 160 98.4 89.4 75.7 52.5 
08a ABL1 16058491 104.81 51 96 148 98.2 89.4 75.5 47.2 
08b ABL1 15413341 100.6 51 91 142 98.5 88.9 75 44.6 
08c ABL1 15381300 100.39 49 92 142 98.6 88.9 74 45.3 
08d ABL1 15289529 99.79 48 91 141 98.6 88.7 73.7 45 
09a ABL1 14592066 95.24 52 88 130 98.9 90.9 76 42.3 
09b ABL1 15353248 100.21 55 92 138 99 90.9 77.9 45 
09c ABL1 15046751 98.21 53 90 134 98.4 90.7 76.7 43.7 
09d ABL1 14682601 95.83 53 88 132 98.5 90.4 76.4 42.7 
10a ABL1 15505023 101.2 50 89 136 98.6 89.7 74.4 44.2 
10b ABL1 16400009 107.04 53 94 144 98.8 90.3 76.3 46.5 
10c ABL1 16070544 104.89 51 92 143 98.7 90.2 75.1 45.2 
10d ABL1 15801952 103.14 51 91 140 98.9 90.1 75.1 44.6 
Table 27. ABL1 lane-level capturing and coverage 
The table shows the coverage and capturing statistics related to ABL1 targeted 
region across lanes. From left to right column: sample and lane, region name, 
number of bp that cover the region, average coverage, coverage at 1
st
 quartile 
(Q1), median coverage, coverage at 3
rd
 quartile (Q3), percentage of targeted 
region captured with an average coverage greater or equal to 1X,20X,50X and 
100X. Data included in this table are plotted in Figure 20.     
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Sample Target 
Total 
cov 
Average 
cov 
Q1 median Q3 1X 20X 50X 100X 
02a BCR-MAJOR 1387439 154.19 123 155 186 100 99.8 98.7 90.1 
02b BCR-MAJOR 1199975 133.36 99 132 168 100 99.9 97.7 74.1 
02c BCR-MAJOR 1224217 136.05 102 133 169 100 100 98.5 76.4 
02d BCR-MAJOR 1201963 133.58 101 135 165 100 99.9 97.6 75.5 
03a BCR-MAJOR 1204656 133.88 96 132 171 100 100 97.1 73.1 
03b BCR-MAJOR 1256548 139.65 102 141 178 100 100 97.4 75.9 
03c BCR-MAJOR 1278401 142.08 105 145 176 100 99.8 97 76.7 
03d BCR-MAJOR 1233997 137.14 101 140 176 100 99.8 95.8 75.4 
04a BCR-MAJOR 1423376 158.19 129 158 188 100 100 98.6 88.6 
04b BCR-MAJOR 1479552 164.43 130 162 197 100 100 98.2 87.5 
04c BCR-MAJOR 1481600 164.66 133 162 201 100 100 98.4 90.3 
04d BCR-MAJOR 1439454 159.97 130 162 190 100 100 98.7 91 
05a BCR-MAJOR 1679913 186.7 150 179 216 100 100 99.3 92.8 
05b BCR-MAJOR 1771687 196.9 159 188 232 100 100 99.4 93 
05c BCR-MAJOR 1743931 193.81 159 188 229 100 100 99.5 92 
05d BCR-MAJOR 1723298 191.52 160 186 222 100 100 99.3 92.1 
06a BCR-MAJOR 1179753 131.11 106 125 153 100 100 97.8 80.6 
06b BCR-MAJOR 1081331 120.17 96 113 146 100 99.1 96.6 70 
06c BCR-MAJOR 1065464 118.41 93 114 140 100 99.3 95.2 67.7 
06d BCR-MAJOR 1069290 118.84 97 114 138 100 99.5 96.1 70.4 
07a BCR-MAJOR 1394863 155.02 124 152 184 100 100 97.7 86 
07b BCR-MAJOR 1269227 141.06 109 143 178 100 100 97.7 80.8 
07c BCR-MAJOR 1253465 139.3 109 136 173 100 100 97.6 81.2 
07d BCR-MAJOR 1262030 140.26 109 139 175 100 100 98 81.1 
08a BCR-MAJOR 1622035 180.27 149 174 212 100 100 99 93.4 
08b BCR-MAJOR 1383234 153.73 120 149 186 100 99.9 98.1 86.6 
08c BCR-MAJOR 1383015 153.7 120 150 183 100 100 97.7 87.5 
08d BCR-MAJOR 1386669 154.11 122 151 188 100 100 98.3 86.6 
09a BCR-MAJOR 1198975 133.25 106 129 159 100 100 98.1 79.9 
09b BCR-MAJOR 1267942 140.91 107 138 171 100 100 98.5 81.6 
09c BCR-MAJOR 1259015 139.92 108 138 170 100 100 98.2 80.1 
09d BCR-MAJOR 1199192 133.27 106 128 160 100 100 98.1 79.8 
10a BCR-MAJOR 1545958 171.81 139 166 206 100 100 97.7 89.9 
10b BCR-MAJOR 1603633 178.22 147 171 211 100 100 98.3 91.8 
10c BCR-MAJOR 1617798 179.8 146 173 214 100 100 97.6 93.4 
10d BCR-MAJOR 1543451 171.53 136 162 209 100 100 98.2 90.2 
Table 28. major-BCR lane-level capturing 
The table shows the coverage and capturing statistics related to ABL1 targeted 
region across lanes. From left to right column: sample and lane, region name, 
number of bp that cover the region, average coverage, coverage at 1
st
 quartile 
(Q1), median coverage, coverage at 3
rd
 quartile (Q3), percentage of targeted 
region captured with an average coverage greater or equal to 1X,20X,50X and 
100X. Data included in this table are plotted in Figure 21. 
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Sample Target 
total 
cov 
average 
cov 
Q1 median Q3 1X 20X 50X 100X 
02a BCR-MINOR 10990319 150.51 96 157 213 98.2 92.8 87.8 73.7 
02b BCR-MINOR 9961355 136.42 86 140 194 98.1 92.5 86.6 68.5 
02c BCR-MINOR 10082112 138.07 87 144 196 98.1 92.3 86.6 69.3 
02d BCR-MINOR 10061237 137.79 89 141 195 98.4 92.3 86.6 70.4 
03a BCR-MINOR 9596364 131.42 78 132 189 96.3 90.5 83.5 66 
03b BCR-MINOR 10020216 137.23 83 137 197 96.8 90.5 84.4 67.4 
03c BCR-MINOR 9949180 136.25 83 137 193 96.7 90.4 84.3 67.8 
03d BCR-MINOR 9666079 132.38 80 133 191 96.5 90.4 83.9 66 
04a BCR-MINOR 9610234 131.61 84 136 186 96.3 90.8 85.1 68.2 
04b BCR-MINOR 10139793 138.86 87 144 197 97.6 90.8 85.8 69.3 
04c BCR-MINOR 10038410 137.47 87 142 193 96.9 90.9 85.4 69.9 
04d BCR-MINOR 9857992 135 87 140 190 96.5 91 85.2 69.1 
05a BCR-MINOR 10549734 144.48 86 145 202 96.4 90.8 85.1 69.3 
05b BCR-MINOR 11151755 152.72 91 152 215 97 90.9 85.8 72.4 
05c BCR-MINOR 11012295 150.81 90 150 213 96.5 90.7 85.7 71.9 
05d BCR-MINOR 10738066 147.06 88 147 206 96.2 90.7 86 71.4 
06a BCR-MINOR 7695616 105.39 63 104 145 98.8 91.7 81.8 51.9 
06b BCR-MINOR 7124091 97.56 59 96 135 97.7 91.2 80.1 47.1 
06c BCR-MINOR 7133764 97.7 59 96 134 98 91.3 80 47 
06d BCR-MINOR 7130775 97.66 60 95 135 98.1 91.5 80.8 46.1 
07a BCR-MINOR 10054197 137.69 88 144 194 98 92 86.5 70.2 
07b BCR-MINOR 9263296 126.86 80 129 180 97.3 91.5 85.3 65.2 
07c BCR-MINOR 9262246 126.85 81 130 180 97.5 91.4 85 65.6 
07d BCR-MINOR 9349568 128.04 82 132 181 97.9 91.5 85.4 66.6 
08a BCR-MINOR 10411220 142.58 92 144 197 97.5 92 86.6 71.8 
08b BCR-MINOR 9647763 132.12 83 133 186 98.2 91.7 85.6 67.1 
08c BCR-MINOR 9616149 131.69 83 134 184 98.8 91.5 86.2 67.7 
08d BCR-MINOR 9522240 130.41 82 131 184 98.5 91.6 85.2 67 
09a BCR-MINOR 8302666 113.7 72 116 158 97.8 91.7 84 59.7 
09b BCR-MINOR 8690212 119.01 77 120 165 97.9 91.8 84.8 62.8 
09c BCR-MINOR 8550245 117.09 77 118 162 98.6 91.6 84.5 62.7 
09d BCR-MINOR 8404465 115.1 74 116 159 98.3 91.7 84.1 60.6 
10a BCR-MINOR 9919724 135.85 84 134 189 97.6 92.1 85.9 67.7 
10b BCR-MINOR 10386588 142.24 88 139 197 98.7 91.8 86.4 69.8 
10c BCR-MINOR 10321866 141.36 86 141 195 97.7 91.8 86.4 69 
10d BCR-MINOR 9993624 136.86 85 135 190 97.8 91.8 86.2 67.9 
Table 29. minor-BCR lane-level capturing 
The table shows the coverage and capturing statistics related to ABL1 targeted 
region across lanes. From left to right column: sample and lane, region name, 
number of bp that cover the region, average coverage, coverage at 1
st
 quartile 
(Q1), median coverage, coverage at 3
rd
 quartile (Q3), percentage of targeted 
region captured with an average coverage greater or equal to 1X,20X,50X and 
100X. Data included in this table are plotted in Figure 23. 
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Sample Target Total 
cov 
Average 
cov 
Q1 median Q3 1X 20X 50X 100X 
02a BCR-MICRO 1208070 156.63 119 152 188 100 100 96.6 86.4 
02b BCR-MICRO 1041932 135.09 98 134 163 100 99.4 95.7 72.9 
02c BCR-MICRO 1026152 133.04 97 130 162 100 99.2 95.2 72.9 
02d BCR-MICRO 1022616 132.58 96 130 164 100 98.8 95.7 71.6 
03a BCR-MICRO 1061446 137.62 90 141 172 100 98.7 95 69.2 
03b BCR-MICRO 1105325 143.31 98 141 181 100 98.8 94 73.4 
03c BCR-MICRO 1120843 145.32 97 147 188 100 99.2 94.6 73.4 
03d BCR-MICRO 1073728 139.21 96 138 169 100 99.7 93.8 73 
04a BCR-MICRO 1149866 149.08 109 148 187 100 98.3 94.7 80 
04b BCR-MICRO 1204271 156.14 118 153 190 100 100 96.3 84.1 
04c BCR-MICRO 1199496 155.52 113 154 195 100 98.5 94.9 82.1 
04d BCR-MICRO 1185594 153.71 115 155 188 100 100 95.7 82.4 
05a BCR-MICRO 1089888 141.31 94 137 179 100 99.1 94.3 72.3 
05b BCR-MICRO 1133742 146.99 99 143 180 100 99.6 96.3 74.6 
05c BCR-MICRO 1131154 146.66 105 147 179 100 99.5 96 76.8 
05d BCR-MICRO 1070474 138.79 91 137 168 100 100 94.8 72.9 
06a BCR-MICRO 908549 117.79 82 116 146 100 100 93.1 63.1 
06b BCR-MICRO 834879 108.24 71 110 138 100 100 88.9 56.9 
06c BCR-MICRO 827638 107.3 75 106 137 100 99.5 87.7 54 
06d BCR-MICRO 803957 104.23 72 104 133 100 100 88.7 53.1 
07a BCR-MICRO 1075784 139.48 96 134 174 100 100 95.7 72.5 
07b BCR-MICRO 951647 123.38 83 121 158 100 99 90.4 67.5 
07c BCR-MICRO 933486 121.03 81 120 150 100 98.9 90.2 65.9 
07d BCR-MICRO 955228 123.85 83 122 154 100 99.3 91.6 64.1 
08a BCR-MICRO 1177187 152.62 102 156 193 100 99.8 96 76.2 
08b BCR-MICRO 1007750 130.66 87 135 169 100 99.3 94 68.2 
08c BCR-MICRO 1028521 133.35 94 135 167 100 99.8 95.6 71.4 
08d BCR-MICRO 1033451 133.99 91 136 175 100 99.2 95.1 69.7 
09a BCR-MICRO 945414 122.57 84 126 156 100 97.8 85.5 67.4 
09b BCR-MICRO 968251 125.53 88 129 156 100 97.9 86.7 69.8 
09c BCR-MICRO 975760 126.51 85 131 159 100 98.7 86.3 67.9 
09d BCR-MICRO 945139 122.54 88 126 154 100 98.4 87 67.1 
10a BCR-MICRO 982413 127.37 84 130 167 100 94.2 86.4 68.9 
10b BCR-MICRO 1016777 131.83 89 134 177 99.3 93.7 87.4 68.4 
10c BCR-MICRO 1011911 131.2 87 138 174 100 93.8 86.4 68.6 
10d BCR-MICRO 989168 128.25 87 132 172 100 94.2 86.8 68.3 
Table 30. micro-BCR lane-level capturing 
The table shows the coverage and capturing statistics related to ABL1 targeted 
region across lanes. From left to right column: sample and lane, region name, 
number of bp that cover the region, average coverage, coverage at 1
st
 quartile 
(Q1), median coverage, coverage at 3
rd
 quartile (Q3), percentage of targeted 
region captured with an average coverage greater or equal to 1X,20X,50X and 
100X. Data included in this table are plotted in Figure 22. 
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Sample Lane SV_type type pairs bp1_start1-end1 (chr9) bp2_start2-end2 (chr22) 
1a TRANSLOC UNBAL 270 133606918-133607140 23632762-23632892 
2a TRANSLOC UNBAL 43 133648580-133648887 23631908-23632079 
4a INS_FRAGMT BAL 91 133590218-133590566133590575-133590896 23575267-23575207 
4a TRANSLOC BAL 80 133590575-133590566 23575267-23575207 
6a TRANSLOC UNBAL 60 133657725-133658098 23634042-23634274 
7a TRANSLOC UNBAL 49 133683996-133684302 23634584-23634859 
7a INV_TRANSLOC UNBAL 47 133684244-133684515 36900842-36901057 
9a TRANSLOC UNBAL 35 133663802-133663988 23631896-23632112 
10a TRANSLOC BAL 32 133696775-133697006 23634479-23634637 
      
      
Sample Lane SV_type type pairs bp1_start1-end1 bp2_start2-end2 
1b TRANSLOC UNBAL 253 133606948-133607140 23632757-23632890 
2b TRANSLOC UNBAL 35 133648594-133648885 23631883-23632051 
4b INS_FRAGMT BAL 86 133590333-133590561 - 133590576-133590916 23575268-23575209 
4b INS_FRAGMT BAL 81 133590206-133590561 - 133590576-133590829 23575251-23575209 
6b TRANSLOC UNBAL 64 133657743-133658098 23634051-23634315 
7b TRANSLOC UNBAL 53 133684061-133684302 23634592-23634863 
7b INV_TRANSLOC UNBAL 49 133684247-133684481 36900847-36901145 
9b INV_TRANSLOC UNBAL 30 136985435-136985697 23631670-23631890 
9b TRANSLOC UNBAL 29 133663780-133663990 23631882-23632117 
10b TRANSLOC UNBAL 30 133696781-133697038 23634348-23634646 
10b TRANSLOC UNBAL 21 133696693-133697006 23634577-23634793 
Table 31. SVDetect breakpoints detection: A and B lanes 
Table shows the breakpoints coordinates identified by discordant pair reads using SVDetect. The columns describe: patient and 
lane number, SV type, balancing, number of pairs supporting the SV event, start and end of breakpoints coordinates 
(chromosome 9 and chromosome 22). 
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Sample Lane SV_type type pairs bp1_start1-end1 bp2_start2-end2 
1c TRANSLOC UNBAL 273 133606917-133607140 23632756-23632890 
2c TRANSLOC UNBAL 29 133648582-133648884 23631918-23632210 
4c INS_FRAGMT BAL 85 133590292-133590563 - 133590576-133590916 23575267-23575207 
4c TRANSLOC BAL 76 133590582-133590572 23575267-23575207 
5c INS_FRAGMT BAL 21 133708178-133708501 - 133708502-133708895 23654742-23654792 
6c TRANSLOC UNBAL 57 133657679-133658098 23634042-23634181 
7c INV_TRANSLOC UNBAL 52 133684252-133684542 36900846-36901211 
7c TRANSLOC UNBAL 41 133683951-133684306 23634592-23634979 
9c TRANSLOC UNBAL 37 133663859-133663988 23631897-23631955 
9c INV_TRANSLOC UNBAL 33 136985532-136985698 23631680-23631884 
10c TRANSLOC UNBAL 37 133696775-133696978 23634410-23634637 
10c TRANSLOC BAL 32 133696775-133697005 23634504-23634640 
      
Sample Lane SV_type type pairs bp1_start1-end1 bp2_start2-end2 
1d TRANSLOC UNBAL 274 133606908-133607140 23632757-23632916 
2d TRANSLOC UNBAL 39 133648547-133648886 23631930-23632155 
4d TRANSLOC BAL 62 133590569-133590563 23575249-23575214 
4d INS_FRAGMT BAL 59 133590249 -133590561 - 133590561-133590908 23575249-23575214 
5d TRANSLOC BAL 24 133708451-133708500 23654734-23654777 
5d TRANSLOC BAL 21 133708502-133708500 23654734-23654777 
6d TRANSLOC UNBAL 46 133657686-133658101 23634042-23634259 
7d TRANSLOC UNBAL 70 133684020-133684300 23634602-23634852 
7d INV_TRANSLOC UNBAL 37 133684242-133684530 36900845-36901164 
9d INV_TRANSLOC UNBAL 38 136985515-136985697 23631698-23631905 
9d TRANSLOC UNBAL 31 133663703-133663995 23631873-23632051 
10d TRANSLOC UNBAL 31 133696775-133696992 23634342-23634635 
10d TRANSLOC BAL 21 133696775-133696999 23634569-23634645 
Table 32. SVDetect breakpoints detection: C and D lanes 
Table shows the breakpoints coordinates identified by discordant pair reads using SVDetect. The columns describe: patient and 
lane number, SV type, balancing, number of pairs supporting the SV event, start and end of breakpoints coordinates 
(chromosome 9 and chromosome 22). 
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Chr Start End Name 
K562 2 3 4 5 
S E S E S E S E S E 
9 133590053 133590178 MIR3       518 393   
9 133590241 133590294 Charlie4z       330 277   
9 133593422 133593728 AluSz     406 100     
9 133593728 133593794 Charlie1a     100 34     
9 133593834 133593985 Charlie1a     -6 -157     
9 133593985 133594276 AluJo     -157 -448     
9 133606692 133607233 L1ME3A 453 -88         
9 133607299 133607432 L1MD -154 -287         
9 133648425 133648741 AluSp   466 150       
9 133648741 133648826 L1MEd   150 65       
9 133648839 133649166 AluJb   52 -275       
9 133649174 133649743 L1ME1   -283 -852       
9 133707880 133708012 MIR          484 
 
Table 33. BP4 distance to repeated elements: samples 2,3,4,5 and K562 cell lines. 
The table shows the distance of BP4 (which spots the BCR-ABL1 fusion at ABL1) to repeated elements in a region of 800bp 
(400 upstream and 400 downstream) surrounding the breakpoint. From left to right: the chromosome, start and end of the 
repeated element, the name of the repeated element, samples column (S indicates the start of the repeated element and E the 
distance from the end of the repeated element). Bold and underline numbers denote that the BP4 in that sample maps within 
the repeated element. In this case sample 2 and K562 cell line have the BP4 that maps within AluJb and L1ME3A respectively. 
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Chr Start End Name 
6 7 8 9 10 
S E S E S E S E S E 
9 133657438 133657747 AluSz 664 355         
9 133657747 133657844 MER112 355 258         
9 133657863 133658070 MIRb 239 32         
9 133658393 133658520 L1MC4 -291 -418         
9 133663584 133664351 L1MC4       411 -356   
9 133664415 133664487 L1MC4       -420 -492   
9 133683619 133683929 AluSx   691 381       
9 133683947 133683994 (TAGG)n   363 316       
9 133684052 133684161 L2   258 149       
9 133684218 133684749 L1MEc   92 -439       
9 133694459 133694769 AluSg     458 148     
9 133694919 133695226 AluSx3     -2 -309     
9 133696312 133696616 AluSc8         689 385 
9 133696616 133697051 L1ME1         385 -50 
9 133697051 133697227 AluSx3         -50 -226 
 
Table 34. BP4 distance to repeated elements: patients 6,7,9,10 
The table shows the distance of BP4 (which spots the BCR-ABL1 fusion at ABL1) to repeated elements in a region of 800bp 
(400 upstream and 400 downstream) surrounding the breakpoint. From left to right: the chromosome, start and end of the 
repeated element, the name of the repeated element, samples column (S indicates the start of the repeated element and E the 
distance from the end of the repeated element). Bold and underline numbers denote that the BP4 in that sample map within the 
repeated element. In this case sample 7,9 and 10 have the BP4 that maps within L1MEc, L1MC4 and L1ME1 respectively. 
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chr Start End Name 6 S 6 E 7 S 7 E 8 S 8 E 10 S 10 E 
22 23633112 23633411 AluSx1     299 0   
22 23633413 23633642 L1ME1     -2 -231   
22 23633846 23634014 L2b 187 19       
22 23634391 23634475 L2b   187 103   182 98 
22 23634614 23634637 AT_rich   -36 -59   -41 -64 
 
Table 35. BP1 distance to repeated elements 
The table shows the distance of BP1 (which spots the BCR-ABL1 fusion at BCR) to repeated elements in a region of 800bp 
(400 upstream and 400 downstream) surrounding the breakpoint. From left to right: the chromosome, start and end of the 
repeated element, the name of the repeated element, samples column (S indicates the start of the repeated element and E the 
distance from the end of the repeated element). 
 
chr Start End Name K562 S K562 E 2 S 2 E 5 S 5 E 7 S 7 E 8 S 8 E 
22 23633112 23633411 AluSx1 -138 -437 444 145 
  
-204 -503 
  
22 23633413 23633642 L1ME1 
  
143 -86 
      
22 23633846 23634014 L2b 
  
-290 -458 
      
22 23634391 23634475 L2b 
    
248 164 
  
249 165 
22 23634614 23634637 AT_rich 
    
25 2 
  
26 3 
 
Table 36. BP2 distance to repeated elements 
The table shows the distance of BP2 (which spots the ABL1-BCR fusion at BCR) to repeated elements in a region of 800bp 
(400 upstream and 400 downstream) surrounding the breakpoint. From left to right: the chromosome, start and end of the 
repeated element, the name of the repeated element, samples column (S indicates the start of the repeated element and E the 
distance from the end of the repeated element). Bold and underline numbers denote that the BP4 in that sample map within the 
repeated element. For instance sample 2 has the BP2 that maps within a L1ME1. 
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chr Start End Name 2 S 2 E 3 S 3 E 4 S 4 E 6 S 6 E 8 S 8 E 10 S 10 E 
9 133590241 133590294 Charlie4z 
    
328 275 
      
9 133593422 133593728 AluSz 
  
382 76 
        
9 133593728 133593794 Charlie1a 
  
76 10 
        
9 133593834 133593985 Charlie1a 
  
-30 -181 
        
9 133593985 133594276 AluJo 
  
-181 -472 
        
9 133648425 133648741 AluSp 356 40 
          
9 133648741 133648826 L1MEd 40 -45 
          
9 133648839 133649166 AluJb -58 -385 
          
9 133657863 133658070 MIRb 
      
447 240 
    
9 133658393 133658520 L1MC4 
      
-83 -210 
    
9 133694459 133694769 AluSg 
        
530 220 
  
9 133694919 133695226 AluSx3 
        
70 -237 
  
9 133696195 133696312 L1ME1 
            
9 133696312 133696616 AluSc8 
          
469 165 
9 133696616 133697051 L1ME1 
          
165 -270 
9 133697051 133697227 AluSx 
          
-270 -446 
 
Table 37. BP3 distance to repeated elements 
The table shows the distance of BP3 (which spots the ABL1-BCR fusion at ABL1) to repeated elements in a region of 800bp 
(400 upstream and 400 downstream) surrounding the breakpoint. From left to right: the chromosome, start and end of the 
repeated element, the name of the repeated element, samples column (S indicates the start of the repeated element and E the 
distance from the end of the repeated element). Bold and underline numbers denote that the BP3 in that sample map within the 
repeated element. In this case sample 2,8 and 10 have the BP3 that maps within L1MEd, AluSx3 and L1ME1 respectively. 
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Chr Exon Start End 4 S 4 E 
        
22 1 23523147 23524426 52101 50822 
        
22 2 23595985 23596167 -20737 -20919 
        
 
 
            
Chr Exon Start End 2 S 2  E 3 S 3 E 9 S 9 E 
    
22 13 23631703 23631808 207 102 425 320 172 67 
    
22 14 23632525 23632600 -615 -690 -397 -472 -650 -725 
    
 
 
            
Chr Exon Start End K562 S K562 E 6 S 6 E 7 S 7 E 8 S 8 E 10 S 10 E 
22 14 23632525 23632600 217 142 1508 1433 2053 1978 886 811 2048 1973 
22 15 23634727 23634825 -1985 -2083 -694 -792 -149 -247 -1316 -1414 -154 -252 
 
 
            
Chr Exon Start End 5 S 5 E 
        
22 19 23653883 23654023 882 742 
        
22 20 23655073 23655208 -308 -443 
        
 
Table 38. BP1 distance to BCR exons 
This tables summarize the distances between BP1 and flanking exons. The first 4 columns describe the chromosome, the exon, 
and the start and end coordinates of the exon. The further columns represent the distance of the BP1 to the flanking exons.  
The first one describes the patient 4 whose BP1 maps at the m-BCR between 1
st
 and 2
nd
 exon, the second table describes 
distances of BP1 to flanking exons in patients that carry the b2a2 BCR-ABL1 transcript, in the third the distances in patients that 
carry the b2a3 isoform and in the last one patient 5 which has the BP1 located in the micro-BCR region between exon 19 and 
20. 
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